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Summary 
It has been shown that 153Sm complexed with the bone seeking ligand ethylene-
diaminetetramethylene phosphonate (EDTMP) is effective in pain palliation therapy of 
bone cancer. Blood plasma models for this ligand with Sm(III) and Ho(III) have been 
successfully constructed explaining the differences between 153SmEDTMP and 
166HoEDTMP. The latter isotope is preferred because of its more energetic f3 particle, 
thought to improve the therapeutic effect of the radiopharmaceutical. However, 
166HoEDTMP is not an effective pain palliation agent and consequently the search for a 
more effective bone cancer therapeutic radiopharmaceutical involving 166Ho continues. A 
ligand is being sought which complexes Ho(III) with a formation constant high enough to 
survive competition from blood plasma ligands but not so high to prevent 166Ho from being 
accessible to metastases. EDTMP is unsuitable as such a ligand because of its inability to 
compete with citrate for complexation of Ho(III). 
For this study three diphosphonate ligands applied in radiation imaging of bone or non-
radiative treatment of osteoporosis were chosen. They are APD (1-hydroxy-3-amino-
propylidene-diphosphonic acid), MDP (methylenediphosphonic acid) and HEDP (1-
hydroxy-ethylene-diphosphonic acid). Formation constants for the complexation of Ca(II), 
Mg(II), Zn(II), Sm(III) and Ho(III) with all of these ligands were measured using 
potentiometry and polarography. The latter was used to complement potentiometry in 
systems where precipitates formed. The complexation of Cd(II) by HEDP was used to 
compare the two techniques and to show that the values found by either technique are 
comparable. NMR studies were attempted on some complexes in solution to investigate 
the role the of the hydroxy-group (APD and HEDP) in complexation. The program 
ECCLES was used together with the formation constants measured in this study to predict 
the speciation of Ho(III) and Sm(III) with these three ligands in blood plasma. The results 
gathered for Ho(III) and APD were used as an indication and in an application to an 
ethical committee before animal testing. A baboon test was carried out using 166HoAPD, 
the most promising system. 
vi 
ethical committee before animal testing. A baboon test was carried out using 166HoAPD, 
the most promising system. 
The resulting bone-uptake and side-effects found in the animal study confirmed the 
predictions made by ECCLES. It proved that 166HoAPD would be ineffective as a 
therapeutic agent due to high liver uptake. Valuable information on how a future 
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- Ethylenediaminetetramethylene phosphonate 
- l-Hydroxy-3-amino-propylidene-diphosphonic acid 
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- Atomic Energy Corporation of South Africa Ltd. 
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Bone-seeking radiopharmaceuticals are receiving considerable attention for therapeutic 
treatment of bone metastases (commonly known as bone cancer). In this regard 
satisfactory results were achieved using 153SmEDTMP [I], in the pain palliation therapy of 
patients suffering from this form of cancer by a multi-disciplinary task group, from which 
the AEC of SA is a member. 
1.1 Bone cancer and pain palliative therapy 
Although direct tumour invasion of bone can occur, the most common pathway for the 
spread of malignancies is from the bone marrow, which is affected first, to the firm bone 
matrix [2]. Secondary bone metastases occur commonly in advanced cancer of the bone, a 
feature of i.a. breast, lung and prostate cancer patients [2,3]. (Metastatic sites are 
commonly found in the axial skeleton rather than the appendicular skeleton.) This follows 
an increased rate of bone resorption mediated largely by the osteoclasts. Osteoclasts are 
responsible for bone resorption in normal remodelling of bone. On the other hand, 
osteoblasts handle bone deposition as the other half of the remodelling of bone, a process 
undergone throughout life [2]. The disruption of the structural integrity of bone is what 
causes so much pain to the patient. A good quality oflife can be maintained by an effective 
pain palliation therapy. There are a few therapeutic options available. Chemotherapy, 
hormone manipulation agents to inhibit bone resorption and radiation therapy using 
radiopharmaceuticals. The research described herein and already used by the AEC is 
related to the latter 
The mechanisms by which pain relief is thought to occur is still speculative. One theory on 
how radiopharmaceuticals work in pain palliation treatment is that the radioactive isotope 
chemisorbs to areas of increased osteoblastic activity due to the bone seeking ligand. 
Radiation will then cause death in a percentage of cells within ~-range (3 mm for Sm-153 
and 8 mm for Ho-166). The resulting decrease in intraosseous mass and pressure bringing 
relief to the patient. However, it is found that the reduction in pain levels occur within a 
few days, i.e. before the tumour cell mass shrinks. The mechanism is therefore more 
complex. One of the most radiation-sensitive cell types is the lymphocyte, which secretes a 
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variety of cytokineses that have been associated with pain modulation. Perhaps lymphocyte 
cell death at the tumour site is responsible for this rapid pain reduction [4]. 
153SmEDTMP as a radiopharmaceutical is a very successful pain palliation agent for 
patients suffering from bone metastases. It consists of 153Sm complexed to a phosphonate 
viz. ethylenediaminetetramethylphosphonate (EDTMP) and has been studied extensively 
by our department [5]. 
Photo 1. Skeletal image of a patient injected with 153SmEDTMP taken by a y-camera. 
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Photo 2. Comparison between a visible and y-ray image of a patient's spinal cord. Note 
that the lighter areas on the visible image indicate cancer tissue which correspond to 
the darker areas on they-image indicating higher uptake of 153SmEDTMP. The round 
spot on the third vertebra from the right is a good example of 153SmEDTMP's selective 
uptake. 
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153Sm has a half-life of 46.7 hours, emits W-rays with energies 805[21%]; 702[44%] and 
632[34%]keV and a y-ray with energy I03[28%]keV with a max. soft tissue penetration 
of -0.3 cm [6]. This illustrates that 153Sm is a mild treatment and after 9 weeks further 
treatment is necessary once radiation levels have declined and the pain palliation subsides 
[7]. The corresponding figures for 166Ho are tYz = 26.9 hr; fr 1776[48%]keV and 
1840[51%]keV; y (81 keV [6.2%] and 1380 [1%]keV); max. soft tissue penetration 0.84 
cm [6]. This suggests that 166Ho might be a better therapeutic radionuclide especially for 
large lytic type tumours, broadening the scope from palliative purposes to use in curative 
therapy [7,8]. Together with the high natural abundance of 165Ho (100%), from which 
166Ho is produced by neutron activation, and a neutron capture cross-section = 64 barns, 
the cost of production is much lower. (152Sm enriched Sm is used to produce 153Sm). This 
is why Mumper et. al. chose Ho-166 as their radioactive isotope for the internal radiation 
therapy of hepatic tumours [9]. 
To get a better understanding of this phenomenon a skeletal image taken using a y-camera 
is presented (Photo 1 ). The image (taken 3 hrs after injection) is of a patient who was 
injected with 153SmEDTMP on a Thursday and died over the week-end. The photograph 
shows the selectivity of this pharmaceutical for bone tissue alone. The darker areas show 
higher 153 Sm absorption and correspond to the bone areas mostly affected by the cancer. 
Because of the patient's death an autopsy could be performed and a closer look could be 
taken at the vertebral column. Photo 2 shows the remarkable selectivity of 153SmEDTMP. 
The two photos compare the cross sectional cut of the spinal cord in visible light and as a 
y-image. On the visible picture the cancer affected areas of the spinal marrow show as 
lighter areas; light brown to milky white. The brown-red segment, second from the left is 
unaffected tissue. The thin horizontal bands represent the cushions between the dorsal 
vertebra. On they-image the darker areas show more absorption of 153Sm and correspond 
to the lighter areas on the visible image viz. the cancer cells. Thus 153 SmEDTMP is not 
only selective for bone tissue but also prefers the cancer cells above normal tissue. 
Although the chemistry of Ho and Sm is similar (both are lanthanides ), the skeletal 
localisation of 166HoEDTMP proved to be inferior to 153SmEDTMP [l]. From a medical 
viewpoint, the spread of radioactivity throughout the body should be avoided because of 
the ineffective dose reaching the tumour cells and the side effects of radiation throughout 
the body. 
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Photo 3. A computer enhanched image of 153Sm uptake in various parts of the body. 
The white areas show the highest levels of radiation being emitted and thus the highest 
uptake. 
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Photo 4. Comparative y-images for 99mTcMDP, 153SmEDTMP and 166HoEDTMP (from 
top to bottom). No clear skeletal picture is produced by 166HoEDTMP (bottom). 
7 
This is just what Photo 3 shows. In Photo 3 the bone uptake of 153Sm in various parts of 
the body is displayed. This is a computer enhanced image in which the reddish to blue to 
white areas correspond to the higher levels of radiation being emitted and therefore the 
higher uptake. The maximum bone accumulation of 153SmEDT.MP in a baboon (used as a 
model for humans) has been reported to be 53% 4 hrs after intravenous injection [6]. The 
bone to background ( cardiac pool) uptake for 153 SmEDTMP was 91 % in comparison to 
95% for 99mTcMDP (a bone imaging agent). The figures for 166HoEDTMP are 45% and 
69% respectively. The 45% total accumulation is not worrying because it only leads to a 
higher urine excretion of 166Ho. The bone to blood ratio of 69% is the concern. This can 
be seen quite clearly on Photo 4 which shows comparative y-images of 153 SmEDTMP and 
166HoEDTMP 4 hours after administration. The bottom side shows the 166Ho uptake. No 
clear skeletal picture is produced. The bone uptake of 166HoEDTMP from blood plasma 
seems to be insufficient [ 6]. 
153SmEDTMP will shortly be marketed as a pain palliation therapy for bone cancer. Pre-
clinical and clinical trails tests were successful. The search for better radiopharmaceuticals 
to treat bone cancer has not stopped here but continues. 
1.2 Ligands tested as possible bone cancer remedies. 
This dissertation has focused on three diphosphonate ligands viz. APD = 1-Hydroxy-3-


















All three of them are currently used as bone-seeking ligands. 
1.2.1. APD 
Since 1994, APD has been commercially produced by Ciba, Switzerland, and marketed 
under the trade names Pamidronate or Aredia (disodium pamidronate). It is used to 
suppress osteolytic bone metastases by inhibiting both bone resorption and osteolytic 
activation. Both these are features of bone cancer and cause increased 'bone turnover'. 
APD as well as the other diphosphonates have the ability to sorb strongly to 
hydroxyapatite and thus inhibit bone resorption [10]. According to Ciba, APD functions by 
binding to the bone surface thereby inhibiting resorption, the functioning of osteoclasts and 
interferes with the maturation of osteoclast precursors [3]. A further aspect is that APD 
mobilises Ca(II) and Mg(II) in blood plasma to such an extent that an increased amount of 
these two metal ions is available for deposition on the bone, thus assisting in regenerating 
bone tissue [11]. In short this remedy is used to stop the "eating away" of the bone by the 
cancer cells. It does not destroy the cancer cells but repairs the damage they do to the 
bone. The resorption of bone causes pain and therefore APD is marketed as a pain 
palliation therapy for osteolytic bone cancer patients. A study of this ligand would be 
interesting as it already has palliative effects on its own and if it could deliver a radioactive 
metal-ion to the bone, it may be a highly effective therapeutic agent. 
9 
1.2.2. MDP 
MDP ( also known as Medronate) is commercially applied in the radionuclide bone imaging 
agent 99mTc(Sn)-MDP. Because of the soft y-ray it emits, 99mTc is widely used as an 
imaging agent [12]. Different ligands deliver Tc-99m to different organs. The presence of 
Sn(II) in the above skeletal imaging agent helps to reduce pertechnetate. To what 
oxidation state the Tc is being reduced is still one of the unknown aspects of the chemical 
composition of 99mTc-radiopharmaceuticals [13]. HMDP (hydroxymethane diphosphonate) 
is sometimes used to replace MDP in targeting the bone. Studies showed that the 
cancerous/compact bone uptake is greater for HMDP than MDP [14]. Another ligand used 
is HEDP. The bone uptake of 99mTc HEDP is lower than that of MDP but gives a greater 
contrast between regions of higher and lower calcification rates. However Tc-99m MDP 
has a faster rate of blood clearance [15]. Both HEDP and HMDP have an hydroxy-group 
which MDP lacks. It was therefore decided to choose MDP and HEDP for further studies 
as possible pain palliative radiopharmaceuticals. 
Degrossi, Oliveri and Garcia del Rio et. al. compared 99mTc-MDP with 99mTc-APD as bone 
scanning agents [ 16]. They were able to show that APO appears to be an adequate agent 
for bone scintigraphy. The whole body retention after 24-hrs was 17.6% ± 4.6 for 99mTc-
APD as compared to 28.6% ± 3.9 for 99mTc-MDP. The blood clearance time was similar 
for both compounds and the lesion/normal bone ratio was found to be 4.6 in studies using 
APO and 4.8 using MDP. 
1.2.3. HEDP 
HEDP (also known as Etidronate) is sometimes used as 99mTc(Sn)-HEDP because of its 
higher specific bone uptake than MDP [15]. As the areas with higher rates of calcification 
should be the target of a possible palliative radiopharmaceutical HEDP seems to be a 
promising candidate. HEDP has also a unique relationship with rapid growing 
hydroxyapatite which gives it the potential in controlling abnormal high rates of bone 
growth as occurs in Paget's disease [17]. In the above pharmaceutical application the 
diphosphonate is the bone seeker and it localises the 99mTc at the bone to give the skeletal 
image wanted. 99mTc is not a ~-emitter, has a half-life of 6.0 hours and emits only y-rays 
and therefore has no therapeutic effect. Research is being done on replacing Tc by Re (an 
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element with similar chemistry to Tc) which is a strong ~-emitter. Studies on the use of 
188Re (half-life of 16.0 hours) complexes of MOP and HEDP as bone therapeuticals is 
currently underway [18,19]. 188Re-HEDP may also be used therapeutically in the future. 
The high bone uptake ofHEDP makes it worth investigating complexes of this ligand with 
the lanthanide's 153Sm and 166Ho. 
1.2.4. Theories on the hydroxy-group function in bone uptake 
In the literature various theories on the purpose of the hydroxy-group in diphosphonate 
ligands have been suggested. In this study, only MOP lacks this group. The most popular 
postulate is that the hydroxy-group binds to the hydroxyapatite of the bone and so 
increases the ligand's selectivity for bone. This postulate is supported by a comparison of 
MOP and HEDP. HEDP has a higher bone uptake than MOP and co-ordinates much faster 
to hydroxyapatite than MOP[15]. This leads one to believe that the hydroxy group plays 
an important role in adsorption on hydroxyapatite. However, the hydroxy group may 
paradoxically also be involved in complexing the metal ion. For 153SmEDTMP adsorption 
on hydroxyapatite, Chirby et al [20] have found that 153Sm is adsorbed as part of the 
153SmEDTMP complex and not as free 153Sm(III) which would follow the dissociation of 
the complex just before adsorption. There is however some evidence to support the idea 
that dissociation takes place first [21]. 
1.3 Chemical speciation 
To elucidate the performance of these chosen ligands in treating bone cancer the reactions 
between metal-ions and ligands needs to be understood [22]. When looking at bonding 
between a ligand and a metal-ion one way to describe this phenomenon is to consider the 
thermodynamic equilibria occurring. The formation constant, ~ for the equilibrium of 
complex formation is defined as follow: 
~pqr = [MpLqH,] / [M]P[L]q[H]' for the reaction pM + qL +rH ~ MpLqH, 
(M = metal-ion, L = ligand and H = hydrogen ions bonded to the complex) 
Where p = 0 the protonation constants are used to describe the protonation of bases. 
For a particular ligand and metal-ion several complexes may form at different pH values 
e.g. ML, MLH, M2L, ML2 and MLOH. The distribution between these different species is 
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called the speciation of that ligand. Duffield and Williams [23] have defined speciation as 
follows: Speciation defines the oxidation state, concentration and composition of each of 
the species present in a chemical sample. Better computing and analytical methods in 
recent years have led to an increased understanding of the speciation underlying many 
chemical reactions, with interesting conclusions in medicine, industry and the environment 
[23]. An example of this are broad-breasted bronze turkey chicks who failed to grow 
despite having a balanced diet which contained Soya meal and the required metal ions like 
zinc. It was shown that that the zinc firmly complexed with the Soya protein and were 
therefore unavailable to the animal. The solution to this problem was the introduction of a 
complexing ligand which removed the zinc from the protein, making it bioavailable. 
Prolinate was such a ligand which did not complex too strongly to zinc so that the body 
would be stripped of zinc [24,25]. 
Findlow et. al. [26] were able to show with chemical speciation that the link between high 
levels of aluminium in the blood and Altzheimer' s disease is rather tenuous. Only a small 
percentage of dietary aluminium exists in neutral lipid soluble fractions which can migrate 
across intestinal mucosal cells into blood plasma. 
On the same note it was shown that only 2-3 % of cadmium metal in crabmeat is available 
from the gastrointestinal tract [27]. This observation saved the crabmeat industry from 
closing down when the levels of cadmium in this meat exceeded the limits set by the UK 
ministry of Agriculture and Fisheries and Food. This gave the food a safety factor of one 
or two orders of magnitude. In this context Jones et. al. [28] also used speciation to assess 
the ability of various pharmaceutical agents to remove Cd(II) from humans. 
Huang et. al. [29] were able to show that Razoxane, a drug used in cancer treatment, may 
influence cancer cell growth as follows: Firstly being lipophilic in blood plasma it is able to 
enter cells. Once inside the cell, the molecule's ring opens and forms a chelating ligand 
which seeks out essential metal ions and so stops cell growth. 









If the molecule is subjected to peptide hydrolysis by enzymes which are ubiquitous in 
0 H 
II I . 
humans, the R-C-N- R bonds are cleaved giving the parent RCOOH and NH2R' 
agents. If two of the four possible sites in thalidomide are cleaved, an agent similar to 
EDT A may result. This is capable of sequestering calcium ions near to the limb buds in the 
developing foetus, with the risk of deformation. By using speciation data one could 
optimise the desirable reactions and suppress threatening reactions. 
Hurford et. al. [31] described the benefits of zinc's addition to toothpaste. Because of its 
bacteriostatic effect upon oral flora, zinc hinders calcium deposition on plaque and is 
responsible for the anti-swelling effect in dental calculus. Speciation showed how the 
toothpaste must be formulated. The zinc species must be lipophilic to be bioavailable to 
the bacteria, have the correct speciation to poison calcium plaque bonding and penetrate 
the tissue to ease gum inflammation. 
CH2-COOH 
HOOCCH2""' I / CH2COOH 
N-CHCH~N-CHCH-N 









On environmental issues, speciation has also proved to be a handy tool. Duffield et.al. [32] 
showed, by using ECCLES to simulate chemical speciation in blood plasma, that Puchel 
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(as shown above) would not be such a good plutonium chelation therapy. Intravenously 
administered CaDTP A however binds much better to Pu(IV) and is probably the best 
prompt treatment for plutonium contaminated people [32]. 
Radioactive waste storage is a controversial issue because plutonium and other waste 
products have such long half-lifes. Speciation can be used to predict how safe a particular 
storage area is [33]. Jarvis et. al. [34] commented on the transportation of plutonium 
around South Africa. They showed, using chemical speciation, that an accident causing 
contamination of South-Africans was very unlikely. If plutonium were to be released into 
the marine environment the physical spreading of Pu02 is minimal and is largely non-
bioavailable to marine organism. 
1.4 Chemical speciation and the blood plasma 
The human body consists of cells which are surrounded by an aqueous medium. Since 70% 
of the body is water, life is sustained by reactions between metal-ions and ligands which 
occur in vivo in this medium. Studying the reactions between metal-ions and ligands is 
therefore needed to understand more of the biochemistry in the human body [22]. 
The delivery of radioactive nuclides such as 153Sm, 99mTc and 186Re to the bone by bone 
seeking ligands is well known. Calculating the speciation for a particular ligand in blood 
plasma will tell whether a complex will survive the competition of metal-ions and ligands 
occurring naturally in blood plasma. If so, the ligand will be able to deliver the radionuclide 
to the bone and may be successful in the treatment of painful bone metastases. The 
computer program ECCLES [35] predicts the speciation of metal ions or ligands in 
biological fluids like blood plasma. ECCLES stands for Evaluation of Constituent 
Concentrations in Large Equilibrium Systems. May et. al. [35] wrote this program to 
simulate the nature of the metal ion binding to low-molecular-weight ligands (LWL) in 
human blood plasma seeing that they play such an important role in biological systems 
[36]. This program uses the fact that the percentage distribution of transition-metal ions 
among L WL is not controlled by protein binding to bypass the exclusion of protein-metal 
equilibria. The distribution of Ca(II), Mg(II), Mn(II), F e(III), Cu(II), Zn(II) and Pb(II) 
amongst 5000 complexes formed with 40 or more ligands is computed, clearly justifying 
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the use of a computer to speed up calculations. Binary and ternary complexes (like MLL' 
and MLL'L" where L,L' and L" are different ligands binding to the same metal ion) are 
also taken into account. Introducing a new ligand as a pharmaceutical requires that the 
program's database of formation constants be expanded by constants describing the 
complexation of the ligand with the various metal ions (including the metal ion used as 
source of radiation) in order to elucidate the in vivo behaviour of the 
radiopharmaceuticals, like it was done for 153SmEDTMP in blood [5]. 
Constants for important blood plasma metal-ions with EDTMP as well as those for 
Sm(III) and all blood plasma ligands were added to the database. Speciation calculations 
with ECCLES showed that EDTMP effectively competes with blood plasma ligands such 
as citrate for Sm(III) and thus 153Sm is likely to be successfully delivered to the bone. 
166Ho on the other hand forms a weaker complex with EDTMP [7] and therefore may be 
complexed by plasma citrate accounting for the high levels of 166Ho in the blood of the 
baboon model [ 6]. As previously mentioned, 166Ho would possibly treat some tumours 
more effectively. 166Ho has the advantage that a higher dose is delivered in a shorter 
period. The results of the baboon tests showed that a bone to background ( cardiac blood 
pool) uptake for 166Ho-EDTMP, was 69% in comparison to 91 % 153 Sm-EDTMP [6]. In 
this case ECCLES confirmed that 166HoEDTMP would not survive blood plasma even 
though the difference between the values of logK for the formation of ML for Ho and Sm 
is only 1.2. This is due to the fact that Ho(III) is a smaller ion than Sm(III) and therefore 
the complexation between Ho(III) and EDTMP is weaker due to steric hindrance. This 
allows citrate to compete more effectively for Ho(III) in blood plasma. It might therefore 
be worthwhile developing more suitable bone localising ligands for 166Ho which will have a 
similar biodistrubution as 153SmEDTMP. In this respect the choice of the radionuclide (of 
which the half-life and radiation emissions dictate its radiobiological effects) and the bone 
localising agent ( of which the biochemical properties dictate its pharmocokinetics and 
biodistrubution) determine the therapeutic success of the modality [37]. 
Computer simulation (ECCLES) was used to confirm results achieved with 153Sm- and 
166HoEDTMP as possible radiopharmaceuticals as had been tested in baboons [7]. 
Computer simulation may now be considered to be a screening method before pre-clinical 
and clinical trails. This research is useful as now it is not necessary to test all the available 
ligands with a radioactive lanthanide (normally this type of metal-ion has radioactive 
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isotopes that are suitable for radiation in humans) in baboon tests. It is expensive to 
manufacture the radioactive isotope and the required concentration of the injected metal-
ion can only be estimated. Unnecessary and expensive baboon tests (to which there is 
growing objection) are reduced. The minimum of baboon tests are now needed and the 
best concentrations are known beforehand. There is also the possibility of predicting side 
effects of the treatment in advance. In the case of 153SmEDTMP it was predicted that a 
stripping of Zn(II) out of the body via the urine would occur. This was later confirmed by 
urine tests. Patients may thus need to receive Zn additives while being treated with 
153SmEDTMP [7]. 
Another example where ECCLES was used is the previously mentioned article by Duffield 
et. al. [32]. ECCLES calculated the distribution of Pu(IV) in normal blood plasma 
showing that it complexes with citrate. The competition of the studied chelation therapy 
ligand with citrate for Pu(IV) gave an indication of how successful Pu(IV) would be 
mobilised from the blood and excrete it. Jones et.al. [28] investigated the mobilisation of 
cadmium from blood plasma using ECCLES. 
1.5 Research objectives. 
To assist in the understanding of the function of a ligand in blood plasma, its speciation 
may be calculated. The purpose of this thesis is to construct blood plasma speciation 
models for the three diphosphonate ligands, using the program ECCLES [3 5]. Various 
techniques were used to arrive at the constants needed. From the results achieved by 
ECCLES a ligand is chosen and tested together with 166Ho(III) as a radiopharmaceutical in 
the baboon model. 
The complexation of APD, MDP and HEDP with various metal ions was studied in 0.15M 
NaCl (the approximate ionic strength of blood plasma) and at 37°C [39]. The calculated 
formation constants assist in predicting the speciation of metal ions and the ligands in 
human blood plasma. Important metal-ions in blood plasma complexed by these ligands are 
Ca(II), Mg(II) and Zn(II), and these equilibria must be studied. The aim is to find a 
suitable ligand to complex Ho(III) and Sm(III) in blood plasma in such a way that it will 
survive competition from blood plasma ligands and release the metal-ion at the bone. The 
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formation constants of these metal-ions with each of the ligands are thus required to 
complete the blood plasma model. Because of reasons given below formation constants for 
the lanthanides fall beyond the scope of this thesis but will be completed at a later stage. 
The three metal-ions Ca(II), Mg(II) and Zn(II) and their complexation with the three 
ligands have been studied extensively in this work. 
1.5.1 Techniques used to derive complexation constants 
The main technique used in this dissertation for determining formation constants was 
potentiometric titrations. The data is fed to the library of computer programs, EST A which 
was written to fit the titration curve to a series of complexation reactions chosen by the 
user. From this the best protonation and complexation constants are calculated for a 
particular system [5]. For Zn(II), Ho(III) and Sm(III) precipitates formed between pH= 4 
and pH = 7. Potentiometry proved therefore to be inappropriate for the calculation of the 
complexation of Zn(II), Ho(III)and Sm(III) with these ligands. Another technique was 
required. 
Polarography is able to use lower concentrations of the metal-ion and thus avoids 
precipitation. It can measure low concentrations of metal-ions very accurately as well as 
the reduction potential by differential pulse polarography. With this technique two possible 
complexes are studied viz. labile or non-labile [38]. The data is treated on a computer 
program called ML-SPEC [38] or CV-FIT. From this the constants for Zn(II) with the 
three ligands were derived. 
A comparison of these two techniques was necessary to ascertain whether both gave 
similar results. A system in which no precipitate forms at the required potentiometric 
concentrations using a metal-ion that is polarographically active was studied. As Ca(II) 
and Mg(II) are not polarographically active, Cd(II) was studied with HEDP. 
1.5.2. NMR studies on the complexation sites involved in these ligands 
The three ligands chosen have the diphosphonate group in common. Starting with MDP, 
the most simple ligand, the idea was to study how a 'tail' will affect the complexation 
(APD), what effect the amino group has (APD) and what contribution the hydroxy group 
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makes to the complexation (HEDP). Potentiometry and polarography describe the 
thermodynamics of these systems in solution. These two experimental techniques do not 
describe the structure of the complex. An NMR-study on a complex may yield a 'visual' 
picture of the solution structures. This was attempted using 13C and 31P NMR. Ultimately 
we hope that answers to some of the questions posed in this thesis may lead to a 
radiopharmaceutical that will not only have pain palliation applications but also be useful in 
the treatment of secondary bone metastases . 
1.5.3. Layout of this dissertation 
This dissertation will be presented in the order of the five mam techniques viz. 
potentiometry, polarography with the comparative study between these two, NMR studies, 
ECCLES simulation and baboon studies. For each section the material will be reported in 
this order. The sections discussed will be Theoretical background, Experimental, Results 
and Discussion and Conclusion. 
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2. Theoretical Background 
2.1 Potentiometry as a tool to derive formation constants 
The measurement of metal-ligand formation constants is nowadays considered as almost 
routine although there are still difficulties involved in determination of reliable values [ 4 7]. 
Potentiometry is often used as a technique to calculate formation constants but the same 
chemical systems studied by different research groups often result in considerable 
discrepancies in their results. It is considered by some to be necessary to evaluate calculated 
constants by a second technique to verify the results. In this work polarography was used to 
support constants found by potentiometry. 
In this study the potentiometric data was analysed using the ESTA (Equilibrium Simulation 
by Titration Analysis) suite of computer programs as described by P.M. May et al. [47,48,49] 
ESTA imposes the conditions of mass-balance in the standard way by equating calculated total 
concentrations with real ( analytical) concentrations: 
(The meanings of the symbols are listed in Appendix Al) 
T[=~, I=l, ... ,NC 
where NJ NC 
~ = CX;1 + I: r1t)3JJ cxJjn 
j•I n=I 
The potential of the electrode can be written in the form 
Ek = E~ + Els + EP 









Unlike some programs [50,51] ESTA accommodates the well-known effects of interfering 
ions. It uses the Eisenman equation [52] ::s a basis to derive eq (6). It has the advantage that 
suitable choices for ex and Kki can be made. 
Liquid-junction potential 
"F4s = sk log[{Xk}l/<t + L (Kki{X;}'/z;)ll<t]<t 
i (6) 
Unlike [50,51] the liquid-junction term E~ is not taken constant but is derived from the 
Henderson equation as described by Biedermann and Sillen [53]. It has the form 
Ef' = -(RTIF)ln(I +d[XH]/1) 
(7) 
where I is the concentration of the background univalent electrolyte. This is used to correct 
for liquid-junction potential changes in the calibration of glass electrodes. The Henderson [54] 
equation ( eq 8), itself is used to predict potentials across junctions of different univalent 
electrolytes at constant ionic strength. 
(8) 
For the purposes of this dissertation there was no liquid-junction and it was therefore not 
necessary to employ this correction. 
Activity coefficients 
For the calculation of activity coefficients the most common extension to the Debye-Htickel 
formula has been used. 
-log y = Az2./l + cl 
1 + Ba./] (9) 
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Conversion into thermodynamic constants 
Equations (2), (6) and (8) require "thermodynamic" values of the parameters Pj, E~, Kki Af and 
A? i.e. those that are defined with respect to a standard state based on reactions occurring 
1' ' 
at infinite dilution in water at zero ionic strength. However, it is established practise to work 
with conditional constants ( Ipj, IE~, IKki IA;, IA~) which refer to some other ionic strength (I). 
The formation constants reported are thus conditional formation constants characterised by 
the medium in which they were determined. Such constants can be converted into the 
corresponding thermodynamic values in the following way: 
A.= IA.f1r. 
PJ PJ J 
Irj is defined as in eq. (4). Eq. (6) now yields: 
The supplied value of~ and the ion selectivity coefficients are converted into thermodynamic 
values as follows: 
The supplied ionic conductivities to be used in the calculation of~J are treated similarly: 
A~= IA~!1y~· A?= IA?/1y? 
1 1 1' 1 1 1 
Conditional constants are to be supplied by the program user. The same values (say, for 
electrode potential) are calculated for any point in the titration which actually has the 
reference ionic strength. 
Solution of mass-balanced equations 
The NC mass-balance equations (m.b.e.) eq.(1 ), can be solved for any NC unknowns as long 
as all the other parameter are known. There are NC free concentrations that can be 
determined. If one of the free concentrations has been measured experimentally, the remaining 
free concentration and one other parameter (such as um, ~ and 1'1 can be calculated. It 
follows that the procedure for solution of the m.b.e. falls into two categories. First the 
equations are solved for NC free concentrations without any reference to the electrode 
equaticr__ Next the electrode potential can be obtained by substitution into eq. (5), (6) and (9). 
In the second category, it is necessary to solve the electrode equation to obtain the free 
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electrode-ion concentrations, [Xk], (given an observed potential, &), before solution of the 
m. b.e. Solving the electrode equation for [Xk] requires a knowledge of all the free 
concentrations. It is therefore necessary to implement an iterative solution of this equation and 
the m.b.e. 
A Newton-Raphson procedure is generally the most efficient way to solve the m.b.e. The 
equations can be setup in terms of the absolute values of the unknowns except for the free 
concentrations, [Xk], and formation constants, ~, for which natural logarithms are more 
convenient. The equations can rapidly solved by forward and backward substitution. If a 
failure in the Newton-Raphson procedure occurs in those tasks for which the only unknowns 
are free concentration, the slower but more robust secant method [55] can be used to solve 
the equations. 
Initial estimates 
It is well known that the efficiency of the Newton-Raphson method is considerably improved 
if good initial estimates can be obtained for the unknowns. There are two classes of 
unknowns. The first is the free concentration of the components which have to be derived 
from the electrode equations otherwise they are difficult to estimate. Secondly, there are those 
unknowns which are experimental parameters such as total titrand concentration and titrand 
volume. Formation constants can also be included in this class. Generally it is possible to 
estimate reasonable initial values in this instance. 
At the first and second titration points, initial estimates for the unknown values of the second 
type are readily calculated from experimental values. Electrode potentials are available and 
initial estimates of the corresponding free electrode-ion concentration can thus be calculated. 
Initial estimates of all parameters at the third and each subsequent point of a titration are best 
obtained by linear extrapolation of the solution from the previous two points. This based on 
the change in electrode potential. 
This approach to simulate titration data is optimised by algorithms. Simultaneous optimisation 
of!\ parameters pp (where Pr may be pj, ~' sk, V0 , er, or CtJ is performed by minimising an 
objective function, U, defined as 
N n, 
U = (N _ )-1 '°' -I '°' (yobs _ calc)z nP L.; n. L.; wnq nq Ynq 
n=I q=I (10) 
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where y~~ and y~~1c may be either a T nq or an Enq· Weights are introduced by w nq [ 49]. 
The Gauss-Newton method is the most frequent approach used for minimising U, as is used 
in EST A In general, given good initial estimates and a reasonable well behaved system, the 
Gauss-Newton method described above performs extremely well. It often converges in 3-6 
cycles. Unfortunately the solution is sometimes obviously unsatisfactory (for example produce 
a shift vector with a upward gradient). If the shifts are not too excessive a Levenberg-
Marquardt [56] method may be applied to reduce them otherwise the program will terminate. 
When the estimates of the parameter being refined are judged to be sufficiently close to the 
solution., standard deviations of the parameters may be calculated from 
<J = [U x Grr]Yz 




Correlation coefficients can be calculated by using the formula 
Gsr 
r =---
sr (G G )Yz 
ss rr (12) 
and the Hamilton R-factor, RH, is given by 
u Yz RH= 
N nc L -I L (yobs)2 ne wnq nq 
(13) n=I q=I 








ESTA accommodates chemical systems ofup to 10 components forming up to 99 complexes. 
23 
Titrations involving up to three electrodes and three burettes are permitted. The program 
permits corrections of titration data affected by liquid-junction potentials and imperfect ion-
selectivity of electrodes. The ESTA library contains program modules, which perform one 
or more kind of calculations (specified as a different "task"). The modules that have been used 
will be described. 
EST Al: the simulation mode 
By setting up and solving the mass-balance equations, EST Al can determine, on a point-by-
point basis, single values for almost any titration parameter. The calculations fall into two 
categories: (i) species-distribution calculations and (ii) potentiometric titration calculations. 
The latter include determination of emf values, formation constant estimates, total analytical 
concentrations , initial vessel concentrations and initial burette concentrations. This program 
most commonly used to generate formation function values (task ZBAR), deprotonation 
function values (task QBAR) and protonation values (NBAR). ZBAR can be described as the 
number of ligands bound per metal ion at a certain pH value. QBAR is the number of protons 
lost by the ligand due to complexation taken at a certain pH value. NBAR is the number of 
protons bound per ligand at a certain pH value in the absence of complexation. These 
functions can be mathematically described as follows: (The meanings of symbols are listed in 
Appndix Al) 
The protonation formation constant is described as 
z = TH - H + OH 
H 
and the metal formation function is defined as 
TL - A(l + LPm Hn) 




where A = (TH - H + OH) IL Pm Hn. ZH is plotted against pH and z against pA = -log A, 
n n 
as can be derived from the equations 15 and 16. 
The deprotonation function is defined as 
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Q= (17) 
where T; is the calculated total concentration of protons in the system at the observed pH 
ignoring the presence of all metal complexes. The following two mass balance equations are 
solved forT; and TL. 
where p = 0. 
NJ 
T; = H - OH + L r[Mj,/f,] 
j•I 
NJ 




By using this program graphs can be drawn of pH vs ZH or Q and z vs pA where the 
observed and calculated functions can be compared andE;hs , Et1c evaluated respectively. If 
the calculated and observed curves match each other closely in the pH region of interest, the 
proposed model of formation constants can be accepted. n is used together with Q to identify 
species like MLOH at high pH values not included in the EST A2A model. 
ESTA2: the optimisation modules. 
There are two optimisation programs, EST A2A and EST A2B, differing only in the way data 
is weighted [ 49]. They are used when it is desired to determine, for one or more parameters, 
the "best" values, based on a least-square procedure applied to a whole system of titrations. 
In this way the following parameters can thus be refined: formation constants, vessel and 
burette concentrations, electrode slope and initial vessel volume. It is possible to group 
together, over any combinations of titrations, local parameters of the same type and with the 
same value so that they are refined together as a single parameter. 
The approach is to model with EST A2 the formation constants untill the best values for the 
standard deviations and Hamilton factors are reached. After this hurdle is crossed the 
proposed model of formation constants is tested by QBAR or ZBAR comparisons. 
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2.2 Polarography as a tool to derive formation constants 
Two types of complexes can be distinguished according to the polarographic time scale viz. 
labile and non-labile. Complexes that have a quick exchange rate between the metal-ion and 
its ligand if compared to the polarographic time scale are classified as labile. It follows that 
the polarographically active peak is that of the metal-ion. The peak height and shift in peak 
potential as compared to different pH values is observed. For non-labile systems the exchange 
rate between metal-ion and ligand is slow relative to the polarographic time scale. What is 
observed is the peak corresponding to the reduction of the complex if polarographically 
active. The peak height is a function of the concentration of the active redox species which 
is characterised by a peak potential. Thus as the pH of the solution is changed the 
concentration of the species present in the solution changes and this change is reflected in a 
change in the polarographic peak height. The peak height as compared to pH values as well 
as the peak potential is observed. The pH region where the particular complex is predominant 
will show the peak height small at the lowest pH of this region, will rise to a maximum as the 
pH increases, decrease again and finally disappear. A new peak corresponding to another 
complex is now formed. 
The computer program :ML-SPEC and its update, CV-FIT, was written by Cukrowski and 
co-workers [38, 102] to treat the polarographic data and calculate formation constants from 
it. The programs calculate formation constants for complexes that are labile as described 
above. 
Labile complexes 
The program ML-SPEC is able to treat a system in which more than one ligand is co-
ordinated to a central metal-ion and where there is a region of pH in which one complex is the 
predominant species present in the solution. To do this the Lingane equation [57], at 25°C, 
VlZ. 
(E ) _ (E ) "' 0.0591 / K _ . 0.0591 l C y. C y. s og C J og X 
n n 
(1) 
was used in a modified form (the subscripts "c" and "s" refer to the complex and free metal 
ion respectively). For CV-FIT, which calculates labile and non-labile complexes together the 
shift in in peak potential (Eq. (1)) caused by the formation of metal complexes and can be 
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calculated as follow 
fiE - E (M ) - E (M ) - ( RT) 1J MFre.(I) ca(2) I 
P - P Free P Comp - nF Xu\ MFree(2) X ca(l) 
(2) 
If the reduction current is sampled at a fixed interval of a mercury droplife-time then ca(2) / 
ca(l) can be replaced by ip(Mcomp) / ip(MFree)· For the ith pH(i) value the term MFreeO) can be 
substituted by M/i) because MFreeO) is equivalent to the total metal ion concentration Mii) 
at each pH(i) value of the solution after ith consecutive additions of sodium hydroxide in the 
absense of complexes. Eq. (2) can thus be rearranged to the folowing 
!iE (i) - ( RT) x J i/Mcomp)(i) l = ( RT) x J M.JJ) l 
P nF u1 i/MFre.)(i) nF u' MFre/i) (2a) 
However the program ML-SPEC, used to generate initial values for CV-FIT, is used where 
protonated complexes are formed and where one such complex will be the predominate 
species in a particular pH region, the equilibrium may be written as has been done previously 
M + JL + bH .. ML]Ib 
and the Lingane expression can be readily expanded to: 
/iE _ RT 1n [~J = RTln R + .RT 1n [L] + bRT 1n [H]. 
peak nF i nF t'MIBb 1 nF nF (3) 
s 
In this equation ( expanded for general use and not only for titration point i), M represents the 
metal-ion, L the ligand and the brackets denote molar concentrations as the experiment is 
performed at constant O .15 mol. dm-3 ionic strength ( charges on ions are omitted for simplicity 
as well as the subscripts "c" and "s" used which refer to the complexed and free metal ion 
respectively ). ~Epeak is the difference in the DPP (Differential Pulse Polarography) peak 
potentials between the simple metal-ion and the complexed ion. RT/nF has the usual meaning 
and is and ic represent the peak currents for the simple and complexed metal-ion, respectively. 
Eq. (3) still holds if hydroxide is considered as a ligand and [H] is thus replaced by [OH] in 
(3). If complexes of the form ML1 are being considered, b becomes zero and Eq. (3) simplifies 
to the usual form of the Lingane equation. This approach is similar to that used by Fisher and 
Hall [58] although the program ML-SPEC and especially CV-FIT is extended to present 
graphical representation of achieved results as well as the capability of comparing calculated 
peak potential curves, for a chosen model, with the real peak potentials. (Almost like Zbar 
curves for potentiometry). From this fit, a standard deviation can be calculated. 
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By substitution and rearranging Eq. (3) as has been done in [59] the complexation constant 
for a chosen complex species (fixed} and b values) can be calculated for each data point (Eq. 
5). 
ilE _ 0.06154 l { ic) 
peak O . 
n ls 
0.06154 l n. .0.06154 l [L] _ b 0.06154 ff og..,MLH + J og P 
n ;-b n n (4) 
which gives 
log~"'fl• c lo{~) , j log[LJ ·· b pH · o.0:154 (<lli,,..J (5) 
The value for log[L] at a certain pH is calculated from the known pKa values for the ligand 
by the general equation : 
(6) 
If the constant calculated by Eq. 5 holds in a certain pH region, the complex formed is 
probably as chosen. This is further confirmed by graphical representation of the shift of the 
polarographic peak as a function of calculated free ligand concentration and of pH. This also 
helps in the interpretation of the electrochemical processes occurring at the mercury micro 
electrode and in identifying the complex species within a certain pH region. Complexes are 
identified from the slope of the graph representing potential shift against pH which is given 
in m V per pH unit. In such a given region the predominant form of the ligand is known and 
the shift in potential is visible as the slope of the graph. At 37 °C the term RT/nF is equal to 
about 61.54 mV, and since the number of electrons involved in the reduction of the M(II) 
species (where M(II) represents Cd(II) or Zn(II) ) at the mercury drop is two, the slope 
should be 30.8 mV per pH unit per proton involved in the reaction. If the slope is 61.5 mV 
a proton transfer of two would have been proposed for the electrochemical process taking 
place. From the above gathered information the complex can be deduced out of the general 
equation of the reaction occurring at the electrode: 
(7) 
The amount ofligand per metal ion is taken as one for simplicity. The way to proceed is from 
right to left. ML~r2 is the unknown and can be found by substituting x, y (number of 
protons involved int he titration) and n ( charge on a deprotonated ligand). Equation 7 will 
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now reveal the reaction taken place at the electrode. In support of the found result a Lingane 
approach can be used. The slope of 6.Epeak vs log[L] in this pH region should exhibit a 
constant value of 31 m V per log[L] unit, which would indicate the formation of a metal 
complex involving one molecule of the ligand only [38]. 
Non-labile complexes 
The first section of ML-SPEC deals with non-labile complexes according to the polarographic 
time scale. Two peaks are observed on a polarogram at the same time at a particular pH value 
of the sample solution studied. The concentration of the complex is calculated from the 
decrease in the polarographic peak height for the metal ion, since 
(8) 
According to Cukrowski et al. [60]. I represents the ith polarogram with two peaks observed, 
that of the metal ion and its complex. Cif tot is the total metal ion concentration in the ith 
solution on which an ith polarogram was recorded, ~ is the concentration of the complex 
MxLrHz (negative Z values represent hydroxide ions) and c~ is the concentration of the 
hydrolysis product of the metal ion i.e. the species MxHz. The concentration ofligand c~!01 not 
bonded to the metal ion is calculated from 
(9) 
At each pH value and thus for each polarogram, a trial concentration of free ligand dL is 
calculated from 
(10) 
where Ki, Kz, ... represent stepwise protonation constants for the ligand. Trial concentrations 
of free metal ion, c:i and of the complex~ are calculated. From this a trial value for the 
formation constant is obtained. 
•i 
CMT H, P: = ___ ,..,_y_·_ 
(cs·Y(c{l(H i)2 
The appropriate mass-balance equations are solved 




LTotal = Lfree + [YMxLyHz (13) 
for metal-ligand complexes thought to be present in the solution. The calculated formation 
constants and known formation constants for complexes are incorporated. The known 
constants are kept fixed during solving of the mass balance equations. Corrections for 
hydrolysis of metal ion is allowed during the iteration to find the best values for the trail 
formation constants. The latter normally applies to high pH values. 
2.3 NMR studies of complexes 
Over the years the study of complexation by NMR techniques has proved to be very useful. 
For example, for DTPA, the determination of the sequence ofprotonation on nitrogen and 
carboxyl sites was contested by Langer [61] and Sawyer [62]. Sawyer proved by using NMR 
that nitrogen sites were protonated preferentially before the carboxyl groups. 
The approach of such a study is to titrate a ligand or complex in its deprotonated form with 
acid and record NMR spectra at various pH values. The observations made, are related to 
shifts in various peaks corresponding to a C-, H- or P-atom in the ligand. If enough data 
points are gathered the order of protonation can be followed, the structure of the complex 
found and even an estimate of the protonation or complexation constants in favourable 
systems may be determined. 
To a first approximation one can assume that the chemical shifts for a proton, carbon or 
phosphorous atom will be affected mostly by a change in chemical environment occurring only 
one bond length away. It follows that the position of a proton signal can be given ( at any pH) 
by eq. 1 
(1) 
where NA, NB, oA and oB are, respectively, the mole fractions (N) and the chemical shifts (o) 
of the protonated (A) and non-protonated (B) forms. Therefore the basic oB's can be taken 
at pH= 12 and oA at pH= 2. The fraction (f) of time that a particular site is protonated can 
be defined as 
(2) 
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where i refers to the various donor sites, for example, two different nitrogen atoms and two 
different carboxyl groups. 
In following the chemical shifts of a particular signal one finds a point of inflection where o 
= l/2(oA + oB) or where the concentrations of the protonated and non-protonated forms are 
equal. Here it is possible to calculate the dissociation constants, because if in general 
(3) 
then pl<..= pH (since NA= NB). Similarly the NMR data can be used to calculate the formation 
constants for protonated complexes do in most cases. If the formation constants for example 
ML, MLH and MLH2 are not separated by more than two log units the NMR technique for 
log K determination will fail [ 63]. 
The structure of a complex or possible structures for a complex can be determined if the atom 
on the ligand which is bound firmly to the metal ion can be distinguished. This will generally 
be where the biggest shift in NMR peak will occur. 
Some cases are unclear even where it is possible to assign pKa values to different protonation 
sites. For example the three carboxyl-carbon resonances (13C NMR) in citrate [64] were found 
to shift in unison, i.e. there was no preferred site of protonation. In determining a structure 
of such a ligand complexed to a metal ion the spectra at low pH (no complexation) and high 
pH ( where complexation has taken place) are recorded. A ligand to metal ratio of 1 : 2 is 
taken to ensure complexation is complete.Most of the times it is possible to point out, from 
the differences in the spectra before and after complexation, the peaks most effected by the 
complexation. In this particular case one of the carboxyl groups (the central carboxyl group) 
is unaffected by complexation and is therefore not participating in it. Further deductions about 
the structure of the complex depend on the proposed structures of the complex and will differ 
according to the system studied. 
Phosphorous-31 NMR can also be used to study complexation phenomena. Since the ligands 
discussed in this dissertation have diphosphonate structures,useful information may be 
obtained. As example the complexation ofNTMP (a nitrilo-triphosphonate) as described by 
Sawada et al. [65] is taken. The spectra ofNTMP at pH values below 12 show only one peak 
on the 31P NMR. Since NTMP has three phosphonate groups this fact indicates that the 
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proton 1:xchange ofNTMP is very fast. The three phosphorous atoms ofNTMP are averaged 
and the chemical shift given by 
(4) 
where c\ andXHJ, are the chemical shift anrl the proportion of each protonated or unprotonated 
species, H,,L (n = 0-5), respectively. By the use of the protonation constants, the individual 
chemical shift c\, was evaluated by non-linear regression. These q values are plotted as a 
function of the number of protons bound to the ligand, n. For the complex formation the same 
is done and the pattern and pH dependence of c\ is found to be similar. The chemical shift of 
the metal-ligand solution is written by a non-linear combination of the chemical shifts of each 
species present in the solution as 
(5) 
where om and XMHJ, are the chemical shift and the ligand proportion of protonated and 
unprotonated complex, MH,,,L, respectively. The chemical shift of each species of a complex, 
om was evaluated by linear regression. Th~:.;e chemical shifts of complexes, om are also plotted 
as a function of the number of protons, m, bound to the complex MHmL. From this the 
formation constants are evaluated. In both the protonation and formation constant values 
good agreement with potentiometry was achieved. 
Not only the chemical shift but also the broadening of an NMR peak can be used in 
interpr~ting the structure of a complex. In the case ofNTMP [65] the 31P{1H} signal of the 
metal-ligand 1: 1 mixture becomes quite broad in the region of the pH jump where ML and 
MLH are predominant. The broadening is largest at pH= log KMLH where [ML]= [MLH]. 
However the ligand shows a sharp 31P NMR shift in the whole range of pH. The broadening 
of the M:L = 1: 1 solution in this pH region is interpreted in terms of a slow protonation 
equilibrium of the metal complex, ML + H ~ MLH, and will suggest a drastic change in the 
proposed structure of the complex. Under these conditions (M:L = 1: 1 ), some portion of 
NTMP dissociates into free ligand. It was, however, confirmed by studies of solutions 
containing an excess of metal ion (M:L = 2: 1) that the dissociation of the complex , ML ~ M 
+ L, had little effect on the broadening of the signal. On the other hand, sharp signals indicate 
fast protonation equilibria and a different structure. 
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To conclude, a rapid and simple method of visualising the bonding mode of trivalent metal 
ions to ligands is by using Gd(III) as a line broadening agent in proton NMR spectra. Jarvis 
[66] used this approach to show that bonding of DHDECMP (dihexyl-N,N-
diethylcarbamoylmethylene phosphonate) to trivalent metals is via the phosphoryl and not the 
amide centre. Being a highly paramagnetic, symmetrical metal ion, Gd(III) broadens but does 
not shift NMR peaks.The closeness of the proton(s) to the metal ion is in this case a function 
of the extent of the broadening. A comparison of the proton spectra of the ligand without the 
shift reagent with that of the Gd(III)-DHDECMP complex revealed the protons near the 
complexation centre and delivered the required result. 
2.4 ECCLES modelling 
Peter Letkeman [67] said "Have you ever wondered what it would be like to wear a 'virtual 
reality helmet' and so experience the microcosmic world of ions in solution?". This is what 
computer-modelling of metal speciation in human blood plasma does. It might not be a 
physical picture but it gives the bioinorganic chemist, by means of numbers, a snapshot of 
what is happening with the metal ions in the blood. It is a complex scene. It is known that 
human blood plasma contains 20 essential amino acids, 12 essential metal ions, at least another 
100 ligands, numerous low molecular weight [LMW] complexes as well as alp macro-
globulins such as albumin (complexes Z: 1 very efficiently).The absolute concentrations of 
metal complexes in blood plasma is determined by protein binding, but not the percentage 
distribution of transition metal ions amongst low molecular weight ligands [68]. 
Computer simulation of speciation calculations are important to show whether a metal ion or 
its complex will be toxic. The relative concentrations of toxic compounds can be found 
because of the mathematical ability of these simulations which have no limits to the 
concentrations employed. No detection limits and disturbance by instrumental techniques can 
hinder the process. The ability to handle all the metal ions and ligands at once was a limit until 
D.R. Williams et al. introduced ECCLES (evaluate constituent concentrations in large 
equilibrium systems) [69]. It can handle up to 50 metal ions and 100 ligands simultaneously 
and produces the exact concentration of each complex in order of decreasing concentration 
and relative percentage of each component. The algorithm used to get these concentrations 
is as follow: 
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ECCLES algorithm. 
It is required to find the free concentrations of the components (metal ions and ligands) in a 
multi component metal-ligand system at equilibrium. The concentration of each complex 
species is determined according to eq. 1. (the meanings of the symbols are listed in 
s. = A_ rr xkf..i,J) 
) t') . I 
(1) 
I 
Appendix A2). An iteration process of the free concentrations improves the estimates until 
they satisfy the mass-balance equations for each component viz. 
Ti = :~i + L Si k(i, }). 
j 
A variety of optimisation techniques can be applied to the problem. A successive procedure 
of some of these techniques is followed 
The first few iterations employ eq. 2. 
(2) 
Where G'= II(Ti,!Tic)kf..iJ)f(Tm,/Tmc) 
J i 
and is an approximation for G=II<X; ,/Xi c)kf..iJ)f(Xm,/Xm c) 
I 
These first few iterations rapidly produce values in close proximity of the final solution. 
However the number of iterations is the limiting criterion here. Because of its vast number of 
computation needed, it is not employed exclusively. Once the application of eq. 2 is completed 
the program moves into an intermediate phase. The expression now used is that of Perrin and 
Sayce [70], rewritten as eq. 3 
(3) 
It is used solely and uses considerably less computation time. As the solution is approached 
there is a fall off in convergence rate, as is usual with many successive-approximation 
techniques. At this stage eq. 4 is used to improve the rate of convergence in the final stages. 
(4) 
This completes the three-tier successive-approximation procedure which gives rapid 
convergence, but at the same time keeping the computer core-store requirements low. 
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Program description 
Most constants for complexation of metal ions with amino acids and low-molecular-weight-
complexes have been fed into the program by the authors [69]. These constants were found 
in the literature although corrections for ionic strength were employed using Debye-Hiickel-
type and van't Hoff-type extrapolations for temperature corrections. For other published 
constants, for which different values were reported, the authors took the average after critical 
evaluation. The constants that were still missing when the program was written were 
estimated using a variety of methods. These were based on linear free-energy-relation 
principles like the extension proposed by Sigel [71], the Irving-Williams rule, and educated 
guesses based on the authors' observation of chemical analogies. In the computation of the 
distribution of the metal ions other than Ca2+ among the low-molecular-weight complexes a 
range of plausible free concentrations for each, which bracketed an estimated average value, 
was taken [69]. Since mixed-ligand (ternary) complex formation occurs widely in systems 
containing metal ions and two or more different ligands [72] as many as possible ternary 
constants have been included in the program. Because of the expected dominant role of these 
complexes, estimates of a further 4000 ternary constants were made, employing relevant 
binary constants and stabilisation factors . . u order to correct the ternary constants, which had 
been experimentally measured, for physiological conditions, a scaling operation was 
performed with each respective stabilisation factor using eq. 5 [73]. Here, ~logpMAB(model) 
is the scaled stabilisation factor applicable to the model (i.e. physiological) conditions 
[ 
PM4 (model) . PMB (model) 
LllogpM4B(model) = LllogpM4B(expt.) 2 2 
PM4 (expt.) . PMB (exp!.) 
2 2 
~logpMAB( expt) is the observed scaling factor [7 4] obtained under non-physiological 
conditions = logpMAB( expt) - Yz[logPMA2( expt) + logp.MBz( expt) - log2, PMAB is the formation 
constant of the ternary complex, MAB, formed between a metal, M, and two ligands, A and 
B, PMA2 and P.MBz are the cumulative formation constants of the binary complexes, MA2 and 
MB2. (expt) refers to experimental constants determined under non-physiological conditions 
and (model) applies to formation constants measured at or corrected to model conditions. 
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The procedure first invokes the program MIX to prepare input data for the program 
ECCLES. The user defines the system in terms of its components and their respective 
concentrations and MIX generates the intermediate data file by performing three tasks. These 
are (i) the selection of the applicable binary formation constants for the system in question, 
(ii) the calculation of formation constant estimates for all ternary complex species that may 
be assumed to exist according to the chosen binary formation constants and (iii) the 
substitution, adjustment or extension of these constant estimates in respect of those for which 
experimental data has been collected. The MIX program produces an output file that becomes 
the complete input for ECCLES. ECCLES is run and delivers the relative concentrations of 
all species at equilibrium. 
2.5 Baboon tests with 166Ho-APD 
Baboon tests are carried out to validate the predictions made by ECCLES and as a precursor 
to clinical trails. Baboons are widely used as analogues for humans due to their similar 
physiology [ 46]. The in vivo distribution of a radionuclide can only be predicted to a certain 
extent by ECCLES. To see if the comple)~ indeed survives blood plasma, is not filtered by the 
liver ( colloids can be retained by the liver) and its bone uptake is as predicted can only be 
done with a human analogue [ 46]. 
Lin has showed in his review article on diphosphonates [75] that the binding of alendronate 
( 4-Amino-1-hydroxybutylidene-diphosphonate) in other words ( ABD) to serum albumin is 
calcium-dependant. The binding to albumin helps in the transport of the diphophonates to 
bone tissue. This would imply that the addition of Ca(II) is necessary as proved to be the case 
with other drugs such as pamindronate (APD) used as a anti-osteoporosis agent. However 
the amount of APD needed in our case is only IE-05 M which is orders of magnitude smaller 
than that used for the above drugs. For the baboon test it was decided not to investigate the 
calcium-dependence. 
The preparation of the sample for the test has to be done carefully since these tests are 
expensive and the time available for them limited. It has to be shown that the solution to be 
injected into the baboon is indeed fully complexed [43] using ECCLES at first at the 
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theoretical level. To show complexation on laboratory scale, two techniques are employed. 
The first is thin layer chromatography. The chromatographic plates are not developed but 
merely scanned on a radioscanner which detects the patterns of activity across the 
chromatographic plate [ 44]. 
The second method is liquid chromatography on a sephadex column. Sephadex is a 
polysaccharide resin which is employed as a mild ion-exchanger. It has the advantage that it 
does not denature proteins as other ion-exchangers do. Carboxymethyl Sephadex retains free 
metal ions like 166Ho. A packed column of this resin contains carboxy groups to complex the 
metal ions. By keeping the free metal ions and letting the complexed ions go through, the resin 
can show how complete the complexation is by the following equation [ 45] 
o/ I · Id 100 [l Isotope activity after elution ] 10 comp ex y1e ~ x -----"----'---~---
Isotope activity before elution 
The next step is to validate a new drug on well-established experimental animal models e.g. 
baboons. The baboon is phylogenetically close to humans and therefore permits more 
meaningful extrapolation of results [46]. Because the animals are large, a good model for use 
in nuclear medicine techniques can be achieved. All parameters of human physiology can be 
measured in the baboon model, from circulation (through e.g. arteries and the heart) to 
skeletal uptake. Some categories of research on the baboon model are as follows [ 46]: 
i. Cardiology studies, where it finds application in the Wolff-Parkinson-White syndrome [76]. 
ii. Septic shock, where microvascular plasma leakage is detected [77]. 
iii. Detection of inflammatory lesions by scintigraphy and skeletal uptake of radiological 
cancer drugs [ 46] and various other studies. 
The baboons available at the H.A. Grove Research Centre of the Department of Hospital 
Services are chacma baboons (Papio ursinus). The protocols prepared for research projects 
are screened by an internal ethics committee in accord with the legislation pertaining to the 
use of vertebrates in biomedical experiments. The centre only excepts research of a high 
standard and which is aimed at human and veterinary advancement. The centre supplies 
veterinarians which assist in the supporting procedures and the well-being of the animals [46]. 
The research animals are captured from private farms or nature reserves where they are 
considered problem animals. The baboons are numbered, blood evaluated, checked for 
infections, dipped in insecticide and placed in quarantine. After it is established that there are 
no heart abnormalities an ideal healthy biomedical research animal is available and housed in 
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an individual cage to avoid fighting [ 46]. 
Prior to an experiment the animal is tranquilized and brought from its cage to the preparation 
room where the appropriate anaesthesia is administered and a endotracheal tube inserted. The 
baboon is injected with a sterile solution which has a pharmaceutically acceptable 
composition. The dosage of radionuclide is at least 0.2 mCi per kilogram of body weight of 
the baboon [ 43]. This gives a figure of a.Lout 3 to 4 mCi per animal per injection. Fluids are 
routinely given through an intravenous cannula. The animal is unconscious for a few hours 
and kept under narcosis while the distribution of the activity is studied by y-scintography. 
Kinetic studies are performed at the same time taking blood and urinal samples to understand 
more of the biodistribution of the radioactive drug. After completion of the experiments the 
animal is transferred to the postexperimental observation room where they are monitored and 
in due time discharged by a veterinarian. 
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3 Experimental 
3.1 Synthesis of APD 
The synthesis of 1-hydroxy-3-amine-propilylidenediphosphonic acid (APD) was based on 
the method of Worms et al [40]. 95 ml (1 mole) of POCb was added to a three-necked 
flask containing 82 g (1 mole) of crystalline phosphorous acid (H3PQ3). The mixture was 
stirred magnetically in a closed vessel for one hour in order to dissolve the acid. The flask 
was then fitted with a mechanical stirrer. AT-shaped glass rod was used as the stirring bar 
instead of an ir011 bar because of the HCl gas that is formed in tht: reaction. Care was also 
taken to protect the stirring apparatus from these corrosive gasses. To the solution 
prepared above, 41g (0.5 mole) of ~-Alanine was added portion-wise while stirring fast 
with the mechanical stirrer. Each portion was added quickly to minimising the amount of 
HCl escaping. After the addition the sticky mixture was stirred at 98°C for 4 hours. A 
white foam was produced after which the mixture was stirred for an additional hour. Care 
was taken that the foam did not turn yellow because oflocalised heating. After stirring was 
complete, the flask was transferred to an ice bath where the product was hydrolysed with 
300 ml of water. This reaction is exothermic and addition of water had to be done slowly. 
The resulting solution was transferred to a beaker and evaporated to 200 ml. It was cooled 
and left overnight in the freezer to crystallise. The c1 ~ stals wlr.ch formed were washed 
with a cold methanol/H20 (1:1). The mother liquor was kept as precipitation continued 
while being ker,i in the freezer. 23 g (20 % ) of product was collected in three fractions 
_which all had a melting point of 231-23 2°C as has been reported [ 40]. 
To verify that the product synthesised is indeed APD, a double CHN analysis was 
performed on a few milligrams of the compound. The results are presented in Table 1. The 
calculated % of C,H and N, according to the chemical structure of the ligand, and the 
experimental results are similar enough to except APD as synthesised purely. 
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Table 1. CHN analysis of APO 
For the other two ligands used, HEDP and MDP, a similar analysis was performed. The 
results are given Table 2 and 3. Both were acquired commercially and dried prior to 
analysis and use. 
Table 2. CHN analysis of HEDP 
Table 3. CHN analysis of MOP 
To find whether the correct concentration of ligand was reported a potentiometric analyses 
was carried out. Results for the various ligands are displayed in Table 4-6. The ESTA2A 
input files used to calculate these values are included in Appendix B2. 
Tables 4-6 show that experimental values for the concentration of the ligands match the 
potentiometric calculated values. The experimental concentrations in all three cases were 
thus accepted. 
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Table 4. Results of the potentiometric analysis of APO. 
it;§timtnf~:iir 
0.0010228 ± 0.0000055 470 . 0.0107 
0.0011905 0.0011874 ± 0.0000061 
0.0018367 0.0018404 ± 0. 0000064 
Table 5. Results of the potentiometric analysis of MOP 
0.0010239 ± 0.0000025 600 0.00593 
0.0011929 0.0011906 ± 0.0000027 
0.0018404 0.0018388 ± 0.0000030 
Table 6. Results of the potentiometric analysis of HEOP 
1Jt1@n,1n1 :1:::!i:l:l!i'=imniiii I 1 
0.0010190 ± 0.0000010 600 0.00235 
0.0011905 0.0011810 ± 0.0000011 
0.0014894 0.0014876 ± 0.0000012 
3.2 Potentiometric Titrations 
Potentiometric titrations for Ca(II)-, Mg(II)-, Zn(II)-, Ho(III)- and Sm(III)-L systems 
(where L represents the three possible ligands viz. APD, MDP and HEDP) as well as the 
Cd(II)-HEDP system were controlled by a Metrohm Titroprocessor 670 using a Metrohm 
665 Dosimat and a combination glass electrode (Ag-AgCl reference). Electrode constants 
were calculated regularly using strong acid-strong base titration data. All titrations were 
performed under inert atmosphere using high purity nitrogen gas. 
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Solutions were held at a constant ionic strength of 0.15 mol.dm·3 NaCl and at a 
temperature of 37.0 ± 0.1 °C. The titrations were performed beginning at low and ending 
at high pH, adding 0.10 cm3 aliquots of 0.050 mol.dm·3 NaOH (carbonate-free to avoid 
complexation of the latter with any of the metal-ions) in 0.10 mol.dm·3 NaCl. Protonation 
constants for each of the three ligands were calculated from data obtained from titrations 
of the ligands in the presence of various hydrochloric acid concentrations. These 
protonation constants were held constant in the metal-ligand titration data modelling. 
Three different metal:ligand ratios were used for each system. 
The different compositions of the titration solutions are reported in Table 7-9 
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* Solutions made up as follows: 0.0181 M CaCl2 in 0.11 M NaCl, 0.0202M MgCl2 in 
0.11M NaCl, 0.0209M ZnClz - 0.11M NaCl, 0.022M SrCl2 in 0.11M NaCl, 0.026M SmC'3 
in 0.05M HCI and 0.025M M NaCl and 0.027M HoCl3 in 0.0476M HCI and 0.025M NaCl. 
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* Solutions made up as follows: 0.0181M CaCb in 0.11M NaCl, 0.0202M MgCb in 
0.11 M NaCl, 0.0178M NiCb - 0.11 M NaCl, 0.0209M ZnCl2 in 0.11 M NaCl, 0.026M SmCl3 
in 0.05M HCI and 0.025 M NaCl and 0.027M HoCl3 in 0.0476M HCI and 0.025 M NaCl. 
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* Solutions made up as follows: 0.0181 M CaClz in 0.11 M NaCl, 0.0202M MgCl2 in 
0.11M NaCl, 0.0214M CdCl2 0.11M NaCl, 0.0209M ZnCl2 in 0.11M NaCl, 0.026M SmCl3 
in 0.05M HCI and 0.025 M NaCl and 0.027M HoCl3 in 0.0476M HCI and 0.025 M NaCl. 
The titrations were monitored for possible precipitates that might form in some of the 
systems. The pH region at which these precipitates occurred was noted and the 
corresponding data points ignored in further calculations. Data collected in non-precipitate 
pH regions were analysed by the ESTA library of programs [41]. Hydrolysis constants and 
pKw were taken from the literature [ 42] and held constant during optimisation procedures. 
The model obtained for each system was tested for plausibility by comparing experimental 
and calculated formation and deprotonation curves. 
Reagents.-Three ligands were used. APD was synthesised as described above, ~p and 
· HEDP were obtained commercially. All three were dried at 90 °C and were found to be 
pure by (microanalysis see results above). Solutions of the ligands were made in 0.15 
mol.dm-3 NaCl by weighing dried amounts of ligand. Stirring for an hour ensured that all 
of the ligands (APD dissolves very slowly) dissolved in this medium. Fresh metal-ion 
solutions were employed in the titrations. These were made by dissolving reagent-grade 
chloride salts of the metal ions in distilled water and standardised by ICP atomic 
absorption spectroscopy. Where necessary, solutions were acidified to prevent hydrolysis. 
Fresh solutions of the titrant viz. 0.050 mol.dm"3 NaOH in 0.10 mol.dm"3 NaCl were 
regularly made using Merck titrisols. These solutions were made under inert atmosphere to 
avoid carbonate formation. 
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3.3 Polarographic titrations 
Differential pulse polarograms were obtained with the use of an EG&G Princeton Applied 
Research Potentiostat/Galvanostat Model 273. A multimode electrode Model 303A 
SMDE was employed as the working electrode and used in the dropping mercury 
electrode mode with a drop time of 1 s. A Ag-AgCl electrode and a platinum electrode 
(both EG&G PARC) were used as reference and auxiliary electrodes, respectively. A pulse 
height of 50 m V and a step height of 4 m V were used. The pH of the solution was 
measured to within 0.002 pH units with the use of a Beckman <1>72 pH meter and the 
corresponding combination glass bodied electrode (saturated calomel). The normal set-up 
of the Model 303A was modified to contain the pH electrode as well as the glass reaction 
vessel to have a water jacket. The temperature was thus controlled at 37 °C within 0.1 °C. 
As with the potentiometric titrations the solutions were kept at a constant ionic strength of 
0.15 mol.dm-3 NaCl. High purity argon was used for deaeration of sample solutions. 
In a typical titration the polarographic cell contained metal-ion, Cd(II) or Zn(II) at 10-5 M 
in 0.15 mol.dm-3 NaCl. The pH was lowered with hydrochloric acid to the starting value of 
pH 2. The reference potential and peak height of the metal-ion were established in this 
medium. The ligand ( one of the three used in this dissertation) was introduced by addition 
of a standard solution to give three different ligand:metal ratios in the range of 3-100: 1 in 
order to establish the correct speciation model. After recording a polarogram, the pH of 




















































































* Solutions made up as follows: 0.0209M ZnCb in 0.11M NaCl and 0.0214M CdCb in 
0.11M NaCl 
the solution was adjusted upwards in steps of about O .100-0 .200 pH units, by addition of 
NaOH (0.15 mol.dm-3) solution from an Eppendorf micropipet graduated to 0.1 µl, and a 
new polarogram recorded. In this way a set of between 40 to 50 polarograms of the 
species present in the solution was obtained as a function of pH. Polarograms of the metal-
ion alone were also run in a similar way to identify possible metal hydroxide-species. 
Equilibrium for the metal-ligand solutions occurred within a few minutes. 
A computer program .ML-SPEC [38] and CV-FIT was used to calculate formation 
constants from the polarographic data. The section of the program used for Zn(II) and the 
lower pH regions of Cd(II) is that which deals with complexes which are labile on the 
polarographic time scale. Only one metal-ion peak is observed and the shift in peak 
potential as a function of pH is used to calculate the formation constant for a dominant 
species in a certain pH region. In the Cd(II)-HEDP system at high pH values, non-labile 
complexes are formed and are dealt with in another section of the program that calculates 
the formation constants from the appearance of a second peak (the non-labile complex 
under investigation). The composition of the titration solutions are listed in tables 10 to 12. 
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Table 12. Composition of experimental solutions for polarographic studies with MOP. 
Metal ion 
0.15M solution O.OlMMDP 0.15MHC1 
Cation Titration NaCl (ml) (µ!)* (ml) (ml) 
Zn(II) 1 50 10 
2 56 10 
3 63.5 10 
4 5 50 5 
5 5 97.8 5 
6 7 40 50 0.7 
* Solutions made up as follows: 0.0209M ZnC'2 in 0.11 M NaCl 
3.4 NMR studies 
Stock solutions of 0.05 mol.dm-3 HEDP and 0.05 mol.dm-3 MgCh both in 99.7% D20 
were prepared. D20 was used so that 
1H NMR spectra of the ligands and complexes 
formed could be obtained. However due to a fast exchange rate of the hydroxy-hydrogen 
on the ligand with the D20 it was impossible to study the hydroxy-group's influence on 
complexation by 1H NMR. The ionic strength of these solution were adjusted to 0.15 
mol.dm-3 NaCl by addition ofNaCl salt. 1 cm-3 samples were made in two series. The first 
series contained only the ligand adjusted to various pH values by O .15 mol. dm-3 Na OH 
also in D20. The pH values were chosen according to the species distribution obtained 
from protonation constants for HEDP. The second series consisted of solutions where 
ligand and metal solutions were mixed in the ratio 1: 1. The pH values of this series were 
chosen by the species distribution diagram obtained from the formation constants for the 
system Mg(II)-HEDP. Where precipitates formed these solution were rejected and the 
data in that pH region could not be collected. 
For clear (no precipitate) solutions 31P and 13C NMR spectra were run on a 400 MHz 
Brucker Avance DRX400 spectrometer. Spectra were recorded at 37 ± 1 °C. 31P chemical 
shifts were measured relative to an external orthophosphoric acid reference. D20 was used 
as internal reference for 13C. For the 31P NMR spectra the number of scans taken with the 
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ligand alone were± 60 but for the complex± 200. The corresponding figures for the 13C 
NMR were 400 and 4000. The latter is a time consuming procedure. To fit in with the 
little time available it was thought to increase the concentration of the ligand and metal-
ion, fourfold which would reduce the number of scans 16 times. However at these elevated 
concentrations more precipitates were formed especially in the pH region of interest viz. 6-
8. 5. 
The D20 used in these experiments had a purity of 99. 7 % and was double distilled to give 
a conductivity of 1.3 µS. All reagent solutions used were made using this solution. 
The composition of the NMR solutions are listed in Table 13. 






















































0.5 0.5 2.988 
0.5 0.5 4.970 
0.5 0.5 5.959 
0.5 0.5 6.506 
0.5 0.5 6.995 
0.5 0.5 7.589 
0.5 0.5 8.094 
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8 622 0.5 0.5 9.091 
9 638 0.5 0.5 9.987 
10 645 0.5 0.5 10.501 
11 700 0.5 0.5 11.50 
* Solutions made up as follows: 0.15M MgCb in 020 
3.5 Preparation of 166HoAPD for baboon test purposes 
The complexation of Ho with APD was carried out in similar fashion to the description of 
the complexation of Ho to EDTMP as described by the Dow Chemical Co. patent [43]. 
Preparation of 166Ho solution (48) · 
2.5 mg Ho20 3 was weight off in a quarts vial. The vial was sealed and placed in an 
aluminium can and irradiated in the SAFARil research reactor for 24 hrs at a neutron flux 
of 4 x 1013 neutron/cm2.sec (equivalent of 10 megawatt). The can was opened in a hotcell 
and left to cool for a further 24 hrs. The vial was placed in a lead container and shipped to 
the laboratory were it was kept behind a lead window while being processed. The vial was 
opened by crushing the small quarts window on top. 100µ1 of a 2N HCI solution was 
added and heated at 60°C for 1 hr. 2 ml of water was used to rinse the HoCh formed into 
the solution, making sure it is a homogeneous solution. As in most of this process syringes 
were used to add or transfer liquids, because of the small volumes dealt with and a lesser 
chance of spilling radioactive solutions. 
Preparation and validation of 166HoAPD 
200 µl of the 166HoCh solution was transferred to a 10 ml vial, containing a solution of 
700 µl IN NaOH in which 50 mg of APD was dissolved. The resulting mixture had an 
activity of± 17.5 mCi. The pH was -12. Two 0.5µ1 samples were taken and spotted on 
cellulose chromatographic plates. 23 5 µl of a 1 N HCl solution was added to reduce the pH 
to - 7.8. The pH was checked with universal indicator strips. This was the stock solution 
from which samples were taken for validation of complexation and for the preparation of 
the 3 mCi injecting solution. Another two 0.5 µl samples were spotted on two different 
plates. The chromatographic plates were run in two different eluant mobile phases. The 
first one was a mixture of Pyridine, Ethanol and Water in a ratio of 1 :2:4 and took 2 hrs to 
complete. The second contained Ammonia, Methanol and Water in the ratio of 1: 10:20 
and took 45 min to complete. The chromatographic plates were scanned by a radioscanner 
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while passing by the detector, recording a radiochromatogram scan [ 44]. The amount of 
activity was plotted vs. the channels as the chromatographic plate passed by. If a complex 
has formed it should be carried on the front of the mobile phase and therefore the activity 
should appear in a sharp peak near the end of the chromatogram. Reference runs were also 
recorded with 166HoCh using both mobile phases. Here no ligand is present and the 166Ho 
activity should remain at the origin. A sharp peak at the start of the chromatogram is 
expected. 
Another way to validate if complexation has occurred is by using a small column of 
Carboxymethyl Sephadex (it retains all uncomplexed metal ions). This procedure was 
carried out according to Dormehl et. al. [ 44,45] 
The column was prepared by putting 200 mg column of Carboxymethyl Sephadex in 20 ml 
of water and leaving it overnight to swell. While stirring, to give a homogenous 
suspension, 5 ml of the suspension was taken, put on a column and sucked dry. 
20 µl of the stock solution was loaded on the column. The column was placed in an 
ionisation chamber, which had been zeroed for background measurement, and the activity 
measured. The column was washed (complex eluted) with 20 ml of saline (0.9% or 0.15M 
NaCl) and the activity measured. From the difference the percentage complex yield could 
be calculated. 
Injection of baboons 
0.5 ml of the 166HoAPD stock solution was diluted with water to 1.5 ml to give a total 
activity of 9 mCi. Since the half-life of 166Ho is 26. 7 hrs and 1 ml is injected, the sample's 
activity would have decayed to 3 mCi the following day which is the dose injected into the 
baboon at the H.A. Grove Research Centre in Pretoria. The water used for dilution was 
· highly purified to avoid sickness in the animal when administered with the solution. A 
sterile vial was used and the outside of the vial and lead container was sterilised by 
incubation at ± 121 °C in an Autoclave apparatus for 40 minutes. The lead container was 
then placed in a, polystyrene containing, pot (normally used to transport radiological 
solutions) and taken to the H.A. Grove Research Centre. 
At the centre a baboon (nr. P20/92) which had recovered sufficiently from previous 
radiological tests was chosen from the number of baboons kept at the centre. The 
personnel at the centre darted the animal with Ketamine HCl (± 1 O mg/kg), weighed it 
(23. 8 kg) and transferred it to the surveillance room The blood volume was estimated at 
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1.8 L via the equation 75.5 ml/kg. It was strapped on a bed with they-camera over head. 
To get a better understanding of the set-up, photo 5 is included. 
Photo 5. Laboratory set-up used for baboon tests at the H.A. Grove research Centre. 
An arterial line was fitted to the animal's leg and the narcotic, Sagatal 6%, administered 
intravenously via this device to keep the animal unconscious for the three hours needed to 
complete the study. The same line was used to inject the 166HoAPD. The electrodes for the 
heart monitoring system were clamped to the body. At the arm another arterial line was 
fitted to take blood samples and add a diluted solution of s~e. The bladder was emptied 
via a urinal catheter before the complex was introduced to study the excretion of 166Ho 
more accurately. A reference blood sample was taken. 
I ml of the prepared 166HoAPD was taken and registered 3 .25 mCi in the ionisation 
chamber just before injecting. After injection the spread of the activity could clearly be 
seen on the camera. 166Ho was monitored by a y-camera (Siemens Orbiter), which was set 
at 85 keV (20 % window) to record the strongest y-line of 166Ho. To give an image, the 
dataprocessor (A2/A3 MDS) was used [44,46]. At the start, blood and urine samples were 
taken at 5 minute intervals. After 20 minutes, s~ples were taken every 30 minutes up to 
the two hour mark. At the three hour mark final samples were taken. Images were 
registered continuously but at two and three hours after administration static y-scans were 
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taken at three positions viz. head, chest and pelvis. Computer enhanced images of this 
were recorded as the results. The blood and urine samples were taken back to the AEC 
and analysed in a multi-channel analyser. From this data the amount of 166Ho in various 
parts of the body could be calculated. 
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4 Results and Discussion 
4.1 Potentiometric titrations 
4.1.1 Protonation formation constants 
The protonation constants for APD, MDP and HEDP are shown in Tables 1-3 . The accuracy 
of the results is illustrated by the Hamilton R-factor and shown graphically in the experimental 
and calculated formation curves (Figures 1 to 3). 
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Figure 1. Experimental (points) and calculated (lines) formation curves for APO. Z H is the formation 
protonation function. The separate titrations are presented by (O), (D) and (L>). 
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The formation curves help to verify a certain chosen model, showing how well the data points, 
gathered in the potentiometric titration, fit the chosen model between pH = 4 and 10. This pH 
region is considered important when dealing with the simulation of blood plasma. 
The best fit (experimental vs calculated ZH values) displayed is that for the protonation model 
ofHEDP. There is a significant difference between the models for HEDP and MDP vs APD. 
The species H6L is not included in the model for APD. Inspection of species distribution 
curves indicates that ~L would form at very low pH When included it raised the standard 
deviations, Hamilton R-factor and the difference between experimental and calculated 
formation curves grew bigger. If the species H5L was included in the model for MDP and 
HEDP the same observations were made. Leaving out the H6L species in these models 
resulted in a slightly worse fit. This fact is demonstrated by Figure 4 which shows the model 
for HEDP without HJ,. The results of the modelling without ~Lis shown in Table 4_ Visual 
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Figure 2. Experimental (points) and calculated (lines) formation curves for MDP. Z H is the formation 
protonation function . The separate titrations are presented by (O) , (D) and (ts). 
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Table 2. Protonation constants for MOP 
Cation Eguilibrium LoBK Hamilton R factor 
H+ H+L """ HL 9.97 ± 0.01 0.0138 
H + HL """ H2L 7.01 ± 0.01 
H + H2L """ H3L 3.26 ± 0.02 
H+H3L"""H4L 2.19 ± 0.05 
2H + H4L """ g,L 5.13 ± 0.05 
Table 3. Protonation constants for HEDP 
Cation Equilibrium LogK Hamilton R factor 
H+ H + L """ HL 10.11 ± 0.005 0.00474 
H + HL """ H2L 6.81 ± 0.01 
H+ H2L """ H3L 2.97 ± 0.01 
H + H3L """ H4L 2.43 ± 0.02 







Figure 3. Experimental (points) and calculated (lines) formation curves for HEDP. Z H is the formation 
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Figure 4. Experimental (points) and calculated (lines) formation curves for HEDP excluding H6L. The 
separate titrations are presented by (O), (D) and (6). 
Table 4. Protonation constants for HEDP without H6L 
Cation Equilibrium LogK Hamilton R factor 
H+ H+L~HL 10.02 ± 0.01 0.00933 
H+HL~H2L 6.82 ± 0.01 
H + H2L~H3L 2.86 ± 0.02 
H+HL~HL 2.48 ± 0.03 
For all the titrations 600 data points were used. The data points of each protonation titration 
are found in Appendix C 1. All titration data gathered from titrating ligands with metal ions 
are found in Appendix C2-C4. Appendixes C 1-C4 contain all the data points for EO titrations 
( a titration between a strong base and acid done before and after a series of titrations to 
standardise the acid and to calculate the reference potential of the glass electrode) in between. 
The final outputs of the computer program ESTA2A reached for each model describing the 
protonation of a ligand are found in Appendix B2. The same type of output for EO titrations 
are for reference in Appendix Bl. Appendixes B3-B5 display metal ion - ligand complexation 
model output. (The data and input files are presented on micro floppy disk for easy access) . 
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Previously reported values 
Protonation constants for the ligands used in this study, are compared with literature values 
in Tables 5 and 6. 
Table 5. Reported protonation constants for APO and HEDP 
APD HEDP 
This work Kabachnik This Martell and Dietsched et. Nashe 
[79]a work Smithb.c al. [81] et.al. 
[80] [82] 
LogK1 10.95 10.8 10.11 10.98 10.60 9.12 
LogK2 9.80 9.9 6.81 6.75 6.89 6.20 
LogK3 6.01 5.83 2.97 2.33 2.5 2.20 
Log Ki 2.56 2.55 2.43 (1.4) <2 1.56 
Log K43 3.76 
4.66 LogK!i 
a 0.1 mol.dm-3, background electrolyte not stated, 25"C; b1 .0 mol.dm-3 K+, 25°C, c1 .0 mol.dm-3 
Na+, 25~c; d 0.1 mol.dm-3 KCI, 25°C; e2.0 mol.dm-3 NaN03 ,25°C; 
It is clear from these tables that the medium in which experiments are carried out, have an 
significant influence on the resultant constants. This was described by De Stefano et. al. [87]. 
Protonation constants in (CH3}iNCl are significantly higher than those in KCl and NaCl, and 
follow the trend (CHJiNCl )> KCl > NaCL Furthermore with higher ionic strength, lower 
protonation values are expected. 
For APO little literature is available. The values measured in this study are in close agreement 
with results reported in the literature [79] for similar conditions. 
For HEDP a wider variation of protonation constants is seen. The values compiled by Martell 
[79] for P 1 are higher than the value found here but Nash reports lower values. This could be 
explained by the use of KCl instead of NaCl as pointed out by De Stefano et. al.[86]. The 
constant would be expected to be lower in this case. For the next three protonation constants 
the opposite is true. The medium is now the same but a lower ionic strength is used causing 
higher values. A similar pattern is found for the values reported by Dietsche et. al. [81] 
although the difference is smaller. Here the ionic strength is lower than in this work but KCl 
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was used representing two opposing influences. The influence of a different medium is bigger 
and therefore one would expect the values of Dietsche to be higher than reported. All are in 
good agreement except the second protonation constant. Looking at the values ( and 
considering the temperature difference ) it is fair to say that the protonation constants reported 
here are in agreement with literature. However the first two references are both unsure about 
the fourth protonation constants. This might be explained by the use of the H6L species as has 
been done here. The value for the third protonation constant is also slightly affected in a 
negative direction by the absence of this species (as shown above). The values found by Nash 
et. al. [82] are different. The background electrolyte used is 2. 0 M NaN 0 3. The protonation 
constants are therefore much smaller than reported by the others. In this case all values are 
proportionally smaller than reported here. Once again it is possible to argue that good 
agreement with literature has been attained. 
The same tendency is noticeable for MDP. Martell [83] and others report higher, and Nash, 
lower values. The same arguments apply here. With the opposing effects of KCl vs ionic 
strength in Martell's values the theory outlined above is inconsistent. However the use of 
(CH3) 4NC1 by Van der Linde et. al. [84] and Grabestetter et. al. [85] are consistent with the 
values reported here. Once again there is uncertainty in the fourth protonation constant. This 
could be explained by the absence of~L. 
Table 6. Reported protonation constants for MOP 
This work Martell, Nash et. al. b Van Der Grabenstetter 
Smitha,b [82] Linde et. et. al. [85]c 
----- --- BPl_ _!1/.l~c 
LogK1 9.97 10.33 8.90 10.75 10.57 
LogK2 7.01 6.87 6.34 7.10 7.00 
LogK3 3.26 2.5 2.35 2.75 2.78 
LogK4 2.19 (1.7) 1.30 
Log K4,3 3.65 
LogK6 2.56 
a O 1 mol dm-3 K+ 20°c; 6 2.0 mol.dm-3 NaN03 ,25°C; c 0.1 mol.dm-
3 (CH3) 4N+, 25°C. . . ' 
However this is not the case in the values reported by Nash et. al. [82] which are, as expected, 
proportionally lower. For both HEDP and MDP, a standard deviation of 0.01 is reported for 
the fourth protonation constant. It is important to note that they included another equilibrium 
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in their model, seemingly to help with the fit, viz. Log K4,3. This is the constant for the 
equilibrium: 2H + H2L ""' H4L . 
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Figure 5 . Species distribution curves for the protonation of APD at 37°C and 0.15 mol.dm-3 as 
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Figure 6. Species distribution curves for the protonation of MDP at 37°C and 0.15 mol.dm-3 as 
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Figure 7 . Species distribution curves for the protonation of HEDP at 37°C and 0.15 mol.dm-3 as 
calculated from protonation constants in Table 3. The initial HEDP concentration was taken as 0.00103 
mol.dm-3. 
From the reported constants it is possible to draw species distribution curves for each of the 
ligands. These are shown in Figures 5 to 7. In blood plasma, which has a pH = 7. 4, LH and 
LH2 are the major species for MDP and HEDP while H2L and, to a lesser extend, H3L are the 
major species of APD. 
The crossing of the lines, corresponding to two species for instance H2L and HL in the HEDP 
model, coincide at the same pH where the inflections are visible in Figure 3 (ZH vs pH). At 
first glance the curves for APD look totally different from the other two which have the same 
outline, although at low pH there is some difference visible. The similarity is mostly due to 
their structural resemblance, the same model applied and the similarity of the first three 
constants. APD however has a big structural difference in that it has an amine group which 
may also be protonated and deprotonated. This group is deprotonated last (at the highest pH) 
corresponding to the H + L ~ HL equilibrium. The log K1 value in this case is thus higher than 
for MDP and HEDP which lack this amine group. The value, for log K2 of APD corresponds 
to deprotonation of the first of the diphosphonate groups' protons, as in the case ofMDP and 
HEDP where this is reported by the log K1 value. If these values are compared for APD and 
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MDP there is good agreement. The same applies for log K3 of APO and log K2 ofMDP etc. 
Visually, the curves for APO are shifted one to the left, to ignore the effect of the amine 
group. For example, the H2L curve of MOP or HEDP appears at the same pH as the Ijl L 
curve of APO. 
Between HEDP and MOP there is only a slight difference between all the constants reported. 
For instance, although the difference is small, the reported log K, value for HEDP is larger 
than that of MOP mainly due the inductive effect of the CH3-group. The hydoxy group plays 
a secondary role withdrawing electrons from molecule and thus lowering the protonation 
constant. 
4.1.2. Potentiometric formation constants for APD 
The next sections will report formation constants calculated by potentiometric titrations for 
each of the ligands, starting with APO. 
Results will be presented tabularly. Sometimes two models for the same system will be 
presented to show why a particular model was chosen. In these tables M will be used to 
represent the metal-ion, L the ligand and H protons. For clarity, the charges on the metal ions, 
ligands and complexes have been omitted. All data measured at 3 7 ° C ± 0. 1 ° C and I = 0. 15 
mol.dm-3 NaCl. pK_, was fixed at 13.42 under these conditions [ 42]. 
Complexation of Ca2+ by APD 
Table 7 contains the values calculated for the complexation of Ca(II) by APO. Two possible 
models were found. The output of the ESTA2A runs are included in Appendix B3 as are the 
rest of the EST A2A outputs for the other APD complexation models. Potentiometric data 
points are shown in Appendix C2. 
The only constant available in the literature is by Kabachnik et. al. [79] describing the 
equilibrium: 
M + L+ 2H~MLH2 Log K = 23.55 
Which compares well with the value for the same equilibrium reported in Table 7. The first 
model (perhaps unconventional) is preferred to the second because of the lower Hamilton 
factor and better deprotonation ( Q) curves. 
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Table 7. Formation constants for APO and Ca(II) 
Cation Equilibrium LogK Data Hamilton R 
points factor 
Ca(II) M + L + H ..,,. MLH 16.65 ± 0.02 600 0.01019 
2M+L ..,,. M2L 12.46 ± 0.03 
M2L+H..,,.M2LH 8.50 ± 0.04 
Ca(II) M + L ..,,. ML 6.70 ± 0.03 600 0.01356 
ML + H ..,,. MLH 10.51 ± 0.03 
MLH + H ..,,. MLH2 6.80 ± 0.03 
The calculated and experimental Q curves vs pH are displayed for both models in Figure 8 and 
9. The calculated and experimental formation (Z) curves, for the first model, are displayed 
in a similar way in Figure 10. The deprotonation curves cast doubt on the vadility of the 
second model. The solid lines are much closer matched in Figure 8 by the points than in Figure 
9. In Figure 8 the species presented in the model are evident from the following: There are 
inflections atQ = 0.5 and 1. From the dashed curve, n (the protonation state of the ligand in 
the absence of the metal ion), H2L is the ligand species available for complexation. With Q 
= 0. 5, one proton is released per two metal ions which means that M2LH is the dominant 
species. For Q = 1 this proton is released (the 0.5 difference with the previous value 
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Figure 8 Experimental (points) and calculated (lines) deprotonation curves for Ca(II) complexation 
by APD. Obar= Q and is the deprotonation function and the dashed line is the n curve. The three 
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Figure 9. Experimental (points) and calculated (lines) deprotonation curves for Ca(II) complexation 
by APO. Obar= Q and is the deprotonation function and the dashed line is the n curve . The three 
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Figure 10. Experimental (points) and calculated (lines) formation curves for Ca(II) complexation by 
APO. Zbar =Z and is the formation function and pA is the negative logarithm of the free ligand 
concentration . The three separate titrations are as shown in Fig. 8. 
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The species distribution curves for the chosen model is displayed in Figure 11 . From this it 
can be seen that the complexes attain maximum concentration at the pH values predicted by 
the deprotonation curves. 
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Figure 11. Species distrubution curves for the complexation of Ca(II) by APO at 37 °C and in 0.15 
mol.dm-3 NaCl as calculated from formation constants in Table 7. 0.00213 M APO and 0.0077 M Ca(II). 
Complexation of Mg(II) by APD 
Table 8 displays the values found for two models achieved from titration data for the 
complexation ofMg(II) by APD. ESTA2A outputs are found in Appendix B3 and titration 
data points in Appendix C2. 
Table 8 Formation constants for APO and Mg(II) 
Cation Equilibrium LogK Data HamiltonR 
points factor 
Mg(II) M + L ""'ML 7.03 ± 0.03 600 0.01588 
ML+H.,,.,MLH 10.24 ± 0.03 





6.90 ± 0.06 
6.79 ± 0.07 
7.56 ± 0.05 
600 0.02004 
No constants were found in the literature for the complexation ofMg(II) by APD. 
In this case the first model ( conventional type) is preferred to the second ( as in the case of 
APD and Ca(II)) because of the lower Hamilton factor, standard deviations and better 
deprotonation ( Q) curves. The calculated and experimental Q curves vs pH are displayed for 
both models in Figure 12 and 13 . This difference in model between Ca(II) and Mg(II) might 
be due to the smaller size of the Mg(II) ion, forming stronger complexes (discussed later) and 
therefore preferring to complex one metal ion with one ligand. Ca(II) on the other hand forms 
a weaker complex and the ligand can accommodate two metal ions. 
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Figure 12. Experimental (points) and calculated (lines) deprotonation curves for Mg(II) complexation 
by APD (first model) . Obar= Q and is the deprotonation function and the dashed line is the n curve. 
The three separate tirations were for the L:M ratio= 1 :1 (o), L:M = 1 :1.25 (D) and L:M = 1 :2.5 (t.). 
The calculated and experimental formation curves for the first model are displayed in a similar 
way in Figure 14. The deprotonation curves show that the second model is more plausible . 
The solid lines (calculated curves) are much closer matched in Figure 12 by the points 
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Figure 13. Experimental (points) and calculated (lines) deprotonation curves for Mg(II) complexation 
by APD (second model) . Obar = Q and is the deprotonation function and the dashed line is the n 
curve. The three separate tirations are as shown in Fig. 12. 
In Figure 12 the difference with Figure 8 (APD and Ca(II)) is especially evident between pH 
= 5.5 to 6.5 where the Q curve is flattened for Mg(II) but climbing for Ca(II). For Mg(II) Q 
= 0.5 in this region and n shows that the ligand changes from H3L to H2L. This indicates that 
complexation occurs but not in a single species. At pH = 5.5 one would expect MLH2 and 
unbound metal ion (M) species to be present lowering the Q value from 1 (which means that 
1 proton is released on complexation. Together with the H3L species this results in MLH2) 
to 0.5. At pH= 6.5 the opposite is true, Hzl, needs no release of protons to form MLH2, thus 
Q should be 0. Another species is thus forming viz. MLH where Q = 1 applies. The Q = 0.5 
is a compromise between them. In between (pH= 5.5 and 6.5) a combination of the two 
factors contributes to Q staying at 0.5 and MLH2 is the major species. These observation are 
confirmed by the species distribution diagram, Figure 15. Between pH = 8 and 9 the 
explanation is simpler. Q = 1 and complexation with H2L results in MLH. No competition by 
other species is evident here. At higher pH values, HL becomes the dominant ligand species 
where Q stays 1. For Ca(II), the Q values started to drop at pH = 10 showing the absence 
of ML and the involvement of M2L. 
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The interesting aspect is that Ca and Mg could be explained by the same two models in each 
case but different ones were chosen. The strength of complexation for Ca(II) and Mg(II) by 
APD does not differ much although Mg(II) has a slightly higher first formation constant. 
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Figure 14. Experimental (points) and calculated (lines) formation curves for Mg(II) complexation by 
APO. Zbar =Z and is the formation function and pA is the negative logarithm of the free ligand 
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Figure 15. Species distrubution curves for the complexation of Mg(II) by APO at 37 °c and in 0.15 
mol.dm-3 as calculated from formation constants in Table 8. 0.00213 M APO and 0.00086 M Mg(II). 
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Complexation of Sr(II) by APO 
Another Alkaline Earth metal is Sr(Il) which was studied to see whether it fits in with the 
model found for Ca(II), as we progress down this group. Sr(II) is also used as the active 
isotope in the radiopharmaceutical Metastron. This consist of 89SrC12 which is used in the pain 
palliation treatment of prostatic bone metastases. Here no phosphonate ligand is used to 
deliver the metal ion to the bone but it relies on phosphate in blood plasma, for which Sr(II) 
has a affinity, to deliver the radioactive isotope to the bone. The possible use of 89SrAPD in 
this respect can be studied by ECCLES modelling as can the working of 89SrC12 and its side-
eff ects, using the constants calculated here. Table 9 displays the values found for the best 
models achieved from titration data for the complexation of Sr(II) by APD. EST A2A output 
in Appendix B3 and titration data points in Appendix C2. 
Table 9 Formation constants for APO and Sr(II) 
--- ---
Cation Equilibrium LogK Data Hamilton R 
poin!~ factor 
Sr(II) 2M + L a=' M2L 9.22 ± 0.05 600 0.00937 
M + L + H a=' MLH 16.06 ± 0.01 
MLH + H a=' MLH2 7.64 ± 0.02 
M7L + H a=' M7LH 10.30 ± 0.06 
No constants were found in the literature for the complexation of Sr(II) by APD. 
Here the same species are reported as in the model for Ca(ll) with the addition of MLH2. The 
calculated and experimental Q curves vs pH are displayed in Figure 16. This fit of 
experimental vs calculated values is very similar to that achieved by Ca(II) and APD. As 
expected the first constant is lower than for Ca(II), following the trend Mg > Ca > Sr (in 
agreement with Ca < Mg < Zn [81] and the Irving-Williams series). This corresponds to the 
ionic radii increasing in the order: Mg(II) (0.66.A) < Ca(II) (0.99.A) < Sr(II) (1.12.A) The 
bigger the ion, the weaker the complexation. The important aspect is that the most plausible 
model here contained the same species as found for Ca(II) which verifies the unconventional 
type of model proposed. Sr(II) also accepts two metal ions bound per ligand (M2L species) 
as was the case with Ca(II). This is surprising Sr(II) is even larger than Ca(II). This might 
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Figure 16. Experimental (points) and calculated (lines) deprotonation curves for Sr(II) complexation 
by APO. Qbar = Q and is the deprotonation function and the dashed line is the n curve. The three 
separate tirations were for the L:M ratio= 1 :1 (o), L:M = 1 :1.25 (D) and L:M = 1 :2.5 (t>). 
Complexation of Zn(Il) by APD 
Table 10 displays the values found for the model achieved from titration data for the 
complexation ofZn(II) by APD. ESTA2A output is found in Appendix B3 and titration data 
points in Appendix C2. In both cases no suitable models were achieved. 
Table 10 Formation constants for APO and Zn(II) 
Cation Equilibrium LogK Data HamiltonR 
points factor 
Zn(II) M+L ,=,,ML 11.19±0.05 600 0.03850 
ML+H,=,,MLH 9.00 ± 0.07 
MLH + H"""' MLH2 5.82 ± 0.06 
ML + OH"""' MLOH 2.64 ± 0.09 
Zn(II) M+L,=,,ML 12.20 ± 0.04 566 0.02658 
ML+ H,=,,MLH 8.79 ± 0.06 
MLH + H"""' MLH2 4.65 ± 0.06 
ML + OH"""' MLOH 2.71 ± 0.06 
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The main reason being the precipitate (seen as a 'milky' solution in the titration vessel) that 
forms between pH = 5 to 7. 5. This precipitate might be due to neutral species (M2L in the 
case ofZn(II) or MLH in the case ofHo(ill) or Sm(ill)) formed at the ligand and metal ion 
concentrations used. The data in this region of the titration are difficult to model. Removing 
data from this region results in cutting out the region of interest in our case (blood plasma has 
a pH round about 7.4). This is illustrated (second set of constants) to demonstrate the 
influence on the Q fit. 
No constants were found in the literature for the complexation ofZn(II) by APD. 
In this case neither model produces a satisfactory fit to the titration data points. This is clearly 
visible from the high Hamilton factors, standard deviations and poor deprotonation ( Q) 
curves. The calculated and experimental Q curves vs pH for the two models are respectively 
displayed in Figure 17 and 18. From Figure 18 it is evident that the cutting of the data points, 
corresponding to precipitation, is not successful in finding a better relation between the 
experimental and calculated Q curves although the Hamilton factor and standard deviations 
are significantly lower. 
4 
3 




4 5 6 7 
pH 
8 9 10 
Figure 17. Experimental (points) and calculated (lines) deprotonation curves for Zn(II) complexation 
by APO. Obar =Q and is the deprotonation function and the dashed line is then curve. The three 
separate tirations were for the L:M ratio= 1 :1 (o), L:M = 1 :1.25 (D) and L:M = 1 :2.5 (6). 
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Another way has to be found to bypass this precipitation problem. One is to have a higher 
ratio of ligand to metal resulting in lower metal ion concentrations. Potentiometry is not 
suitable with low metal ion concentrations but a technique like polarography is. The next 
section will contain formation constants determined by this technique. These values found 
here only serve as an indication for what to expect from this system and will not be used in 
blood plasma modelling. 
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Figure 18. Experimental (points) and calculated (lines) deprotonation curves for Zn(II) complexation 
by APO. Obar = Q and is the deprotonation function and the dashed line is then n curve. The three 
separate tirations as shown in Fig.17. Where precipitation occured the data points were cut. 
Complexation of Ho(Ill) by APD 
Table 12 displays the values found for the model achieved from titration data for the 
complexation ofHo(III) by APO. ESTA2A output is found in Appendix B3 and titration data 
points in Appendix C2. No suitable models were achieved. The main reason being the 
precipitate (as seen as a 'milky' solution in the titration vessel) that forms up till pH= 8 as 
was the case with Sm(III). 
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Table 11 Formation constants for APO and Ho(III) 
Cation Equilibrium LogK Data Hamilton R 
points factor 
Ho(ill) M+L ~ML 13 .81 ± 0.07 1000 0.02841 
ML+H~MLH 9.53 ± 0.09 
MLH+H~MLH, 4.29 ± 0.09 
No constants were found in the literature for the complexation ofHo(ill) by APD. 
The model is clearly provides no satisfactory fit to the titration data points as can be deduced 
from the high Hamilton factors, standard deviations and poor deprotonation ( Q) curves. The 
standard deviations values were slightly better than for Sm(ill). The calculated and 
experimental Q curves are not displayed because they do not differ much from Figure 20. The 
conclusion is the same: an insufficient fit giving only semi-quantitative values. The value found 
for the first complexation constant is what was expected and agrees with the value for the 
complexation ofHo(ill) by EDTMP, Log K1 = 13.32 [5]. The species distribution curves for 
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Figure 19. Species distrubution curves for the complexation of Ho(III) by APD at 37 °C and in 0.15 
mol.dm-3 as calculated from formation constants in Table 11. 5 E-08 M APD and 1 E-06 M Ho(III)). 
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Complexation of Sm(III) by APD 
Table 11 displays the values found for the model achieved from titration data for the 
complexation of Sm(III) by APD. ESTA2A output is found in Appendix B3 and titration data 
points in Appendix C2. No suitable models were achieved. The main reason being the 
precipitate (as seen as a 'milky' solution in the titration vessel) that forms up till pH= 8. 
Cutting out this area of precipitation will result in cutting out more than half of the titration 
and is therefore even worse than in the case of Zn(II). 
Table 12 Formation constants for APO and Sm(III) 
Cation Equilibrium LogK Data Hamilton R 
points factor 
Sm(III) M+L ""ML 9.67 ± 0.10 600 0.02857 
ML+H""'MLH 10.35 ± 0.12 
MLH+H""'MLHl 7.22 ± 0.12 
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Figure 20. Experimental (points) and calculated (lines) deprotonation curves for Sm(III)) complexation 
by APD. Qbar =Q and is the deprotonation function and the dashed line is then curve. The three 
separate tirations were for the L:M ratio = 1 :1 (o), L:M = 1 :1.25 (D) and L:M = 1 :2.5 (1:,.). 
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The model clearly provides no satisfactory fit to the titration data points as can be deduced 
from the high Hamilton factors, standard deviations and poor deprotonation ( Q) curves. The 
calculated and experimental Q curves vs pH are displayed in Figure 20. The cutting of data 
points proved to be fruitless as in the case of Zn(II). This was not even attempted and the 
estimate of the constants were established by taking all data points into consideration. Figure 
20 shows that the fit is inefficient and these values are therefore only an indication and cannot 
be used in the blood plasma model. The value found for the first complexation constant is 
much lower than expected. The value for the complexation of Sm(III) by EDTMP is 14 .44 
[5]. The value for Zn(II) (this work) is 10.0. One would expect the value for Sm(III) to be 
higher because lanthanides are trivalent and will therefore have a stronger electrostatic effect 
than divalent Zn forming a stronger interaction with a ligand [87]. If the approximate value 
for Ho(III), log K1 = 13.81 (this work), is considered the value also seems low. In the case 
ofEDTMP, Sm(III) was complexed stronger than Ho(III) [5]. 
The relative relationship between formation constants ofligands containing negatively charged 
oxygen donor groups and log K1(0ff) for the metal ions was described by Hancock and 
Martell [92]. Hancock and Martell [92] pointed out that there is a remarkable linear 
relationship between Log K1(L) and Log ~ (OH) for negatively charged oxygen donor 
ligands. By plotting these values it is possible to find a linear fit and calculate a formation 
constant for a metal ion for which only the hydroxide constant is known. This approach was 
followed. Figure 20a contains the plot of these sets of constants against each other. The 
formation constants calculated so far (as well as by polarography) for Ca(ll), Mg(II), Sr(II), 
Zn(ll), Ho(III) and Cu(II) [93] were used. Formation constants for hydroxide species were 
taken from Martell [91]. The (D) resemble the real relationship. The line is the result of the 
linear regression which produced and regression factor (r) = 0.99. From the graph it is clear 
that Sm(III) should have a much bigger first complexation constant. From the regression a 
first formation constant of 13. 0 is suggested. Ho(III) though fits in quite well with the other 
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Figure 20a. Relationship between the stability of complexes of metal ions with APO and the affinity 
of the metal ion for the hydroxide ion. Ionic strength 0.15 mol.dm-3. Note the linear relationship. Sm(III) 
does not fit on the curve therefore the constant calculated may not be accurate. 
4.1.3. Potentiometric formation constants for MDP 
The next section reports formation constants calculated by potentiometric titrations for the 
ligand MDP with various metal ions. Results will be presented tabularly, sometimes two 
models for the same complexation will be presented to show why a particular model was 
chosen. Again all data were measured at 37 °C ± 0.1 °C and/ = 0.15 mol.dm-3 NaCl. p~ 
was fixed at 13.42 under these conditions [42]. 
Complexation of Ca(II) by MDP 
Table 13 contains the values calculated for the complexation of Ca(II) by MDP. Two possible 
models were found . The output of the ESTA2A runs are included in Appendix B4 and 
potentiometric data points are shown in Appendix C3 . 
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Table 13 Formation constants for MOP and Ca(II) 
---- ---·----
Cation Equilibrium LogK 
Ca(II) M+L~ML 4.86 ± 0.01 
ML+H~MLH 7.83 ± 0.03 
2M+L~M2L 8.39 ± 0.04 
Ca(II) M+L~ML 4.96 ± 0.01 









Points up to pH = 4 were excluded as a slight precipitation was observed. In the case of the 
first titration (high metal concentration viz. L:M = 1: 1) from pH = 8 onwards the precipitate 
reappeared. These values were exclude as well, visible in the ( Q) curves (Figure 21 ). 
Constants available in the literature are shown in Table 14. 
Table 14. Reported formation constants for MOP and Ca(II) 
Log K"'11 
Log K"'IHL '.\1.HL 
Log K"'rrn'.\1r.H 
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a 0.1 mol.dm-3 (CH3) 4N+, 25 "C; 
6 0.5 mol.dm-3 (CH3) 4N+, 25 "C; c 0.1 mol.dm-
3 K+, 25°C. 
The values in normal brackets are the standard deviations. The values in {} brackets are 
calculated from the original reported values to give a better comparison. The reason for this, 
is the equilibrium used to describe a complex formation were different. 
The last column in Table 14 is added only as an indication because it describes constants for 
the ligand Cl2MDP. 
The equilibria ML + H ~ MLH has been used here. 
However others use: LH + M ~ MHL. The values reported here compare well with the 
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Figure 21. Experimental (points) and calculated (lines) deprotonation curves for Ca(II) complexation 
by MOP (first model, Table 13). Qbar = Q and is the deprotonation function and the dashed line is the n 
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Figure 22. Experimental (points) and calculated (lines) deprotonation curves for Ca(II) complexation 
by MOP (second model, Table 13). Qbar = Q and is the deprotonation function and the dashed line is 
the ,i curve. The three separate titrations as shown in Fig. 21. 
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The values of Van der Linde et. al. [84] are higher due to the 0.1 mol.dm-3 (CH3) 4N" 
background electrolyte [86]. They included the constant M2L which has a value close to the 
one reported here. De Stefano et. al. [86] also pointed out that a higher ionic strength will 
result in lower formation constants. This partially would explain Carroll et. al. [88] and the 
relatively low values they reported. Here the standard deviations are larger, probably because 
of the exclusion ofM2L as can be seen in Table 12. The values by Dietsche et. al. [81] are 
in KCl and therefore a big difference is not expected. 
The first model ( which includes M2L) is preferred to the second because of the lower 
Hamilton factor, standard deviations and better deprotonation ( Q) curves. The calculated and 
experimental Q curves vs pH are displayed for both models in Figure 21 and 22. The 
calculated and experimental formation curves, Z, are presented in Figure 23 . The 
deprotonation curves show a better fit for the first model. The solid lines ( calculated curves) 
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Figure 23. Experimental (points) and calculated (lines) formation curves for Ca(II) complexation by 
MOP. Zbar = Z and is the formation function and pA is the negative logarithm of the free ligand 
concentration. The three separate titrations were as for Figure 21 . 
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From this figure the species present may be deduced from the following: Above pH = IO the 
dotted line, n, closely follows the Q curves. This means that no proton is left on the ligand 
while complexed thus making ML the dominant species. No MLOH is formed because n does 
not cross the Q curve ( meaning more protons are released than the ligand normally has, 
indicating MLH_1) . Before pH= 5.5 no complexation occurs (Q = 0). After pH = 6 the 
inflections of the Q curve flow one into another, indicating various complexes in competition 
viz. MLH and Mil,. Then curve also drops between pH= 6.5 and 8. This delivers a scenario 
equal to that described in Section 4.1.2 for APD and Mg(II), although different complexes 
are involved here. 
The species distribution curves for the chosen model is displayed in Figure 24. From this it 
can be seen that the complexes attain maxima at the pH values predicted by the deprotonation 
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Figure 24. Species distrubution curves for the complexation of Ca(II) by MOP at 37 °C and in 0.15 
mol.dm-3 as calculated from formation constants in Table 13. 0.00213 M MOP and 0.00077 M Ca(II) . 
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Complexation of Mg(II) by MDP 
Table 15 Formation constants for MOP and Mg(II) 
Cation Equilibrium LogK Data Hamilton R 
points factor 
Mg(II) M+L'<"ML 5.68 ± 0.01 91 0.02009 
ML+H,..,,MLH 7.56 ± 0.01 
2M+L'<"M2L 8.36 ± 0.08 
Mg(II) M+L'<"ML 5.64 ± 0.01 600 0.01315 
ML+H,..,,MLH 7.56 ± 0.03 
2M+L'<"M2L 8.46 ± 0.11 
Mg(II) M+L,..,,ML 5.71 ± 0.01 91 0.01971 
ML +H,..,,MLH 7.57 ± 0.01 
Table 15 displays the values found for two models achieved from titration data for the 
complexation ofMg(II) by MDP. The best model is also displayed without excluding the data 
points at low and high pH values. No precipitation was observed but it was found that in this 
case the already good fit of the model to the data could be enhanced by excluding data points 
at pH levels where the glass electrode is more unstable. Only values between pH = 4 and 10 
were taken. EST A2A output is found in Appendix B4 and titration data points in Appendix 
C3. 
In this case the first model is preferred to the second because of the lower standard deviations. 
The Hamilton R factor is lower for the latter. A better deprotonation ( Q) curve fit was also 
found. The calculated and experimental Q curves vs pH are displayed only for the first and 
third models in Figure 25 and 26. The curves match each other very well producing the best 
fit achieved so far. The cutting of the data helped to reduce the high standard deviation for 
the formation of M2L in the second model. The third model is as good as the first. Only a 
slight difference in the two Q curves was observed. Very similar standard deviations and 
Hamilton factors were reported. The constants also are very similar, almost within the 
standard deviations. The same applies for the second model which has similar values. The first 
model (because it contains all the complexes and has the lowest standard deviations) is 
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therefore reported and used in the blood plasma model. The little difference in the models is 
explained by the species distrubution diagram, Fig.28. The calculated and experimental 
formation Z curves for the first model are displayed in Figure 27. The Q curves have the 
same shape as Ca(II) had with 1\IDP, resulting in the same observations about the species 
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Figure 25. Experimental (points) and calculated (lines) deprotonation curves for Mg(II) complexation 
by MOP (for the first model). Qbar = Q and is the deprotonation function and the dashed line is the n 
curve. The three separate titrations were of L:M = 1 :1 (O) , L:M = 1.25:1 (D) and L:M = 2.5:1 (c.} . 
Table 16. Reported formation constants for MOP and Mg(II) 
This work Carroll Dietche et. al. 
et. al. b [85] b 
[88] (For Cl21\IDP) 
LogKML 5.68 5.78 (0.10) 4.75 
Log KMIIl.JM.HL {3.27} 2.92 (0.05) 2.92 
Log KMLHIML.H 7.56 {7.11 } {7.01 } 
Log KupMLM 2.68 
6 0.5 mol.dm-3 (CH3) 4N+, 25 °C; c 0.1 mol.dm-
3 K+, 25 °c. The values in 
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Figure 26. Experimental (points) and calculated (lines) deprotonation curves for Mg(II) complexation 
by MDP (for the third model). Obar= Q and is the deprotonation function and the dashed line is the n 
curve. The three separate titrations are as shown in Fig. 25. 
Once again the last column in Table 16 is added only as an indication because it describes 
constants for the ligand Cl2MDP. The values reported here compare well with the literature 
if the different media in which experiments were done are taken into account. The values of 
Carroll et. al. [88] are slightly higher due to the 0.5 mot.dm·3 (CH3) 4N+ background electrolyte 
[86]. They did not included the constant M2L which may cause the higher deviations. Only 
the second formation constant reported here seems to be a bit high. The values by Dietsche 
et. al. [81] are in KCl and therefore a big difference is not expected. Here Ca(Il) and Mg(Il) 
take the same model in contrast to APD. As proposed in Section 4 .1.2 the formation of the 
Mil, complex is due to weaker complexation of the metal ion by the ligand. APD forms much 
stronger complexes than MDP, being just strong enough to form no M2L in the case of 
MgAPD. MDP forms weaker complexes and Mil, appears in both cases. The same is true for 
HEDP although an extra species at high pH is formed viz. MLOH is formed for MgHEDP. 
The strength of complexation of MDP by Mg(Il) is significantly higher than by Ca(Il), 
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Figure 27. Experimental (points) and calculated (lines) formation curves for Mg(II) complexation by 
MDP. Zbar = Z and is the formation function and pA is the negative logarithm of the free ligand 
concentration. The three separate titrations were as for Figure 25. 
The species distribution curves for the chosen model is displayed in Figure 28. An interesting 
aspect is how little of the species M2L is formed . This explains why there is little difference 
between the fit for models which included or excluded it. 
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Figure 28. Species distrubution curves for the complexation of Mg(II} by MDP at 37 °C and in 0.15 
mol.dm-3 as calculated from formation constants in Table 15. 0.00213 M MDP and 0.00086 M Mg(II) . 
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Complexation of Zn(II) by MDP 
Table 17 displays the values found for the model achieved from titration data for the 
complexation of Zn(II) by MDP. EST A2A output in Appendix B4 and titration data points 
is found in Appendix C3. No suitable models were achieved. The main reason once again 
being the precipitate that forms between pH = 5 to 7. 5. Cutting out this area of precipitation 
did not assist in achieving a plausible model. 
Table 17. Formation constants for MOP and Zn(II) 
Cation Equilibrium LogK Data Hamilton R 
points factor 
Zn(II) M+L ~ML 8.19 ± 0.09 575 0.06438 
ML+H~MLH 7.35 ± 0.12 
No constants were found in the literature for the complexation of Zn(II) by MDP. 
In this case the model produces no satisfactory fit to the titration data points at all. No 
calculated and experimental Q curves are displayed . Like in the complexation of Zn(II) by 
APD no improvement was made by excluding data. The pictures are the same ( therefore not 
included). Polarography will be used to calculate the constants. 
Complexation of Ni(II) by MDP 
Another transition metal is Ni(II), close to Zn(II) which was studied to see whether it also 
forms precipitates with MDP as Zn(ll) does. It does indeed form a precipitate as expected. 
Although the data points fit better into the model than with Zn(II). Table 18 displays the 
values found for the best model achieved from titration data for the complexation of Ni(II) 
by MDP. ESTA2A output is found in Appendix B4 and titration data points in Appendix C3. 
Table 18. Formation constants for MOP and Ni(II) 
Cation Equilibrium LogK Data Hamilton R 
- -- --
__ pC>ints_ factor 
- -
Ni(ll) M+Ls=ML 7.27 ± 0.01 103 0.02970 
2M+L ~M2L 11.06 ± 0.03 
ML+OH~MLOH 3.60 ± 0.03 
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No constants were found in the literature for the complexation of Ni(II) by MDP. 
Here two of the same species are reported as in the model for Ca(II) and Mg(II) with the 
addition of MLOH instead MLH2 indicating a shift to a more basic system. From the 
calculated and experimental Q curves vs pH, Figure 29, it is evident that one of the species 
is MLOH. This can be deduced from the fact that the n curve crosses the Q curves 
indicating that the presence of more protons than can be supplied by the ligand. One proton 
is released on complexation while the ligand was already in the L form, forming an MLOH 
species. The same is true for Zn(II) where it looks as if MLOH could be included in the model 
although EST A2A rejected it. This however might be because of the precipitation. The model 
for Ni(II) might be used as an indication for Zn(II) which has a worse fit with MDP than 
APD. The proton which is released by ML to form MLOH should be from the coordinated 
water seeing that no hydroxyl group is present in MDP. This is supported by the constants for 
MLOH viz. 3.60 and that for MOH (metal hydroxide), 3.7 which are similar. A full 
explanation of this phenomena is given in the next section (Section 3.1.4.) where the 
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Figure 29. Experimental (points) and calculated (lines) deprotonation curves for Ni(II) complexation 
by MOP. Qbar = Q and is the deprotonation function and the dashed line is the n curve. The three 
separate titrations are as shown in Fig . 25. 
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Complexation of Sm(Ill) and Ho(III) by MOP 
Table 19 displays the values found for the model achieved from titration data for the 
complexation of Sm(III) by MDP. ESTA2A output is found in Appendix B4 and titration data 
points in Appendix C3. No suitable models were achieved. The reason being the precipitate 
that forms belowl pH= 8. 
As has been shown, precipitation causes problems which potentiometry is not able to 
overcome. The reason for the absence of any standard deviations lies in the fact that EST A2A 
finds a correlation between the complexes. (See Appendix B4) These values are therefore only 
an indication. Here the first formation constant is much higher than that reported for APO 
with Sm(III). 
Table 19 Formation constants for MOP and Sm(III) 
Cation Equilibrium LogK Data Hamilton R 
po_i_I!t_s factor 
Sm(III) M+L ~ML 14.71 600 0.02021 
ML+H~MLH 8.73 
MLH+H~MLH~ 4.43 
EST A2A was not able to find any model (how ever bad the fit might be) for titration data for 
the complexation of MDP by Ho(III). The main reason is again the precipitate that forms 
below pH= 8. 
To find an estimate of the first formation constant the method of Hancock and Martell [93] 
was used once again. Figure 30 displays the relation of Log K1(L) vs Log Ki (OH) for the 
metal ions Ca(II), Mg(II), Zn(II), Ni(II) and Sn(II) [84]; Log K1(0H) form Martell [91]. The 
line represents the linear regression (r = 0.998) and the solid squares(•), the first formation 
constants for Sm(III) and Ho(III) from this regression. Here a value for Log K1 = 9.3 is found 
for Sm(III) differing very much from the value reported above. For Ho(III) a first formation 
constant of 9.6 was found as displayed in Table 20. Table 20 also contains the estimated 
second formation constants for the complexation of Ho(III) and Sm(III) by MDP. It was 
estimated from the first formation constant in the following way. Log p2 = Log Kr-1L + (Log 
K.1 - 1 ). The value for Log KMLH is calculated from this value in the usual manner. 
The values reported by Nash and Horwitz [82] for the complexation of Eu(III) by MDP were 
not used for either of the two formation constants. The values reported for Log K1 = 4.04 and 
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Log ~ = 1. 95. These values differ by more than five log units from what is reported here 
and cannot be explained in terms of different media used. The technique they used was solvent 
extraction. Assumptions in calculations made by these authors perhaps need to be tested. To 
support the higher values, Log K1 = ± 10, an analogue for MOP viz. hydrogen diphosphonate 
or pyrophosphoric acid is taken as an example. The values reported by Martell [91] for 
trivalent metal ions complex by pyrophophates are high viz. Log K1 = 16.7 for La(III) etc. 
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From this a higher formation constant for the complexation of MOP and HEDP by lanthanide 









0 2 4 6 8 10 12 
Log K1 (OH) 
Figure 30. Relationship between stability of complexes of metal ions with MDP and the affinity of the 
metal ion for the hydroxide ion. 
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For MDP and 153Sm(IlI), Simon et. al. [43] reported a high liver uptake. To get an idea of the 
species involved at pH = 7.4 a species distribution curve for MDP and Sm(ill) has been drawn 
up from the values estimated in Table 20 which will be used to explain these results found in 
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Figure 30a. Species distrubution curves for the complexation of Sm(III) by MDP at 37 °C and in 0.15 
mol.dm-3 as calculated from formation constants in Table 20. 0.00213 M MDP and 0.00086 M Sm(III). 
4.1.4. Potentiometric formation constants for HEDP 
The next section reports formation constants calculated by potentiometric titrations for the 
ligand HEDP with various metal ions. Results will be presented tabularly. All data measured 
at 37 °C ±0.1 °C and I = 0.15 mol.dm-3 NaCl. p~ fixed at 13.42. Charges of metal ions, 
ligands and complexes have been omitted for simplicity. 
Complexation of Ca(II) by HEDP 
89 
Table 21 contains the values calculated for the complexation of Ca(II) by HEDP. The output 
of the EST A2A runs are included in Appendix B5 and potentiometric data points are in 
Appendix C4. 
Table 21 Formation constants for HEDP and Ca(II) 
Cation Equilibrium LogK Data Hamilton R 
points factor 
Ca(II) M + L ~ l\,1L 5.34 ± 0.01 88 0.01957 
ML+H~MLH 7.83 ± 0.02 
ML+M~M~L 4.19 ± 0.02 
A large number of data points outside pH = 4 and 10 were cut out ( as the pH electrode is less 
stable at very low and very high pH values) was done for the complexation of Mg(II) by 
MDP. The result is that a better fit is obtained as is displayed by the Q curves (Figure 31). 
From Figure 31 one can make the same observations as in previous cases about the species 
dominating and the justification of the absence ofMLOH. Figure 32 contains Z curves. No 
'backfanning' [90 ] (explained in the next section on HEDP and Mg(II)) is visible which 
would indicate MLOH or ML(OH)n species. In addition the Q curves do not cross the n 
curve. Constants available in the literature are shown in Table 22. 
Table 22. Reported formation constants for HEDP and Ca(II) 
This work Van Der Linde Wada Dietche Carroll 
et. al. a et. al. a et. al. c et. al. b 
.. f84J. - [89} - [8?J .. [88J 
Log K'-IL 5.34 6.18 (0.03) 6.84 6.0 5.74(0.10) 
Log K1>.1HL7'1.m {3.14} 3.12 (0.06) 3.35 3.0 3.58 (0.14) 
Log K~ILH\,IL.H 7.83 {8.17} {7.47} {7.6} {7.85} 
Log Ku/Afut 4.19 4.63 (0.06) 5.36 
a 0.1 mol.dm·3 (CH3)4N+' 25 °C; b 0.5 mol.dm-3 (CH3)4N+' 25 °C; C 0.1 mol.dm·3 K+' 25°C. 
The values in O brackets are calculated from the original reported values to give a better 
comparison. 
The values reported here compare well with the literature if the media in which experiments 
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Figure 31. Experimental (points) and calculated (lines) deprotonation curves for Ca(II) complexation 
by HEDP. Obar= Q and is the deprotonation function and the dashed line is the n curve. The three 
separate titrations were of L:M = 1 :1 (0) , L:M = 1.25:1 (D) and L:M = 2.5:1 (t;.) . 
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Figure 32. Experimental (points) and calculated (lines) formation curves for Ca(II) complexation by 
HEDP. Zbar =Z and is the formation function and pA is the negative logarithm of the free ligand 
concentration . The three separate titrations were as for Figure 31 . 
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The values of Van der Linde et. al. [84] are once again higher due to the 0.1 mol.dm-3 
(CH3) 4N+ background electrolyte [86]. For the same electrolyte Wada et. al. [89] report even 
higher values. It has to be said that these constants were published in 1972 and calculated not 
at various ligand to metal (L:M) ratios, like in this work, but at specific ratios different values 
were reported. The values tabled for Wada et. al. are for the ratio 2: 1. If the ratio is lowered 
to 1: 1 the value for Log K1 for instance changes from 6.84 to 6.40 [89], comparing much 
better with the value 6.18, reported by Van der Linde [84]. Both included the constant M2L 
which has a value close to the one reported here with the expected rise due to the background 
electrolyte. The reported standard deviations are higher than in this work indicating a better 
fit of the model to the data here. De Stefano et. al. [86] also pointed out that a higher ionic 
strength electrolyte will result in lower formation constants. This is derived from the Debye-
Htickel type equation where log p ex logTp -112 . This would explain the lower values by 
Carroll et. al. [88] and the even lower for those of Van der Linde and Wada. These values are 
higher than in this work, because of the (CH3) 4N+ background electrolyte [86]. Here the 
standard deviations are even bigger, probably because of the exclusion ofM2L. The values by 
Dietsche et. al. [81] were recorded in KCl which should, according to De Stefano et. al. [86], 
have give slightly higher values than in NaCl medium. 
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Figure 33. Species distrubution curves for the complexation of Ca(II)) by HEDP at 37 °C and in 0.15 
mol.dm~ as calculated from formation constants in Table 21 . 0.00213 M HEDP and 0.00077 M Ca(II). 
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The species distrubution curves for the chosen model are now displayed in Figure 33. From 
this it can be seen that the complexes attain maximum concentration at the pH values 
predicted by the deprotonation curves. There is no single dominant species between pH= 5.5 
and 9. 5 visible from this graph. 
Complexation of Mg(II) by HEDP 
Table 23 displays the best model achieved from titration data for the complexation ofMg(II) 
by HEDP. Only the best model is displayed here. Only data points between pH = 4 and 10 
were taken. EST A2A output is found in Appendix B5 and titration data points in Appendix 
C4. 
Table 23 Formation constants for HEDP and Mg(II) 
Cation Equilibrium LogK Data HamiltonR 
points factor 
Mg(II) M + L -=' ML 6.03 ± 0.01 96 0.03054 
ML + H -=' MLH 7.48 ± 0.03 
ML + M "" M2L 3.67 ± 0.04 
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Figure 34. Experimental (points) and calculated (lines) deprotonation curves for Mg(II) complexation 
by HEDP. Obar = Q and is the deprotonation function and the dashed line is the n curve. The three 
separate titrations were of L:M = 1 :1 (O) , L:M = 1.25:1 (D) and L:M = 2.5:1 (,;) . 
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The Hamilton factor might seem to be relatively high, if compared with previous reported 
values, but this is mainly due to the fewer data points used to fit the model. The standard 
deviations are low and the calculated and experimental Q curves (Figure 34) follow each 
other satisfactorily. The calculated and experimental formation (Z) curves for the model are 
displayed in Figure 35 . From Figure 34 one can make the same observations as in previous 
cases about the species dominating at various pH values. 
There is a difference however at high pH where Q curves cross the n curve. This is the 
reason why MLOH was included in the model. Figure 35 also shows some backfanning 
indicating MLOH or ML(OH)n species. The term 'backfanning' was used int. al. by Jarvis 
et. al. [90] to explain the observation on Z graphs that the curves tum back at low pA 
(negative logarithm of the free ligand concentration) indicating that hydrolysis becomes 
important as the titration proceeds. 
The question remains whether or not the hydroxyl group loses its proton to form MLH_1 or 
if the proton is released from a coordinated water molecule (MLOH). The equilibrium for the 
formation ofMLOH can be written as: ML + OH~ ML(OH) (where Log K = Log Pl\1LoH -
Log Pl\,1L) 
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Figure 35. Experimental (points) and calculated (lines) formation curves for Mg(II) complexation by 
HEDP. Zbar =Z and is the formation function and pA is the negative logarithm of the free ligand 
concentration. The three separate titrations were as for Figure 34. 
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The value found for Log K = 3.24. If the proton was lost from a coordinated water molecule, 
we would not expect a value for the equilibrium constant very different from that of 
magnesium(II)hydroxide [64]. The literature [91] gives Log K = 2.58 for the equilibrium: 
M + OH ~ M(OH). Thus, the proton is released by the hydroxyl group. It would be 
impossible for the constant of the complex to be higher than that of the metal hydroxide if the 
proton were to be released by coordinated water. 
Table 24. Reported formation constants for HEDP and Mg(II) 
Log K.\!L 



























a 0.1 mol.dm-3 (CH3)4N+, 25 °C; b 0.5 mol.dm-3 (CH3)4N+, 25 cc; C 0.1 mol.dm-3 K+, 25°C. 
The values in O brackets are calculated from the original reported values to give a better 
comparison. 
The values by Wada et. al. [89] are expected to be the highest (0.1 mol.dm-3 (CH3) 4N+), 
Carroll et. al. [88] slightly lower due to higher ionic strength, 0.5 mol.dm·3, and this work 
close to Dietsche et. al. [81] (0.1 mol.dm-3 KCl) [86]. Most did not include the constant M2L 
which may cause the higher standard deviations. The MLOH complex also seemed to be 
neglegted in the literature so far. The strength of complexation for Mg(II) is significantly 
higher than for Ca(II) as in the case ofMDP agreeing with the Irving-Williams series [81]. 
The species distrubution curves for the chosen model is displayed in Figure 36. From this the 
various complexes can be seen at the pH values predicted by the deprotonation curves. At 
high pH, MLOH becomes the predominant species. 
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Figure 36. Species distrubution curves for the complexation of Mg(II)) by HEDP at 37 °C and in 0.15 
mol.dm-3 as calculated from formation constants in Table 23. 0.00213 M HEDP and 0.00086 M Ca(II). 
Complexation of Zn(II) by HEDP 
Table 25 displays the values found for the model achieved from titration data for the 
complexation ofZn(Il) by HEDP. ESTA2A output is found in Appendix BS and titration data 
points in Appendix C4. No suitable models were achieved. The main reason once again being 
the precipitate that forms between pH = 5 to 7. 5. Cutting out this area of precipitation was 
not helpfull in modelling. 
Table 25 Formation constants for HEDP and Zn(II) 
Cation Equilibrium LogK Data HamiltonR 
eoints factor 
Zn(II) M+L -="ML 8.85 ± 0.02 600 0.02359 
ML+M -="M2L 4.72 ± 0.04 
ML + OH ..,,,. MLOH 4.38 ± 0.04 
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Constants in literature for Zn(II) with HEDP were only reported by Dietsch et.al. [81] and 
will be discussed together with polarographic data. (For the first complexation constant they 
report Log K1 = 8.19, comparing with the value reported here.) 
The calculated and experimental Q curves are displayed in Figure 36a. This was the main 
reason to doubt the plausibility of the model. The Hamilton factor and standard deviations are 
reasonable. MLOH was included because of backfanning in the Z curve and crossing of the n 
curve by the Q curves. Polarography will be used to accurately calculate the constants. 
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Figure 36a. Experimental (points) and calculated (lines) deprotonation curves for Zn(II) complexation 
by HEDP. Qbar =Q and is the deprotonation function and the dashed line is then curve. The three 
separate titrations were of L:M = 1 :1 (0), L:M = 1.25:1 (D) and L:M = 2.5:1 (t.) . 
Complexation of Cd(II) by HEDP 
Because of the use of polarography as a tool to derive complexation constants, a system had 
to be found to compare it with potentiometry. Such a system should include a 
polarographically active metal ion and one which forms no precipitates with the ligand at 
potentiometric ratios and concentrations. Such a system was found to be Cd(II) with HEDP. 
Table 26 displays the values found for the best model achieved from titration data for the 
complexation ofCd(II) by HEDP using all the 600 data points aquired with the normal L:M 
ratios used. EST A2A output is found in Appendix B5 and titration data points in Appendix 
C4. 
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Table 26 Formation constants for HEDP and Cd(II) 
-------
Cation Equilibrium LogK Data Hamilton R 
points factor 
Cd(II) M+L~ML 7.39 ± 0.03 600 0.01333 
ML+H~MLH 7.31 ± 0.06 
MLH+H ~MLH2 5.75 ± 0.06 
ML+M ~M2L 5.77 ± 0.06 
ML+OH~MLOH 3.14 ± 0.04 
No constants were found in the literature for the complexation of Cd(II) by HEDP. 
The fit of the data to the model is not totally satisfactory but because of a good Hamilton 
factor and standard deviations and a reasonable agreement between calculated vs experimental 
Q curves (Figure 3 7) the model is acceptable. From this graph the species MLOH is very 
evident (the crossing of the curves). From the calculated vs experimental Q curves it seems 
that a complex is missing from the model to fit the calculated curve better to the data. From 
results with polarography at a ratio 30: 1 this complex proved to be ML2. From speciation 
calculations it was evident that only at a ratio higher than ratio 3: 1 this species becomes 
predominant. Potentiometric titrations at this ratio was used to calculated this complexation 
constant. Table 27 presents results from this experiment. 
Table 27 Formation constants for HEDP and Cd(II) ratio 3: 1. 
Cation Equilibrium LogK Data Hamilton R 
points factor 
Cd(II) M+L~ML 6.93 ± 0.04 76 0.020 
ML+L~ML2 3.29 ± 0.07 
ML+ 2H ~MLH2 12.93 ± 0.05 
ML+M ~M~L 6.06 ± 0.05 
Figure 38 displays calculated vs experimental Z curves and figure 39 the corresponding Z H 
curves. From this it is evident that a plausible fit of data to the model has been achieved. 
Table 28 displays the new values found for this model applied to the titration data for the L:M 
ratios normally used. The value for ML2 found in Table 27 was kept fixed during the ESTA 
iterations, but although it is a minor species at this ratio, it still influences the other species 
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Figure 37. Experimental (points) and calculated (lines) deprotonation curves for Cd(II) complexation 
by HEDP. Qbar =Q and is the deprotonation function and the dashed line is then curve. The three 
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Figure 38. Experimental (points) and calculated (lines) formation curves for Cd(II) complexation by 
HEDP (For the ratio of L:M = 3:1). Zbar =Z and is the formation function and pA is the negative 
logarithm of the free ligand concentration. 
99 
formed in the same pH region. It therefore improves the Z fit dramatically. Data points 
corresponding to low and high pH values were cut to improve the fit even further. 
Interestingly enough the ML2 species is prominent only at a ratio higher than 3: 1. This 
explains why in the normal potentiometric ratios one could not find the species absent causing 
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Figure 39. Experimental (points) and calculated (lines) protonation formation curves for Cd(II) 
complexation by HEDP (ratio 3:1). ZH is the protonation formation function. 
Table 28 New set of formation constants for HEDP and Cd(II) 
Cation Equilibrium LogK Data HamiltonR 
points factor 
Cd(II) M+L-,,,,,ML 7.10 ± 0.04 165 0.01566 
ML+L-,,,,,ML2 3.36 ± 0.06 
ML + 2H -,,,,,MLH2 12.92 ± 0.06 
ML + M -,,,,,M2L 5.89 ± 0.05 
ML+QH-,,,,,MLOH 3.86 ± 0.05 
Figure 39 shows the Z H curves for this improved model and proves that it is plausible. 
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Figure 39. Experimental (points) and calculated (lines) protonation formation curves for Cd(II) 
complexation by HEDP. ZH is the protonation formation function. The three curves are as shown in Fig. 
37 and cover the normal potentiometric L:M ratios used. 
For HEDP and Cd(Il) the proton is released by coordinated water and not the hydroxyl group. 
The constant for ML(OH) is 3.14 but for M(OH) it is 3.9 [91]. The values are similar and the 
value for ML(OH) is smaller than for the metal hydoxide, making it possible that the proton 
is released from coordinated water. 
The species distrubution curves for the chosen model is displayed in Figure 40. At high pH, 
MLOH becomes the predominant species. These graphs were calculated for a L:M ratio of 
4: 1. Fig. 40a displays the species distubution curves at a ratio 1 : 1 which illustrates how the 
species MLz changes from a predominant species (Fig. 40 ) to a insignificant one in Fig. 40a. 
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Figure 40. Species distrubution curves for the complexation of Cd(II) by HEDP at 37 °C and in 0.15 
mol.dm-3 as calculated from formation constants in Table 28. L:M ratio= 3:1 . Note the ML2 species. 
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Figure 41 . Species distrubution curves for the complexation of Cd(II) by HEDP at 37 °C and in 0.15 
mol.dm-3 as calculated from formation constants in Table 28. L:M ratio = 1 :1. Note the almost absence 
M~ species. 
Complexation of Ho(III) and Sm(Ill) by HEDP 
ESTA2A was not able to find any model (however bad the fit might be) for titration data for 
102 
the complexation ofHo(IlI) or Sm(ill) by HEDP. The main reason is again the precipitation 
that forms below pH = 8. 
To find an estimate of the first formation constant the approach of Hancock and Martell [93] 
was used once again. Figure 41 displays the relation of Log Ki(L) vs Log K1(0H) for the 
metal ions Ca(Il), Mg(Il), Zn(Il), Cd(II) , Sr(II) and Cu(Il) [80] and Sn(II) [84]; Log K1(0ff) 
from Martell [91]. The line represents the best line ( r = 0. 994) and the solid squares (•), the 
first formation constants for Sm(ill) and Ho(ID) from this regression. The value oflog K1 for 
Sm(ill) is 10.11 and 10.4 for Ho(III). Table 29 contains the estimated constants for the 
complexation of Ho(ill) and Sm(ill) by HEDP. The second formation constant was 
calculated from the first constant in the same manner as explained earlier. From this a species 
distribution curve can be obtained which can be used to explain results found in the literature 
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Figure 41. Relationship between stability of complexes of metal ions with HEDP and the affinity of the 
metal ion for the hydroxide ion. 
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Table 29 Estimated formation constants for HEDP and Ho(III) and Sm(III) 
Cation Equilibrium LogK 
Ho(ill) M+L ~ML 10.4 
ML+H~MLH 9.1 
M+L ~ML 10.1 
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Figure 42. Species distrubution curves for the complexation of Sm(III) by HEDP at 37 °C and in 0.15 
mol.dm-3 as calculated from formation constants in Table 28. HEDP = 0.00213 M and Sm(III) = 
0.00086 M. 
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4.2 Polarographic results 
Polarography was used for metal ions where precipitation occurred with the ligands, as described 
in Section 4. 1 on potentiometric titrations. Ligand to metal ratios used were in the order of 1: 1 
and metal ions like Zn(II) formed precipitates with the ligands at these ratios and ligand 
concentrations. To confirm that formation constants derived from these two techniques are 
comparable, a system in which no precipitation at potentiometric ratios and a metal ion which is 
polarographically active is needed. 
4.2.1 Polarographic results for the complexation of Cd(II) by HEDP 
Such a system was found to be Cd(II) and HEDP. Experiments with different L:M ratios were 
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Figure 42. The species distribution diagram as a function of pH calculated from polarographic results. L:M 
ratio taken as 27:1 at 37°C and 0.1 SM NaCl background solution. (-) Represents fractions of cadmium 
complexes,('"·) fractions of the total ligand and(-) represents the fractions of cadmium complexes with 
OH-_ 
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Fig. 42 represents the species distribution diagram for a ratio of 27: 1. This will be used to discuss 
various tendencies further on. 
In Fig. 43 the shift in the peak potential vs pH is shown. The regions where various protonated 
forms of the ligand HEDP predominate are marked in Fig. 43 to facilitate the discussion of the 
results that follow. It has been demonstrated [38] that when one metal species is predominant in 
the pH range where one form of ligand also predominates, then the slope of about 61 / n m V ( at 
3 7 ° C) per proton involved in the electrochemical reaction should be observed (n = number of 
electrons involved in electrochemical reaction). This value should be expressed per metal ion. In 
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Figure 43. Shift in DP peak potential of cadmium complexes as a function of pH at 37°C and 0.1 SM ionic 
strength. All polarograms were recorded in one solution; adjusted to a particular pH given by data points 
indicated by (o). Dotted vertical lines indicate regions of interest. 
presence of the polynuclear species M2L which undergoes the following reaction 
(Charges have been omitted for simplicity) 
in which two protons are involved to form the HJ., form of the ligand L. Per metal ion (and n =2) 
one would expect 30 mV for the two protons involved. 
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The species M2L continues to dominate in region III although the predominant ligand form 
changes to HL at pH= 6.8. The slope would be expected to decrease (to 15 mV per pH unit) due 
to less protons formed in the electrochemical reaction. 
M2L + H+ + 2e- '? 2M(Hg) + HL 
However ML according to the reaction 
ML + H+ + 2e- '? M(Hg) + HL 
also starts to form in this region, increasing the slope to an expected 30 m V. The resulting 25 m V 
is therefore observed. At higher pH (pH= 7.4) ML becomes the predominant species. However 
in this region (region III) the peak height decreases up to pH = 8 and then decreases sharply (Fig. 
44) indicating that ML is still a labile species but ML2 is non-labile. From the decrease in peak 
height it is possible to calculate the formation constant for ML and ML2. The slope (peak 
potential) decreases to about 13 mV between pH 8.5 and 10.2 where the quasi-labile ML and 
non-labile species ML2, predominate. In region IV the peak height starts to increase again (Fig. 
44) and the measured slope of25 mV indicates the MLOH species which undergoes the reaction 
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Figure 44. Variation in DP peak height vs. pH for the system described in Fig .43. (o) represents the 
expected peak height (a decrease in height is only caused by dilution),(<>) the observed peak (a decrease 
is caused by formation complexes) and (t.) represents the peak height corrected for dilution which indicates 
whether a decrease in peak height is due to a complex formation reaction or not. 
107 
MLOH + H- + 2e- ~ M(Hg) + L. 
To conclude; Almost no shift was found for region I where MLH2 and H2L dominate respectively. 
This can be explained by the absence of protons in the following reaction 
MLH2 + 2e- ~ M(Hg) + H2L. 
The relationship between the expected height of a peak ( (this is calculated from the dilution 
factor in Eq. 2 ,section 2.2, assuming that no metal complexes are formed) and the observed 
height is plotted vs. pH as seen in Fig. 44. This is an important relationship because the expected 
and observed height are both used to calculate the formation constant in Eq. 2a, as a decrease in 
the corrected peak height will contribute to the shift in peak potential. 
One can easily identify that prior to region I, MLH4 and MLH2 complexes are formed because the 
corrected peak height curve shows a decrease. In region I the height stays constant indicating that 
no new complexes are formed and MLH2 predominates in this region. In region II a new species, 
M~, is formed as indicated by the decrease in peak height and stays constant for a short period 
where it predominates (between pH 5.4 and 7.4). In region III the peak height decreases sharply. 
This is due to the formation of quasi-labile ML and non-labile ML2 complexes. Although the shift 
in peak potential decreased in this region, the inclusion of the term describing the decrease in the 
corrected peak height in Eq. 2a made it possible to determine the formation constant not only for 
ML but also for ML2. Region IV shows the rise in peak height as MLOH is formed. 
To support the formation of the binuclear species M2L and not MLH the shift in peak potential 
vs. Log [Li,=] can be used [38] (see Fig. 45). Here the slope in region II is 15 mV per log[LFreeJ 
unit which clearly indicates that one ligand per two metal ions (or Yi a ligand per metal ion) is 
involved. (A slope of 30 mV indicates one metal ion per ligand). Proof to strengthen the 
suggested existence of the M2L species, as deduced from potentiometry which has indicated this 
species to be important in the complexation of all three ligands studied, is provided by 
polarography. This is not only by a mathematical exercise (where a mathematical model is fitted 
to data points using a series of mass-balance equations shown in Fig. 46) but also by this 
interpretation of decreases in peak potentials. In region III the slope is 28 m V indicating the 
formation and predominant presence of the ML species. The slope decreases at higher log[LFreJ 
(less negative values) or higher pH values due to the formation of non-labile complexes. A slope 
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Figure 45. Shift in DP peak potential of cadmium complexes as a function of free ligand concentration 




Model : M(H2L), M2L, ML, 
ML2 and ML(OH) 
4 5 6 7 
pH 
8 
Model : M(H4L), 
M(H2'-), M2L, ML plus 
all Cd, (OH)y species 
Model : M(H.l), M(H2L), M2L, ML, ML2, 
ML(OH) plus all Cd,.(OH)y species 
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Figure 46. Experimental and calculated corrected shift in peak potential for the Cd-HEDP system. The 
corrected shift in the peak potential represents the left-hand side of Eq. 2a. The theoretical curve seen as 
(-) was calculated for the fully metal-ligand system. (-) and (····) represent theoretical curves calculated 
in the same way but excluding some complex from the model. 
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The calculated formation constant were refined using Eq. 2a. The expected shift in peak potential 
was calculated for each data point obtained for each pH(I) value obtained after the ith sodium 
hydroxide addition. The values achieved by Eq. 3 were used as starting values to calculated the 
theoretical curve. Throughout the calculations the formation constants for Cd(II) hydroxide 
species was kept fixed. The formation constants were refined by entering improved values by hand 
comparing the theoretical and corrected shift in peak potentials as can be seen in Fig. 46. The 
corrected shift in the peak potential is described by the left-hand side of Eq. 2a where the 
observed shift Mp(I) at each ith pH(I) value is corrected by the logarithmic term from the relative 
decrease in the polarographic peak height caused by the change in the diffusion coefficient for 
each metal complex formed in the solution. Open circles in Fig. 46 represents the experimental 
points and the continuous line is the calculated corrected shift from Eq. 2a for all the complexes 
of cadmium with the ligand HEDP seen in Table 30 as well as the complexes with Off. The other 
lines present other models. If the model derived from potentiometry (without MLH4), the dashed 
line, the theoretical corrected shift values are higher than the observed ones at low pH This can 
be understood as potentiometry cannot calculate formation constants accurately at low pH If 
ML,, and MLOH are excluded the values for the theoretical corrected shift are too low if compare 
with the data points ( dotted line). 
Table 30 Formation constants for Cd(II) and HEDP derived by polarography 
--· -
Cation Equilibrium LogK Data points 
Cd(II) M+L-=':ML 7.18 ± 0.05 46 
ML+ L-=' ML2 3.28 ± 0.06 
ML + 2H -=' MLH2 12.37 ± 0.07 
MLH2 + 2H ""' MLHi 5.53 ± 0.07 
ML+M-='M2L 5.57 ± 0.07* 
ML + OH ""' MLOH 3.76 ± 0.06 
*Note: It is important that the calculation of the formation constant for the non-labile, ML2 species, was 
performed for the first time by Eq. 2a, using only the shift in labile peak potentials and drop in peak height. 
In support of this a good agreement between potentiometry and polarography was achieved for 
the formation constant for the ML2 species as well as all formation constants in general. Table 31 
compares the two techniques by means of Log p values. 
Polarography proved that a non-labile species existed at high pH Potentiometry found this to be 
ML2 found a formation constant for it. This was inserted into the polarographic model and by 
using Eq. 2a the theoretical corrected shift could be calculated from this. It proved after a few 
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iterations by hand that the potentiometric constant value reproducing the observed corrected shift 
the best value. This resulted in similar values for this constant. However for MLOH the similar 
constant was achieved totally independently by the two techniques. 
Table 31. Comparison of results obtained by potentiometry and polarography for Cd(II) 
complexation by HEDP at 37 °C and I = 0.15 M NaCl. 
Equilibrium losdl (potentiometry) losdl (polaroeraphy) 
M+L=ML 7.10(4) 7.18(5) 
2M+L = M')L 12.99(3) 12.75(5) 
M+L + 2H = MLH') 20.02(3) 19.55(5) 
M+L+4H = MLH,, Not found 25 .08(3) 
M + L + OH = MLOH 10.94(3) 10.94(3) 
M+2L=ML1 10.46(5) 10.46(5) 
It is now possible to understand the kind of results that are achieved by this technique. Fig. 4 7 
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Figure 47. Polarograms recorded at various pH values indicating the shift in peak potential and decrease 
of peak height indicating the formation of Cd-HEDP complexes. Note the second peak appearing at pH = 
10 and the reappearance of the original peak at pH = 11 . 
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negative value) and the decrease in peak height. This is as expected up to pH 7. 723 when the 
shift increases and the peak height starts to drop dramatically. Here ML becomes the predominant 
species. When the pH is increased to 9.073, the labile peak decreases sharply and at pH= 10.217 
it totally disappears. The second peak has already the same height as the labile peak at pH = 9. 073 
and corresponds to the non-labile species, ML2. This peak is only briefly the major peak but at pH 
= 11 . 83 5 the original labile peak has reappeared. This is proof of the formation of the labile 
MLOH complex. 
4.2.2 Polarographic results for the complexation of Zn(II) by HEDP 
The next system to be studied was HEDP and Zn(II). Here a similar drop in peak height and shift 
in peak potential was recorded as for Cd(II). (See Appendix E2 to view the polarograms recorded 
at different pH values as in Fig.47). Although the second peak probably appears at higher pH it 
is at a potential where the ligand shows activity and it was therefore impossible to record at more 
negative potentials than -1.1 V .Peak potentials were therefore recorded only up to pH = 6. 5. 
However from the Cd(II)HEDP system it was shown that by using Eq. 2a only the labile part is 
necessary to calculate all the formation constants (including the non-labile). 
In Fig. 48 the shift in the peak potential vs pH is presented. The regions where various protonated 
forms of the ligand HEDP predominate are marked as before. A slope of about 30.7 mV per 
proton involved in the electrochemical reaction, expressed per metal ion, should be observed ( two 
electrons involved for Zn(II)). In region II, between pH 4.5 and 5.7, a slope of27 mV per pH 
unit is observed. It indicates the presence of the polynuclear species M2L which undergoes the 
following reaction 
M2L + 2H,- + 2e- "" 2M(Hg) + H2L 
Per metal ion, one would expect a 30 m V shift per pH unit for the two protons involved. 
This changes in region III, up to pH 6.3, where ML predominates. This is visible from the slope 
of 59 m V for the reaction 
ML+ 2H~ + 2e-"" M(Hg) + H2L 
The formation of ML occurs with Zn(II) at a lower pH as for Cd(II). This indicates that ML is 
a stronger complex for Zn(II)-HEDP. This will result in higher formation constants as is expected 
from the free linear energy plots (Section 4.1.4) for HEDP. This is in correspondence with the 
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Figure 48. Shift in DP peak potential of HEDP-Zn(II) labile complexes as a function of pH at 37°C and 
0.15M ionic strength. All polarograms were recorded in one solution; adjusted to a particular pH given by 
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Figure 49. Variation in DP peak height vs. pH for the system described in Fig.48. (o) represents the 
expected peak height (a decrease in height is only caused by dilution), (<>) the observed peak (a decrease 
is caused by formation complexes) and (t.) represents the peak height corrected for dilution which indicates 
whether a decrease in peak height is due to complex formation or not. 
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Cd(II)) will results in stronger complexes 
To conclude; Almost no shift was found for region I where MLH2 and H2L dominate respectively. 
This can be explained by the absence of protons in the following reactions 
MLH2 + 2e- ~ M(Hg) + H2L. 
At the start of region I however, pH= 1.9 to 2.4 there was a shift in potential. This can be 
explained by more protonated complexes viz. ML~, where Hc;L (together with H4L) predominate 
at lower pH value, according to the reaction 
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Figure 50. Shift in DP peak potential of zinc complexes as a function of free ligand concentration calculated 
for each data point from recorded polarograms (see Appendix E2). 
The relationship between the expected height of a peak and the observed height vs. pH is plotted 
in Fig. 49. One can easily identify that in region I, MLH4 and MLH2 complexes are formed 
because the corrected peak height curve shows a decrease. Between pH= 2.5 and 3 however this 
curve tends to be horizontal, indicating that MLRz is the predominant species. In region II the 
ligand changes from ~L to H2L and the species M2L starts to dominate. The peak height 
therefore drops but the decrease flattens off at pH = 3. 8. In region ill the peak height decreases 
significantly. This is due to the formation of the quasi-labile complex ML and possibly another 
non-labile complex that forms (not polarographically visible). 
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As was the case with HEDP and Cd(II), the formation of the binuclear species M2L, and not 
MLH, is proven by the shift in peak potential vs. Log [Lrrcel graph shown in Fig. 50 [38]. Here 
the slope in region II is also 15 m V per log[LF,eel unit which clearly indicates that one ligand per 
two metal ions is involved in the electrochemical reaction. In region III the slope is 27 m V 
indicating the formation and predominant presence of the ML species. 
The best mathematical model achieved to fit the data points, using a series of mass-balance 
equations, is shown in Fig. 51. Throughout the calculations, the formation constants for Zn(II) 
hydroxide species was kept fixed. The formation constants were refined by entering improved 
values by hand and comparing the curve of the theoretical corrected shift with the observed 
corrected shift in peak potentials as can be seen in Fig. 51. 
Open circles in Fig. 51 represents the experimental points and the continuos line are the calculated 
corrected shift from Eq. 2a for all the complexes of Zn(II) with the ligand HEDP seen in Table 
32 as well as the complexes with Off. The other lines represent other models where some of the 
complexes are missing. If MLH4 (dashed curve) is excluded from the model, the dashed line 
indicates that at low pH the observed corrected shift values are higher than the theoretically 
(calculated) corrected shift in peak potentials. IfMLOH is excluded (dotted line) the values for 
the theoretical corrected shift are too low at higher pH values if compared with the observed shift 
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Model : M(H.l), 
M(H,L), ~ ML 
-10 +---------,---------,--------.----------.--------, 
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pH 
Figure 51. Experimental and calculated corrected shift in peak potential for the Zn(ll)-HEDP system. The 
theoretical curve seen as(-) was calculated for the fully metal-ligand system. (-) and ( ··) represent 
theoretical curves calculated in the same way but excluding some complex from the model 
Table 32 Formation constants for Zn(II) and HEDP derived by polarography 
Cation E uiliprium Lo K Data oints 
Zn(II) M+L~ML 10.30 ± 0.05 25 
ML+2H~MLH2 9.88 ± 0.05 
MLH2 + 2H ~ MLH4 5.50 ± 0.03 
ML+M~M2L 6.16 ± 0.07 
ML + OH ~ MLOH* 7.43 ± 0.07 
* The MLOH species was not deduced from any previous plot. However this value is needed in 
the model as can be seen from Fig. 51 where the theoretical fit is improved by its inclusion. The 
value is nonetheless high if one considers Log K(OH-) for Zn(II) to be 4.8. This value is therefore 
doubtful especially when only a few data points are available at pH values where MLOH 
predominates. It is also possible that other non-labile species are present. 
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Figure 52. The species distribution curve as a function of pH calculated from polarographic results. L:M 
ratio taken as 58:1 at 37°C and 0.15M NaCl background solution. (-) Represents fractions of zinc 
complexes 
4.2.3 Polarographic results for the complexation of Zn(II) by MDP 
The next system to be studied was MDP and Zn(II). Here a similar drop in peak height and shift 
in peak potential was recorded. (See Appendix E3 to view the polarograms recorded at different 
pH values as in Fig.47). The second peak probably appears also at higher pH (above 6.5), at a 
potential where the ligand shows activity making it impossible to record polarograms. 
In Fig. 53 the shift in the peak potential vs pH is presented. A slope of 30 mV per pH unit is 
observed in region II whereas a slope of about 30.7 mV expressed per metal ion should have been 
observed to indicate the species M2L. M2L is thus described by 
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Figure 53. Shift in DP peak potential of MDP-Zn(II) complexes as a function of pH at 37°C and 0.15M ionic 
strength. All polarograms were recorded in one solution; adjusted to a particular pH given by data points 
indicated by (o) . 
In region ill, up to pH 6. 4, ML predominates. This is apparent from the slope of 60 m V for the 
reaction 
ML + 2H+ + 2e·""" M(Hg) + H2L 
The formation of ML for MDP occurs at almost the same pH as for HEDP. This indicates little 
difference between the complexation ofMDP and HEDP. A small shift was found for region I 
where MLH2 and MLH4 dominate. 
The relationship between the expected height of a peak and the observed height vs. pH is plotted, 
in Fig. 54. One can identify that in region I, MLH4 and MLH2 complexes are formed because the 
corrected peak height curve shows a decrease. In region II however this curve tends to be 
horizontal, indicating that MLH2 is the predominant species. In region ill the ligand changes from 
H3L to 1-IzL and the species ML starts to dominate. The peak height therefore drops 
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Figure 54. Variation in DP peak height vs. pH for Zn(ll)-MDP. (o) represents the expected peak height (a 
decrease in height is only caused by dilution), (o) the observed peak (a decrease is caused by formation 
complexes) and (t.) represents the peak height corrected for dilution which indicates whether a decrease 
in peak height is due to complex formation or not. 
The presence of the binuclear species M2L is proven by the shift in peak potential vs. Log [Lfree] 
graph shown in Fig. 55 where a slope of 15 mV per log[4.ree] unit in region II is observed. In 
region ID the slope is 30 mV indicating formation of the ML species. 
The best mathematical model achieved to fit the data points, using a series of mass-balance 
equations, is shown in Fig. 56, open circles representing the experimental points and the continuos 
line is the calculated corrected shift for all the complexes of Zn(II) with the ligand MDP, seen in 
Table 33 . Other lines present other models where some extra complexes are included. 
Table 33 Formation constants for Zn(II) and MDP derived by polarography 
Cation E uilibrium LogK Data points 
Zn(II) M+L""'ML 9.94 ± 0.05 25 
ML + 2H""' MLH2 10.02 ± 0.05 
MLH2 + 2H""' MLH4 5.73 ± 0.03 
ML+M""'MiI, 5.56 ± 0.07 
ML+ OH""' MLOH* 7.46 ± 0.07 
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Figure 55. Shift in DP peak potential of zinc complexes as a function of free ligand concentration calculated 
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Figure 56. Experimental and calculated corrected shift in peak potential for the Zn(ll)-MDP system. The 
theoretical curve seen as(-) was calculated for the fully metal-ligand system. (· ···) represents a theoretical 
curve calculated in the same way but including some extra complexes in the model. 
120 
* The MLOH species is needed in the model as can be seen from Fig. 56 where the theoretical 
fit is improved by its inclusion. However the constant calculated for it is high if one considers Log 
K(OH-) for Zn(II) to be 4.8. This would normally indicate that a hydroxy group takes part in 
complexation. However MOP has no hydroxy group. This value is therefore doubtful which may 
be explained by the few data points available at this pH and other non-labile complexes formed 
in this pH region. 
ML(OH)2 however seems to have an adverse effect on the fit at lower pH and is not included. 
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Figure 57. The species distribution curve as a function of pH calculated from polarographic results. L:M 
ratio taken as 60:1 at 37°C and 0.1 SM NaCl background solution. (-) Represents fractions of zinc 
complexes. 
4.2.4 Polarographic results for the complexation of Zn(II) by APD 
The next system to be studied was APO and Zn(II). Here a similar drop in peak height and shift 
in peak potential was recorded. (See Appendix E4 to view the polarograms recorded at different 
pH values as for Fig.47). The second peak probably appears at higher pH (pH ~ 6), at a potential 
where the ligand shows activity and therefore making it impossible to record polarograms. 
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In Fig. 58 the shift in the peak potential vs pH is presented. A slope of 32 mV per pH unit is 
observed in region II. With APO however the ligand species, H3L is still predominant. This 
corresponds with changing the complex species from M 2L to MLH2 or M2 LH as shown by the 
following reactions. 
M2LH + 2H+ + 2e- ~ 2M(Hg) + H3L 
MLH2 + H+ + 2e- ~ M(Hg) + H3L 
Both would have reported a theoretical shift of 31 . 5 m V / pH unit. From evidence of the 
Log[4-...,J vs peak potential plot (Fig. 59) the M2LH species is accepted. This excludes MLH2 
from the model which would normally form in this region. Therefore in region I, MLH3 and not 
MLH2, will dominate as indicated by the very small shift ( almost zero slope) for this region. 
MLH3 +2e- ~ M(Hg) + H3L (No protons, no shift) 
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Figure 58. Shift in DP peak potential of APD-Zn(II) complexes as a function of pH at 37°C and 0.1 SM ionic 
strength. All polarograms were recorded in one solution ; adjusted to a particular pH given by data points 
indicated by (o) . 
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In region III, up to pH 5. 8, MLH predominates. This is apparent from the slope of 5 5 m V for the 
reaction 
MLH + 2H+ + 2e- ,... M(Hg) + H3L 
The formation constant for ML is calculated from the last few data points. No data is available 
to calculate less protonated species like MLOH. The big difference between the complexation of 
MOP and HEDP on the one hand and APD on the other is once again evident. 
The presence of the binuclear species M2LH, is proven by Fig. 59 where a slope of 13 m V, and 
not 30 mV, per log[LpreeJ unit is observed in region II. M2L is thus absent. If the peak potential 
was plotted vs Log[HLpree] a slope of 30 m V would possible have resulted and delivered direct 
prove ofM:J,H. In region Ill the slope of 30 m V indicates the formation of the MLH species. A 
similar drop in peak height was observed as was the case with Zn(II) and MDP as well as HEDP. 
The drop was more equally spread and no deduction could be made from it. 
This was also the best mathematical model to fit the data points. Formation constants for the 
























-25 -24 -23 -22 -21 -20 -19 -18 -17 -16 -15 -14 -13 -12 -11 
Log[Li,ree] 
Figure 59. Shift in DP peak potential of zinc complexes as a function of free ligand (APD) concentration 
calculated for each data point from recorded polarograms. 
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Table 34 Formation constants for Zn(II) and APO derived by polarography 
Cation Equilibrium LogK Data points 
Zn(II) M+L ,a!, ML 14.55* ± 0.05 33 
ML + H ,a!, MLH 6.33 ± 0.07 
ML + 3H ,a!, MLH3 14.80 ± 0.07 
MLH + M ,a!, M2LH 4.86 ± 0.07 
* This is a high value for the ML species if one considers the Log K(OH) vs Log K1(L) plot 
(Section 4.1 .2) where a value for this constant equal to 12.5 would be expected. This value is 
therefore doubtful and may be explained by the few data points available at this pH. This is very 
possible as no next complex (etc. MLOH for HEOP and MOP) could be calculated. Uncertainty 
seems to be part of the last complex calculated by polarography. 
The opposite is true for MLH where a value of 9-10 is expected as this is the value for the first 
protonation constant for APO. The small value might be due to the large value for ML. 
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Figure 60. The species distribution curve as a function of pH calculated from polarographic results for 
Zn(APD). L:M ratio taken as 60:1 at 37°C and 0.15M NaCl background. 
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The data points (peak potential and peak height) recorded from each polarogram is included in 
Appendix D 1 to D4 for each of the systems in the order as they were discussed in this chapter. 
A summary of protonation and formation constants calculated is included in Table 1 (Appendix 
BO). This will facilitate the comparison of constants for the different ligands with each other as 
well as the identification of tendencies described in the following sections. 
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4.3 NMR results and proposed Structures 
4.3.1 NMR studies 
NMR has been used extensively to study the structure of metal complexes in solution 
[103]. Initially HEDP was studied using 31P NMR. This is an ideal nucleus with which to 
study the complexation ofHEDP as the phosphorous atom is near the site of complexation 
and the 31P nucleus has a high NMR sensitivity. Phosphoric acid was used as an external 
reference. The 31P{1H} NMR spectrum of the ligand alone at low and high pH shows a 
single peak (the diphosphonate groups are symmetrical) at 20.4 ppm (pH = 2) and 20.2 
ppm (pH = 10.5). This difference is within experimental error and as expected, no shift 
was recorded. The reason for this being the two bond distance of a proton from the P-
atom. For example a big change in a phosphonate structure was studied by Li et.al. [100]. 
They observed only a 4 ppm difference in 31P shift before and after the hydrolysis of 
thymidine 5-boranomonophosphate. (The tymidine-boranophophate bond breaks releasing 
boranophosphate). Others [99] confirmed that no shift was expected in this case. At high 
pH the oxygen next to the phosphorous might be protonated but the water solution is still 
negatively charged. Little changes in the environment surrounding the P-atom [101]. 
For complexed HEDP the following changes were observed: as the pH of the solution was 
increased the 31P resonance shifted to 19.0 ppm (pH 3.0), 19.1 ppm (pH 5.0), 19.9 ppm 
(pH 7.0) and 20.0 ppm (pH 11.0). At the same time the peak became very broad indicating 
that the species in solution were fluxional. The change in chemical shift is very small and 
could be ascribed to experimental error. Although one would expect substantial shifting of 
the peak on complexation, it must be concluded that the complex is labile or fluxional by 
nature causing an absence of shift. It is thought that the metal ion associates and 
dissociates at a rate faster than the NMR time scale. For fast exchange with the 31P 
nucleus, the lifetime of the molecule (complex) must be smaller than 12.3 msec (1 / (0.5 
ppm* 162 MHz)(the 31P frequency on a 400 MHz apparatus)) as only a shift of 0.5 ppm is 
observed. As the complexation grows stronger (higher pH) the deviation round the true 
value increases as there is more interaction between ligand and metal ion. This might 
explain the broadening of the peak at higher pH. 
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For H::EDP, besides the phosphonate groups, the central hydroxyl group can be involved in 
metal ion coordination. In order to investigate this possibility, a 13e NMR study was 
undertaken. However, in the case of H::EDP coordination, the study was not entirely 
successful as at the necessary concentrations only small peaks were recorded by 13e NMR. 
The results achieved are none the less reported in this short chapter. NMR spectra are 
included in Appendix F for reference. At the same high metal to ligand ratios, APD formed 
precipitates on complexation with Mg(II). No alternative system was studied. The ligand 
alone produced two peaks at 92.8 and 22.0 ppm with a peak height ratio of 1 :3 at pH= 2. 
This corresponds to the hydroxy containing a tertiary carbon ( a low field value is expected 
with three deshielding groups attached) and the primary eH3-group (relatively high field 
because its one bond from deshielding groups). The ratio of 1:3 is in accordance with the 
tertiary versus the primary carbon. The complexed ligand produced even smaller peaks due 
to line broadening. At pH = 3 two peaks at 3 2. 9 and 21. 7 ppm in the same ratio as before 
were recorded. The peaks are just above the background noise and some uncertainty exists 
as to whether there is indeed a peak at 32.9 ppm. The tertiary carbon peak seems to have 
shifted almost 60 ppm upfield. For the primary carbon the shift is 0.3 ppm but as it is one 
bond away and not expected to be involved in complexation, this is reasonable. At pH = 5 
the number of scans had to be increased to get any useful information. This was done by 
recording overnight and accumulating 5000 scans. The resulting spectrum contains three 
peaks at 60.0, 21.7 and 19.4 ppm. It seems that the peak of the primary carbon was split 
into two. The other peak at 60.0 ppm belongs to the tertiary carbon indicating a 30 ppm 
shift. This value is more acceptable than before and because of the number of scans is 
definitely a peak above background. This result indicates that the molecule is in slow 
exchange with regard to the 13e resonances. In fact it is often observed that a fluxional 
· molecule can be in slow exchange with respect to one nucleus but not with respect to 
another. In this case because there is a shift of 3062 Hz (30 ppm * 100.62 MHz), the 
lifetime of the molecule (complex) has to be smaller than 0.33 msec (1 / (30 ppm* 100.62 
MHz) (13e frequency on a 400 MHz apparatus)), for fast exchange. The lifetime of the 
complex will be larger than 0.33 msec if the exchange with this nucleus is slow (two peaks 
appear). If one considers that the complex had a lifetime smaller than 12.3 msec (the peak 
broadening for 31P NMR) the lifetime of the complex should be in between 0.33 and 12.3 
msec. 
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Because of the large change in chemical shift of the carbon attached to the hydroxyl group 
it is reasonable to propose that the hydroxyl group is involved in coordination. This 
conclusion is supported by the potentiometric results. 
The use of 1H NMR in this problem was not possible as the protons of interest were all 
labile and rapidly exchanged with the D20 solvent [99]. 
4.3.2 Structure 
The following are suggested structures for some of the protonated ligands and complexes 
identified either by potentiometry or polarography. 
As noted in Section 4.1.1 a protonated species of ligand viz. E;L is found for MOP and 
HEDP. It will probable exits for APD as well but at a pH lower than 2. Here it becomes 
difficult to use potentiometry accurately. On first impression it seems an unlikely species 
but it might be explained by the following sequence of proposed deprotonation. 
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Where R can be H-, CH3- or NHrCHrCHr. The OH can also be Hin the case of MOP. The first 
species exists only at low pH values and looses both protons together. The rest of the sequence 
is in correspondence with Wada and Fernando [89]. 
For complex species these structures above are the starting point. :rvrLH2 (or :rvIH2L) 
should however differ from the fourth structure above. On each phosphonate group there 
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should be one protonated oxygen and a negatively charged oxygen that is participating in 
complexation. 11::DP should behave in all the complexes like a bidentate ligand which 
results in a six member ring with the metal ion. HEDP and APD have an extra hydroxy 
group which can take part in complexation. As described in Section 4 .1.4 there is evidence 
that in the complexation of Mg(II) by HEDP the hydroxy group is deprotonated on 
formation of l\1LOH. This would indicate that the hydroxy group takes part in 
complexation. Further evidence comes from the stronger complexes HEDP forms with 
respect to 11::DP. The first formation constant for HEDP with most of the metal ions 
investigated is half a log unit higher than for 11::DP. The main difference between them is 
the hydroxy group. This would suggest that the hydroxy group takes part in complexation. 
One can postulate a possible structure for complexes with HEDP in general (structure I) 
and for octahedral metal ions, structure II. Both structures indicate that HEDP is a 
tridentate ligand. In structure II, the three remaining metal coordination sites are occupied 
by coordinated water molecules. The possibility also exists that each phosphonate group is 
bidentate. Whether this is the case in the ligands studied here can only be confirmed if it is 
possible to isolate the solid form of this complex and do an IR analysis on it. Oakes and 










Structures I and II would suggest an l\1L species but protonation can occur at the 
phosphonate sites to form the species MLH or MLH2. For all the metal ions the pKa of the 
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complex is inbetween the pK.1 and pK.2 of HEDP. This suggest that protonation of the 
complex takes place at one of the two phosphonate sites. 
For APD, R=CH2CH2NH2, which could also coordinate to a metal ion. The first formation 
constant for the various metal ions with ADP is more than one log unit higher than for 
HEDP. The only difference between APD and HEDP is the amino group. This strongly 
suggests that the amino group takes part in complexation. However it is impossible to 
have a structure where APD acts as a tetradentate ligand coordinating with the hydroxy as 
well as the amino group. This can easily be deduced by building a simple framework model 
and is also visible from structure III where APD is complexed to an octahedral metal ion. 
Structure ID. Possible structure of ML for APD. 
If one takes a tetrahedral metal ion it is even more difficult to accommodate four dentates. 
The contribution of an amino group to complexation is bigger than a hydroxide group as it 
· is more basic. It is therefore still theoretically possible that APD will form stronger 
complexes (as is observed) than HEDP. Structure III is a suggested structure for the 
species ML. MLH would be a protonated form of this structure. For Ca(II), Sr(II) and 
Mg(II) the pK. of the MLH complex is between pK.1 and pK.2 of APD. This is evidence 
for protonation taking place at the nitrogen centre. However for Zn(II), Ho(III) and 
Sm(III) the pK. of the complex is below pK.2 of APD, indicating protonation at a 
phosphonate centre. This is in agreement with the tendencies found for EDTMP [7] and 
follow the trend that the less-stable complexes are protonated at a nitrogen which must 
entail metal-nitrogen bond rupture. 
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The structure of M2L is something that has not been reported on very widely. Neither Van 
der Linden et. al. [84] nor Nash [82], who both include M2L in there papers, report on its 
structure. If one accepts the structure III as that for the species ML, it follows that the 
second metal ion might involve the free hydoxide group and a second P-0- dentate (the 
one not involved in complexation of ML). Structure IV proposes such a system. 
Structure IV. Possible structure of M2L for APO 
In structure IV the ammo group can easily change from one metal ion to another. 
However if one suggests that each metal ion is bound to one a phosphonate group (no 
chelate rings can be formed by one phosphonate group to the same metal ion) each, the 
bonding between metal ion and ligand should be weak, resulting in low formation 
constants. For the ligand MDP, Log K values found for the equilibrium ML+ M""" 
M2L are low, ranging from 3.5 to 2.9 for Ca(II), Mg(II) and Ni(II) suggesting these weak 
bonds. However for HEDP the values are higher viz. 4.0 for Ca(II) to 5.9 for Cd(II). No 
weak bonds. For APD the values are even higher viz. 5.7 for Ca(II) and 6.8 for Mg(II). 
HEDP and APD might thus form M2L species according to structure IV. 
Another interesting aspect is that for MDP and HEDP, the formation constant for the M2L 
species is higher for Ca(II) than Mg(II). This is the opposite of the normal stability order 
reported for Ca(II) and Mg(II). This indicates a stabilisation of some kind for Ca(II) or a 
destabilisation ofMg(II). The same tendency was reported by Wada and Fernando [89] for 
HEDP, however they explained this by the hydroxy group taking part in complexation of 
Ca(II) by HEDP. It has been shown here that in the case ofMg(II) and HEDP the hydroxy 
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group already takes part in complexation. Furthermore the same reversed order is found 
for ivIDP which has no hydroxy group. The reason given by Wada and Fernando [89] 
which was restated by Claessens and Van der Linde [84] can therefore not be true. Its 
seems that the reason is located in the structure of the complexes formed. The ligand 
probably does not 'fit' well around the small Mg(II) ion. Ca(II) has a radii of 0.99A and 
Mg(II), 0.66A. The same reason has been advanced for the observed reversal in stability 
order of EDT A [7] 
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4.4 In vivo Speciation by ECCLES 
Since the uptake of 166Ho by bone is rapid and completed in two to three hours after injection and 
metal uptake by proteins is slow, transferrin binding has been neglected in the blood plasma 
modelling of 166Ho-APD. Jarvis et. al. [7] have shown that this assumption is valid for 153 Sm-
EDTMP and 166Ho-EDTMP. We shall also show that this assumption is valid for HEDP and 
Sm(ill). Simulation calculations performed without the inclusion of transferrin binding, can be 
considered to model the speciation immediately after injection / administration i.e. before 
equilibrium with protein binding has been established. For Ho(m), transferrin cannot be included 
as the constants for the complexation ofHo(ill) by transferrin is not available in the ECCLES 
database. 
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Figure 61 . Speciation of Ho(III) in blood plasma with APO added; (Cit) = citrate and (sal) = 
salicylic acid (3-carboxy-3-hydroxy-pentane-1 ,5-dioic acid). 
The output of the ECCLES runs can be found in Appendix G and the ECCLES input files in 
Appendix Gl. (The concentrations taken are 8.Sxl0-5 mol.dm-3 for ligand and 2.0xl0-6 mol.dm-3 
for the metal ion). It is quite clear that, in vivo, citrate competes with APD for Ho(ill). 58% of 
the Ho(III) remains bound to APD while citrate collects 3 8% in total. The remainder of the 
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Ho(III) is distributed between salicylic acid and carbonate. This explains the good bone uptake 
ofHo(III) in the baboon model (Section 4.5). Citrate it self can deliver Ho(III) to the bone but 
is less selective and in a longer time span. Neves et. al. [95] used 166Ho(cit) as a bone localising 
agent. They describe colloid formation on complexation. This should be due to the neutral 
complex. However in blood plasma the complexes that are predominantly formed are 
Ho(cit)(OHr and Ho(cit)(OH)/ (Appendix G) which are soluble. The neutral species, Ho(cit) 
accounts for only 4.3% (1.6/38 * 100%). Citrate will stay in the blood longer than APD and at 
some time pass through the bone blood vessels. Here it will be given of to the diphosphonate 
which can bind to the hydroxy apatite. 
Hydroxy apatite forms a hexagonal crystal lattice in an elongated form on crystallization from a 
supersaturated solution of Ca(II), phosphate and hydroxide. All along the apatite crystals, grooves 
which run parallel with the C-axis of the crystal are formed. These grooves are the outside and 
are surrounded by the perivascular fluid from which the crystals are formed. The diphosphonate 
is believed to be taken up in this fluid and attach to these grooves via their strong affinity for 
Ca(II) which is part of this hydroxy apatite crystal structure. Whether or not a complex like 
SmEDTMP dissociates before absorption is not quite clear. Chirby et. al. [20] reported 
contradictory evidence. Jarvis et. al. [7] then proposed, after some insight by speciation 
modelling, a dual model where the SmEDTMP complex is absorbed on the bone followed by its 
dissociation allowing the uptake of Sm(III) into tumours. 
From the ECCLES modelling (Appendix G) it is clear that citrate does not have the same affinity 
for Ca(II) as APD. It has lower formation constants, (i.e. Log K1 = 3.2) and 23 % of the citrate 
remains as free citrate; 48% complexes with Ca(II) and 27% with Mg(II). Citrate should therefore 
cause less bone uptake than diphosphonates. In clinical trails using 166Ho(I1I) and citrate, Neves 
et. al. [95] have shown this to be true. Because citrate is not exclusively selective for bone, 
Ho(III) will take more time to accumulate in the bone where it loses the Ho(III). This results in 
slow blood clearance and high accumulation in the kidneys. However it does not loose its 
property to deliver some Ho(III) to bone tissue complementing the bone delivering action of a 
diphosphonate. 
It is interesting to compare the selectiveness of HoAPD with other diphosphonate-lanthanide 
combinations. Fig. 62 compares the speciation of HoAPD with that of SrnEDTMP and 
HoEDTMP. The results show that HoAPD behaves different from SrnEDTMP. For HoAPD the 
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complex Ln(Ligand)(H) predominates and almost no Ln(Ligand) is formed . This species is neutral 
in the case of APD and causes the high liver uptake in the baboon model (Section 4.5). In contrast 
to this SmEDTMP stays in the Ln(Ligand) form, 51 % with 28 % in the Ln(Ligand)(H) species. 
Both complexes are not neutral because EDTMP has eight dissociable protons. Thus, the 
SmEDTMP system should not show high liver uptake. This is found in practise [ 6] . The total of 
these two metal species is important for the bone uptake. SmEDTMP scores 79%, HoAPD 58% 
and HoEDTMP 18% indicating the order of expected bone uptake for these three systems. This 
is confirmed by the reverse order found for the combined presence ofHocitrate species; 79% for 
HoEDTMP, 38% for HoAPD and 20% for SmEDTMP. Form this it can be concluded that 
HoAPD should have a better bone uptake and faster blood clearance than HoEDTMP. However 
the bone uptake is not as high as SmEDTMP and one would not expect a 91 % bone uptake found 
for the latter [ 6]. Louw et. al. [ 6] reported only 65 % bone uptake for 166HoEDTMP. This bone 
uptake is higher than the amount of Ln(Ligand)(H)x species calculated to be present in blood 
plasma. This discrepancy might be due to the bone seeking action, although low, of citrate. 
An estimate of the 166HoAPD bone uptake can be made from the speciation data. One would 
expect 85% uptake and a blood clearance close to SmEDTMP ( closer to SmEDTMP than 
HoEDTMP). 
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Figure 62. Comparison of speciation of Sm(III) and Ho(III) with EDTMP or APO in blood plasma. 
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Figure 63. Speciation of APO in blood plasma. Charges have been omitted for simplicity. 
The question remains why does APD not compete as effective as EDTMP for Ho(III) in the 
presence of citrate, even though the first complexation constant for HoAPD is taken at 13 . 81 and 
14 .44 for SmEDTMP. 
One of the reasons might be APD's preference for Ca(II) illustrated by Fig. 63 . Almost 90% of 
APD complexes to Ca(II) in blood plasma in various species, the major species is Ca.zAPD(H). 
The remaining APD is complexed by Mg(II) and Ho(III). It has to be remembered that these 
figures correspond to an injected ratio ofLigand:Metal = 50: 1. None the less this will have an 
effect of the distribution ofHo(ill) in blood plasma where such a high concentration of Ca(II) is 
present, compared to Ho(III). This explains why APD is used in the treatment for osteoporosis 
or malignant osteolytic bone disease [ 11]. APD mobilises Ca(II) efficiently and has the ability to 
bind to hydroxy apatite and stops via this process, the osteolytic resorption of bone. 
Fig. 64. shows the speciation ofHEDP and MDP in blood plasma calculated using the equilibrium 
constants given in Table 20 and 29 and the total component concentrations given in Appendix G. 
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Figure 64. Comparison between the speciation of HEDP and MOP in blood plasma. 
HEDP still mobilises Ca(II) the most ( 62% ), with C<1iHEDP the major species. This is quite 
different from MDP where the mobilisation is divided in three; Mg(II) takes 35%, Ca(II) 33% and 
32% remains as free ligand or protonated ligand. In the case ofHEDP only 8% stayed as ligand 
and for APD no free ligand was observed. This confirms the strength of the bonding of metal ions 
found in blood plasma with the three ligands. APD > HEDP > MDP. The hydroxy group plays 
a vital role in the first two ligands' stronger complexation. HEDP and MDP will therefore not be 
such good inhibitors of osteolytic processes. 
As the formation constants for the complexation of Sm(III) by HEDP could be calculated (Section 
4.1.3 and 4.1.4) and experimental results of 153Sm with these ligands have been reported by Dow 
Chemicals [43] ECCLES modelling was performed for both MDP and HEDP (Appendix G). Fig. 
65 shows the distribution of SrnHEDP amongst low-molecular-weight compounds present in 
normal blood plasma. The speciation without transferrin can be assumed to be the situation shortly 
after the introduction of Sm(III) into blood plasma. Complexation of transferrin is kinetically slow 
and so the speciation in the presence of transferrin reflects the situation after a few hours. It can 
be seen that transferrin will eventually complex 88% of the remaining Sm(ill) (that which is left 
after bone absorption). The relative percentages of the low-molecular-weight complexes of 
Sm(ID) remain unchanged (Fig. 65). 
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Figure 65. Speciation of SmHEDP in blood plasma. Tfm = transferrin; the rest as previously 
defined. 
As the relative speciation of species in blood plasma with or without transferrin is the same and 
bone uptake is supposedly complete within 2 to 3 hours, transferrin has been omitted from Fig. 
66 for simplicity. Fig. 66 shows the various species Sm(III) should form with HEDP and MDP 
and other competing ligands in the blood plasma. 
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Figure 66. Speciation of Sm(III) in blood plasma with HEDP and MOP added. 
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Here the predominant species for both HEDP and MDP is the MLH species which is neutral. This 
explains why Dow Chemicals reported that 85% of the activity of 153SmMDP and 35% of 
153 SmHEDP injected into rats were taken up in the liver [43]. This is in agreement with what is 
found for 166HoAPD (Section 4.5). A total of 61 % of Sm stays bounded to HEDP while the 
percentage for MDP is 47%. This compares favourably with the 57% of APD. The other major 
competing species here is again citrate. 
The question that arises is how it is possible that the percentages of complexed lanthanide in blood 
plasma for HEDP and 1vIDP can be so close to APD although there is a three orders of magnitude 
difference in the first formation constant. (Log K, for APD = 13.81, Log K1 for HEDP = 10.10, 
Log K1 for MDP = 9.3) Two reason can be proposed. The first is the affinity of APD for Ca(II) 
which lowers the percentage of HoAPD(H). As has been discussed is this not the case for HEDP 
and MDP. The second is in the formation constants of Ho(III) and Sm(III) by citrate. For the 
species Sm(cit)(OH), Log K1 = 13.91 and Sm(cit)(OH)i, Log K1 = 19.42. For Ho(III) these 
constants are 14.31 and 19.67 which makes a big difference to the competing ability of citrate. 
The fact that the concentration of citrate in blood plasma is 1. 1 x 10-4 mol. dm-3 ( 1.4 times the 
concentration of ligand injected) enhances its competitiveness even further. 
To conclude this section, an ECCLES calculation was done on the drug, Metastron (89SrClz). 
Clinical trails on this therapeutical have been described in Porter et. al. [96]. The results of the 
calculation are given in Appendix G. Only two species, were found to be significant. APD was 
also include in the model but had no influence. 98.6 % of injected SrCl2 in chloride medium is 
complexed by phosphate and only 1.4% by ascorbic acid. This might explain the success of 
Metastron in that it does not complex to the main in vivo chelator, citrate. Phosphate is used in 
the formation of hydroxy apatite but is a vital metabolic product in various other parts of the 
body. Although the tumours cells could be expected to have a higher metabolism and therefore 
would use more phosphate one would still expect a lower bone uptake than with diphosphonates, 
like 153SmEDTMP, that are bone seekers par excellence. Robinson et. al. [97] have stated that Sm 
and Re diphosphonate compounds have a theoretical advantage over 89Sr. It was hoped that APD 
would remain bound to Sr(II) in blood plasma and in this way enhance the bone uptake of Sr(II) 
using APD as its carrier. It is interesting to note that APO does not compete with phosphate at 
all although the formation constant for the species MLH in the complexation of Sr(II) by APO 
is 16.06. Phosphate however has a higher concentration (5 times) in blood plasma than APO. 
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Another aspect that makes Metastron less attractive is that it only emits P-rays. It is thus difficult 
to see if therapy reached the tumours and difficult to detect whether contamination occurs in 
hospitals. 153Sm and 166Ho are bothy-ray emitters and there is no problem detecting this. Another 
aspect is the long half-life of 89Sr viz. 50.5 days. This means a patient is exposed to radiation for 
longer and has to be confined longer to hospital to avoid contamination. 153Sm and 166Ho have 
very short half-lives and once again minimising these effects. 
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4.5. Results from Baboon tests 
The species distribution curves for APD and Ho(III) have been shown in the previous section. 
From this it is clear that APD will be present as the MLH complex at physiological pH. What 
is also evident is that Ho(III) is indeed bound by the ligand and should survive competition 
from blood plasma ligands. From a calculation with the program SPEC in the ESTA library, 
the species present at various pH values were calculated. The result at pH= 7.5 is include in 
Appendix H. The concentration taken for Ho(III) is 1 x 10·7 mol.dm·3 which is close to the 
concentration that would be injected. 166Ho which is irradiated for 24 hrs has a high specific 
activity of 70 mCi per 2. 5 mg Ho20 3 irradiated. If only 3 mCi is injected, the concentration in 
1. 9 L blood (baboon) is in the same region. This aspect that micrograms ( 100 µg) of a 
lanthanide (which is less toxic than other heavy metals) is injected for radiotherapy compared 
to chemotherapy where these heavy metals are used at milligram scale is the main reason why 
radiotherapy has little side effects if compared to chemotherapy. 
The Ca(II) concentration was taken at 1 x 10·5 mol.dm·3 and 1 x 10·3 mol.dm·3 to verify that 
the ligand APD stays bound to the Ho(III). The ligand concentration is taken at 1 x 10·5 
mol.dm·3, a L:M ratio of 100: 1. For both the concentrations of Ca(II), 99% of the Ho(III) 
stays bound to APD. Most of the Ca(II) stays as the free metal ion, while 2-3 % is bound to 
APD. 1 % of the APD is bound to Ho(III) as expected from the 100: 1 ratio. This theoretical 
evidence is supported by paper chromatography at high pH where ML is the dominant species. 
At physiological pH we know MLH is the dominant species and paper chromatography cannot 
distinguish between undissolved and uncomplexed species. Appendix H shows both these 
chromatograms. This result was achieved for both running solutions used. The sephadex 
column however provided the evidence that the Ho(III) is indeed complexed to APD. 96% of 
the activity was washed out by a saline solution indicating that the Ho(III) is not retained by 
the resin. 
With both the theoretical and laboratory evidence proving that complexation does indeed 
occur an application was submitted to the ethical committee for a baboon test. Permission was 
granted and a solution consisting of 3 .25 mCi 166HoAPD was injected into baboon P20/92. 
The results are shown in recorded static images at 2 and 3 hours after injection, displayed in 
Photo 6 and 7 which do not differ very much. In each image three areas are covered viz. head, 
chest and pelvis. The red areas correspond to the tissue where the highest uptake of radiation 
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occurred. There seems to be a high bone uptake because the shoulder-knots, spine and some 
ribs are clearly visible. Because 166Ho has a weak y-ray (80 ke V), a great amount of scatter 
occurs when an image of the emitted radiation of this isotope is recorded. A ray of this low 
energy is scattered by the tissue as it travels through it on its way to the camera. 
Photo 6. Static y-image recorded 2 hours after administration of 166HoAPD. 
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Photo 7. Static y-image recorded 3 hours after administration of 166HoAPD The images 
were recorded for the head, chest and pelvis. Note the white area in the image on the right 
which corresponds to the high uptake in the liver. 
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This results in an indistinct radiation pattern near the edges of the bone as was the case with 
166HoEDTMP. This is not only due to low bone uptake but the scatter of the y-ray also 
contributes to an unclear picture. It is not possible to expect the sharp diference between bone 
and muscle as was achieved by 153Sm and 99mTc (both have higher energy y-rays). From 
ECCLES modelling it is evident that the competition of citrate with APD causes a bone 
uptake lower than that for 153SmEDTMP. This together with the scattering explains the 
unclear picture above. 
The interesting aspect visible is that a fair amount of radiation locates in the liver ( second 
image). This is unfortunate because this liver uptake is unacceptable for any 
radiopharmaceutical designed for bone uptake and thus rules out the possibility that APD will 
be an effective carrier of Ho(ID) to the bone. However, this liver uptake correlates well with 
that predicted by ECCLES. ECCLES predicted that MLH (HoAPD(H)) would be the 
dominant species at pH= 7.4 with 58% of the Ho(ID) in this form. This is a neutral species as 
APD has a charge of -4. Because of the neutrality, a precipitation would be expected at higher 
concentrations. The low concentrations used here, 1 x 10·7 mol.dm·3, probably prevents 
precipitation. Colloid formation may be possible. The liver filters and captures a great amount 
of these colloids. It is gratifying that the predictions by ECCLES are proved in practise. 
Uptake in the liver was expected even before the baboon test. The baboon test provided the 
evidence that this interpretation of the data produced by ECCLES was indeed correct. 
The same is true for HEDP and MOP thus explaining why Simon et. al. of Dow Chemical Co. 
[74] found a high liver uptake in experiments done with these two ligands together with 153Sm. 
They reported that 4 % of the total activity for 153SmHEDP ended in the liver, where as 21 % 
went to the bone and 13 % remained in the blood. The rest must be in the kidneys and urine. 
Fot 153SmMDP the liver uptake was 85 %, 2% in the bone and 0.2% remained in the blood. 
From the species distrubution curves (Section 4.1.3 and 4.1.4) and ECCLES modelling 
(Section 4.3) of these two ligands it is once again evident that the in vivo behaviour of 
radiopharmaceuticals and other drugs can be accuratedly predicted by ECCLES. 
The dominant species at pH = 7. 4 is the MLH species. This is for all these ligands a neutral 
species. One would expect with HEDP and MOP colloid formation and an uptake in the liver. 
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ECCLES once again proved that it is a very useful tool for the bioinorganic chemist, reducing 
the number of tests on animals and delivering an estimate of the result expected making it 
easier for the ethical committee to grant permission. 
From the static images it is possible to calculate an estimate of the compartmental uptake in 
the three major areas in the body viz. bone, kidney and liver. This was done by comparing the 
activity recorded by the y-camera on a certain organ and that in the soft tissue right next to it. 
The latter is taken as the background. For the bone three areas are used viz. head, spine and 
pelvis. For the kidney the left and right kidney are compared with the background and the liver 
on its own. The average activity for the bone, kidney and liver vs background and the resulting 
percent uptake in each of the organs vs background, after two hours, are reported in Table 35. 
The percentage compartemental uptake is calculated to compare the uptake in the different 
organs. The latter is only a indication if the data from which it is derived is considered. The 
background is calculated from tissue right next to the bone for instance. As explained, the 
scatter of 166Ho's y-ray will contribute to this factor, lowering the percentage uptake. Another 
contributing factor is the colloid form of the complex when moving through the body. This 
will result in a higher background recorded as the mobility of the complex is lower and more 
will be trapped in the tissue surrounding the bone. 
Table 35. Percentage uptake in various organs of the baboon 
Bone 461 333 58.1 26.3 
Kidney 342 244 58.4 29.3 
Liver 259 120 68.3 44.4 
The only way to find a true reflextion of where the activity ended up is to do test with mice 
which are disected three hours after injection. Here an accurate measurement of the activity in 
various organs can be made. The result of such a test will be more correct. 
During the baboon tests blood and urine samples were taken at various intervals. The blood 
samples were 2ml in volume. The blood volume of a baboon is calculated by the following 
equation: V = 75.5 ml/kg* m where mis the mass of the animal in kg. In our 
case this gives a total blood volume of 1.8 L. Fig. 67 contains the normalised blood activity 
curve for 166HoAPD, 153SmEDTMP and 166HoEDTMP. The curve for 166HoAPD is not very 
smooth as the other two (Louw et. al. [6]) because it is not an average of seven animals that is 
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taken. The curve for 166HoAPD shows a fast blood clearance although it seems incomplete. In 
[ 6] the curves shown are also fitted at three hours, showing a lower activity than the data 
point would suggest. If 166HoAPD is compared to 153SmEDTMP the blood clearance is not as 
fast but beter than 166HoEDTMP which had a slow blood clearance indicating an incomplete 
























Figure 67. Normalised blood clearance curves for 166HoAPD, 166HoEDTMP and 
153HoEDTMP 
The size of the urine samples are not standard because the bladder is emptied at specific times. 
Fig. 68 therefore shows the total accumulated activity taken from the bladder up till that point 
in time. These curves are normalised to the total activity injected in the blood. For 166HoAPD 
it is a climbing curve almost flattening after two hours. For 153SmEDTMP and 166HoEDTMP 
the curves are smooth and higher. The reason for this is that with 166HoAPD a high liver 
uptake occured leaving less activity to escape from the body. It is encouraging that a big 
portion of the activity found in the liver can be subtracted here. This indicates that more or 
less the same activity as for 153SmEDTMP and 166HoEDTMP gathered in the bone. 
If the fit is displayed as activity per ml (Fig. 69) vs time a peak is found after 40 minutes. After 
two hours little more activity is excreted. This is in agreement with the blood curve which 
shows in this area that low levels of activity remained in the blood. At this time no additional 
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Figure 68. Normalised urine accumilation curve for for 166HoAPD, 166HoEDTMP and 
153HoEDTMP. Note the significant difference in height for 166HoAPD. 
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To confirm the results gathered with baboon tests and to verify the percentage bone uptake, 
rat tests were performed. 166HoAPD was prepared as before and a dose of 1.64 mCi was 
injected in each of five rats. The rats were dissected after 24 hours and various parts of the 
body were weighed and their activity counted in an ionisation chamber. The results are 
presented in Table 36. To compare these results, a study of 166HoEDTMP was done in parallel 
and previously found values for 153SmEDTMP [6] are included. Although only certain sections 
of some organs, for instance only the femur was taken to represent bone, were counted, the 
percentage reported was calculated per gram of the tissue measured. The percentage reported 
is expressed in terms of the total activity injected. Corrections were made for decay of 166Ho. 
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Table 36 confirms the high liver uptake for 166HoAPD. The bone to tissue ratio however is 
10:_1. This indicates a higher bone uptake (90%) than that calculated from the scintigraphic 
images for the baboon tests. This is however not three hours but 24 hours after injection. A 
great amount of activity has been washed out of the tissue into the urine by this time. A better 
comparison with the baboon tests would have been after three hours. Then no comparison 
with 153SmEDTMP would have been possible which is essential as the metabolism of rats and 
baboons differ. For 166HoEDTMP the ratio is even 100:1 indicating 99% uptake. One has to 
compare the 0.9% per gram of the injected dose located in the bone with that for 
153SmEDTMP viz. 1. 72%. This shows that twice as much of the 166Ho-activity is lost. This is 
due to the competition of citrate with EDTMP for Ho(ill) preventing the uptake of 166Ho in 
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the bone. Citrate locates its portion during this long time in the bladder where it is excreted. 
The final percentage per gram is thus lower. 
For 166HoAPD the bone uptake is only 0.3% of injected dose per gram. This is due to the high 
content in the blood (this also causes the activity in the tissue to be higher than expected) 
which could be the neutral species which is not caught by the liver. Because of the time waited 
one cannot propose that the bone uptake for 166HoAPD is weaker than 166HoEDT:N!P 
especially when baboon tests showed the contrary. 
What is proved by this experiment is that the scatter of the weak y-ray which 166Ho emits 
contributes to a lower reported bone uptake gathered from scintigraphic images of baboons. 
Furthermore 166HoAPD has a definite high liver uptake. 
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5. Future work 
From the above it is clear that 166HoAPD has a very promising bone uptake but due to the 
liver uptake it will not be an acceptable radiopharmaceutical. The reason for this, as 
described earlier, lies in the neutral species NILH that forms at physiological pH. If this 
problem could be overcome, clinical trial on humans may be pursued. One way to change 
the neutrality of the complex is to change the ligand slightly, not effecting the 
complexation centre but adding a charged group or groups. The ligand will then be more 
negatively charged and the complex NILH will have a negative charge. 
Examples of what groups might be added are discussed next: 
The first shows a Mannich reaction with APD to form a tetraphosphonate APDDJ\1P 
(APD dimethylenephophonate). 
The new phosphonate groups (R = the rest of the APD molecule except for the amino 
group) may even take part in the complexation, improving the formation constants. The 
second alternative is to add a carboxyl group. 




Here the product depends on whether one or two equivalent moles of reagent are used. 
Various other reagents like ethylene-oxide can also be used. Whether the complexation 
with each of these proposed ligands is strong enough can only be found by potentiometric 
titrations and ECCLES modelling. 
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Polarographic titrations. 
It would be preferable to actually measure the formation constants for Ho(III) and Sm(III) 
with the various ligands. As potentiometry is not suitable, other techniques should be used. 
Lanthanides are not polarographically active but by means of competition between the 
lanthanide and another metal ions it might be possible to determine the formation constant 
with this technique. A metal ion is needed that is polarographically active and from which a 
high formation constant is expected ( of the same order of magnitude as Sm(III) and 
Ho(III)). Cd(II) has a formation constant a few orders lower than these and will not be a 
suitable competitor for the ligand. Another possible metal ion is Pb(II), but unfortunately it 
forms a precipitate with the ligand at pH= 4.5 even at low concentrations. Another metal 
ion is Bi(III) but it has a very high acidity, limiting the area of study to the low pH range. 
Some other options are Sn(II) and Cu(II) 
Another possible technique for measuring the Ho(III) and Sm(III) equilibria is 
spectrophotometry, but the ligands have no colour and are not UV active, therefore direct 
measurement is also not possible. Competition with another spectoscopically active ligand 
might be an option. 
Crystal structures 
To understand more the structures that the diphosphonate ligands upon complexation, a 
crystal structure is important. This is especially so for APD where there are some 
unexplained results (Section 4.3). The precipitate that forms during the potentiometric 
titrations of Zn(II) with APD may be isolated, analysed and crystallised. The precipitate 
might be re-crystallised out of solutions like methanol and acetonitrile. 
In all these studies, the objective is to gain a greater insight into the complexation and in 
vivo speciation of Ho(III) so that better radiopharmaceuticals may be produced. 
152 
6. Conclusion 
In this dissertation the main objective was to find a radiopharmaceutical which would 
employ 166Ho(III) as its ~-emitter to improve on the pain palliative effectiveness of 
radiopharmaceuticals like 153SmEDTMP used in the treatment of bone cancer. This search 
involved three diphosphonate ligands viz. APD, MDP and HEDP which were studied to 
find whether they would selectively carry 166Ho(III) to bone tissue. To achieve this one 
needs to know the formation constants for the complexation of Ca(II) and Mg(II), Zn(II) 
and Ho(ill) with the ligands and use this information in a blood plasma model to predict 
the speciation of the proposed radiopharmaceutical. Glass electrode potentiometry was 
used to measure the formation constant for the complexation of Ca(II) and Mg(II) with all 
three ligands as well as the complexation of Ni(II), Sr(II), Cd(II), Sm(ill) and Ho(III) with 
some of these ligands. An additional technique, polarography was used to calculated 
formation constants for the complexation of Zn(II) with all the ligands as precipitation 
occurred in these during the potentiometric study. The complexation of Cd(II) by HEDP 
was used to compare the two techniques and showed that the values found by both 
techniques are comparable. Where constants were found in literature good agreement with 
the measured constants was achieved. For the complexation of Sm(III) and Ho(III) by 
these ligands, a linear free energy relationship was employed to calculate the first 
formation constants. The previously found values were used in this relationship and 
provided some proof that the first formation constants (for each ligand) reported here, 
correlate well with each other as well as with literature values. 
The speciation of Ho(III) and Sm(III) with these three ligands in blood plasma was then 
calculated by the program ECCLES using the constants determined in this study, together 
with the published blood plasma database [35]. The results suggested that Ho(III) and 
APD is a very promising systems. For the other ligands the results were not favourable. 
The ECCLES output was used as evidence in an application to an ethical committee 
before animal testing. A baboon test was carried out using 166HoAPD. As in the case with 
HEDP and MDP (complexed to 153Sm(III)), that have been tested before by others [43], a 
high liver uptake was recorded. However 166HoAPD showed none-the-less a high bone 
uptake and fast blood clearance. These results were confirmed by rat tests with 166HoAPD. 
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Based on the ECCLES results, the reason for this liver uptake is postulated to be a neutral 
species, :MLH, forming at physiological pH. Furthermore the comparison between the 
radiopharmaceuticals 153SmEDTMP, 166HoAPD and 166HoEDTMP (in decreasing order of 
bone uptake as measured in animal tests) could be reproduced by ECCLES modelling. The 
results showed that APD competes less effective for 166Ho in blood plasma than EDTMP 
competes for 153Sm but APD competes better for 166Ho in blood plasma than EDTMP 
does. 
The working of another existing radiopharmaceutical,Metastron (9SrClz) could also be 
explained by ECCLES. 
The main reason why only APD seemed suitable as a ligand for complexing Ho(III) is the 
higher formation constants of APD. The APD formation constants are higher than HEDP 
which are in tum higher than those of MDP. NMR studies were attempted on some 
complexes in solution to investigate the role of the hydroxy group (APD and HEDP) in 
complexation as it is believed that when taking part, it improves complexation. The 
complex however changes its structure at a rate faster than the NMR time scale delivering 
little useful information. From the strength of complexation for these ligands with various 
metal ions it is none-the-less postulated that the hydroxy group in HEDP as well as the 
amino group in APD takes part in complexation. As it is impossible for APD to be a 
tetradentate ligand; the hydroxy and amino group cannot be bound to an octrahedral metal 
ion at the same time. The hydroxy group might thus be bound to a second metal ion. This 
resulted in an idea on the structure for the most interesting species, M2L, which is not 
found very often in literature but occurs frequently in the complexation of these ligands 
with the metal ions used. Polarography provided some clear evidence that this species 
· indeed does exists. It was the first time that formation constants for a polynuclear species 
have been measured using this technique. It was also the first time in polarography that 
formation constants for non-labile species could be calculated using only peak potentials 
and peak heights for the labile part. 
Although the main objective, to find a new radiopharmaceutical, was not reached, as 
166HoAPD is ineffective as a therapeutic agent due to its high liver uptake, it is now 
possible to design new ligands who might sustain the high bone uptake capabilities of APD 
but avoid its liver uptake. 
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APPENDIX Al 
T'; = calculated total concentration of component i 
Tf = real (analytical) concentration of compenent i 
[XJ = free concentration of component i 
[Ci] = concentration of complexj 
[SJ = concentration of species i (component or complex) 
{SJ = activity of species i (component or complex) 
{ sn' { sn = activity of species i in the test solution and bridge solution, respectively 
y i = activity coefficient of species i 
Pi = thermodynamic formation constant of complex j 
rii = stoichiometric coefficient of component i in complex j 
NC = number of components appearing in complexes 
NB = number ofburettes 
q = initial concentration of component i in titration vessel 
C~m = concentration of component i in solution in burette m 
v m = volume added from burette m 
V = initial volume in vessel 
sk = electrode response slope 
Kki = selectivity coefficient of component i 
zi = charge on species i 
R = the gas constant 
T = absolute temperature 
F = Faraday constant 
I = ionic strengh 
lr = ionic conductance of species i in the test solution 
lt = ionic conductance of species i in the bridge solution 
a = ionic size parameter 
A, B = parameters in the Debye-Hiickel equation 
U = objective function to be minimized 
RH = Hamilton factor 
11i, = number of parameters to be optimized 
nc = total number of electrodes 
w nq = weight of qth residual at nth point 
Yn~ = observed variable of qth residual at nth point 
Yn~1c = calculated variable of qht residual at nth point 
G = inverse Hessian 
or = standard deviations of the rth optimized parameter 
r,r = correlation coefficient of parameters s and r 
APPEND1XA2 
Meanings of symbols-(a) Concentrations. 
S = the concentration of a complex species 
X = the concentration of a component 
T = the total concentration of a component 
(b) Indices 
i = the general index for components 
j = the general index for complex species 
m = the specific component index 
p = the index for a metal ion component 
q = the index for a ligand component 
r = the index for a hydrogen ion component 
(c) Superscripts. 
c denotes a 'calculated' quantity 
r denotes a 'real' quantity 
o denotes an 'old' value in an iteration 
n denotes a 'new' value in an iteration 
(d) Parameters 
k = the matix which defines the components and their multiplicity in a complex species. 
M, L, H, ~pqr have their usual meaning. 
Appendix BO 
Table 1. Protonation and formation constants (log K) for MDP, HEDP and APD at 
37 °C and I= 0.15 M NaCl. 
7.00(1) 6.81(1) 9.80(2) 
3.26(2) 2.97(1) 6.01(2) 
2.19(5) 2.35(2) 2.56(3) 







ML+H=MLH 7.83(3) 7.83(2) 10.51(3) 




ML+H=MLH 7.56(2) 7.48(3) 10.24(3) 
ML+M=M2L 2.68(8) 3.67(4) 
MLH+H=MLH2 6.77(3) 
ML+ OH= MLOH 3.24(3) 
Table 1 ( continued). 
Metal 
ion 
Equilibrium MDP HEDP 
l\.1LH + H = l\.1LH2 
9.94(5) 
l\.1L + H = l\.1LH 
l\.1L + 2H = l\.1LH2 10.02(5) 9.88(5) 
l\.1LH + 2H = l\.1LH3 
l\.1LH2 + 2H = l\.1L~ 5.73(3) 5.50(3) 
l\.1L + M = M2L 5.56(7) 6.16(7) 
l\.1L +OH= l\.1LOH 7.46(7)* 7.43(7)* 
7.27(1) 
3.79(3) 
l\.1L + OH = l\.1LOH 3. 60(3) 
M+L=l\.1L 9.3 10.1 
l\.1L + H = l\.1LH 9.0 9.1 
9.6 10.4 
l\.1L + H = l\.1LH 9.0 9.1 














* Values calculated by polarography where these values are found to be higher than 
expected. This is possibly due to the few data points available to calculate the 
referrred to formation constants. 
Table 2. Comparison of results obtained by potentiometry and polarography for 
Cd(II) complexation by HEDP at 37 °C and I= 0.15 M NaCl. 





M + L=ML 7.10(4) 7.18(5) 
2M + L=M2L 12.99(3) 12.75(5) 
M + L + 2H = MLH2 20.02(3) 19.55(5) 
M+L+4H = MLH.i Not found 25.08(3) 
M + L +OH= MLOH 10.94(3) 10.94(3) 
M + 2L = ML2 10.46(5) 
APPENDIX Bl: 
EO titrations; ESTA input file and output examples 
See Disk 1 
AB the EO titration is a regular exercise only an example of such an ESTA 
input file is include viz. CALSM.DAT in A:\APPENDBI. The ESTA2A 
output of such a file is attached on paper ( for EO titration E0950117.001 and 
E0950119.001). The data points in CALSM.DAT can be replaced by EO 
titration data points found in Appendix Cl to C4 on Disk 2. 
E0950117.001 
******* ****** ******* ***** 
* * * * * 
* * * * * 
****** ***** * ******* 
* * * * * 
* * * * * 
******* ****** * * * 
PROGRAM ESTA2A VERSION 3.0 
TASK OBJE 1 APD TITRATION 1 ELECTRODE CALIBRATION 
MODL H +1 
CPLX 0 1 -13.4200 H +1(-1) 
CONC 
VESL IVOL 20.000 0 0 
VESL H +1 .0119070 0 0 
BURl H +1 -.0500000 0 0 
ELEC 
ZERO H +1 430.000 1 
GRAD H +1 61.550 0 
WGHT 1 
VESL H +1 .0000250 
BURl H +1 -.0000100 
ZERO H +1 .250 
GRAD H +1 .020 
TITR RNDE .0010 
EOBS RNDE .0800 
DATA 
rIMIZATION CYCLE 0 
~****************** 
~RALL OBJE OBJECTIVE FUNCTION: 
~AL PARAMETERS: 






















SLOPE AT PREDICTED SOLUTION = -1.5220E+02 
171 
TIMIZATION CYCLE 4 (CONVERGENCE) 
******************* 





















MILTON R-FACTOR: .02132 
MILTON R-LIMIT: .00102 
PARAMETERS FOUND 
• OF TITRATIONS: 1 NO. OF POINTS: 
op - Program terminated. 
(N-R ITERATIONS: 983 
100 
E0950119.001 
******* ****** ******* ***** 
* * * * * 
* * * * * 
****** ***** * ******* 
* * * * * 
* * * * * 
******* ****** * * * 
PROGRAM ESTA2A VERSION 3.0 
TASK OBJE 1 APD TITRATION 1 ELECTRODE CALIBRATION 
MODL H +1 
CPLX 0 1 -13.4200 H +1(-1) 
CONC 
VESL IVOL 20.000 0 0 
VESL H +1 .0119300 0 0 
BURl H +1 -.0500000 0 0 
ELEC 
ZERO H +1 430.000 1 
GRAD H +1 61.550 0 
WGHT 1 
VESL H +1 .0000250 
BURl H +1 -.0000100 
ZERO H +1 .250 
GRAD H +1 .020 
TITR RNDE .0010 
EOBS RNDE .0800 
DATA 
rIMIZATION CYCLE 0 
k****************** 
~RALL OBJE OBJECTIVE FUNCTION: 
:::AL PARAMETERS: 






















SLOPE AT PREDICTED SOLUTION = -7.0084E+02 
178 
'TIMIZATION CYCLE 5 (CONVERGENCE) 
******************* 




















SIGNIFICANTLY CORRELATED PARAMETERS FOUND 
MILTON R-FACTOR: .01373 
MILTON R-LIMIT: .00101 
. OF TITRATIONS: 1 NO. OF POINTS: 
op - Program terminated. 
(N-R ITERATIONS: 1162 
100 
APPENDIX B2: 
ESTA input files of protonation titrations with APD, MDP and 
HEDP 
See Disk 1 
The ESTA input files are presented in the same order as discussed in Section 




HEDPHI.DAT (excluding LIL;) 
APPENDIX B3: 
ESTA input files of complexation titrations with APD 
See Disk 1 
The ESTA input files are presented in the same order as discussed in Section 
4.1.2. The files contain the correct concentrations and EO values. 
APDCa.DAT 
APDCal.DAT (2nd possible model) 
APDMgl.DAT 
APDMg.DAT (2nd possible model) 
APDSrl.DAT 
APDZn2.DAT 




ESTA input files of complexation titrations with MDP 
See Disk 1 
The ESTA input files are presented in the same order as discussed in Section 
4.1.3. The files contain the correct concentrations and EO values. 
l\IDPCa.DAT 
l\IDPCa_T.DAT (excluding M2L) 
l\IDPMglS.DAT 
· l\IDPMgl.DAT (uncut model) 





ESTA input files of complexation titrations with HEDP 
See Disk 1 
The ESTA input files are presented in the same order as discussed in Section 




CdHEDPl.DAT (titration 1, ratio L:M = 1:1.1) 
CdHEDP2.DAT (titration 2, ratio 1.2:1) 
CdHEDP3.DAT (titration 3, ratio 2.5: 1) 
CdHEDP4.DAT (titration 4, ration 3: 1) 
APPENDIX Cl: 
Titration data points of protonation titrations with APD, MDP 
andHEDP 
See Disk 2 
The titration data is presented in the same order as discussed in Section 4. I . I 




APD H. 002 - APD H. 003 - -
E0950314.001 




:MDPH A.001 - :MDPH A.002 - -
E0950406.001 
HHEDP.001 - HHEDP.003 
E0960630.001 
APPENDIX C2: 
Titration data points of complexation titrations with APD 
See Disk 2 
The titration data is presented in the same order as discussed in Section 4 .1.2 
with EO titrations in between. Each EO titration is applicable to the preceding 
complexation titrations. 








ZnAPD D.001 - ZnAPD D.003 - -
E0950119.001 
. HoAPD B.001 -HoAPD B.003 - -
E0950203.001 
APDHO D.001 -APDHo D.002 - -
E0950316.001 





Titration data points of complexation titrations with MDP 
See Disk 2 
The titration data is presented in the same order as discussed in Section 4.1.3 
with EO titrations in between. Each EO titration is applicable to the preceding 
complexation titrations. 
Ca.1IDP.001 - Ca.1IDP.004 
E0950425.001 
MgMDP.001 - MgMDP.003 
E0950424.001 









Titration data points of complexation titrations with HEDP 
See Disk 2 
The titration data is presented in the same order as discussed in Section 4 .1.4 
with EO titrations in between. Each EO titration is applicable to the preceding 
complexation titrations. 











Titration data points of complexation titrations of Cd(II) with 
HEDP 
The titration data is presented as used in Section 4 .2 .1 
Hedpcd.pol 
Reference potential 
pH= 2.270 -0.5265V 1.65E-06A 
pH Ep Vtot Ip Iexpect Ip/I expect 
2.002 -532.1 0.000 8.058 8.39 0.960429 
2.214 -532.1 0.370 7.759 8.156944 0.951214 
2.412 -532.6 0.610 7.594 8.012574 0.94776 
2.599 -533.0 0.780 7.336 7.913365 0.927039 
2.779 -534.2 0.900 7.218 7.844801 0.9201 
3.003 -534.8 1.000 7.140 7.788566 0.916728 
3.216 -535.6 1. 075 7.103 7.746916 0.916881 
3.416 -536.1 1.115 7.080 7.724884 0.916519 
3.616 -536.1 1.145 7.053 7.708443 0.914971 
3.800 -536.5 1.165 7.044 7.69752 0.9151 
4.009 -536.5 1.180 7.040 7.689349 0.915552 
4.216 -538.2 1.190 7.030 7.683911 0.914899 
4.527 -538.3 1. 200 7.012 7.678481 0.913202 
4.726 -539.2 1. 205 6.970 7.675768 0.908052 
4.909 -539.8 1. 210 6.877 7.673058 0.896253 
5.108 -541. 0 1. 215 6.793 7.670349 0.885618 
5.314 -542.7 1. 222 6.692 7.666561 0.872882 
5.504 -544.4 1. 230 6.593 7.662236 0.860454 
5.690 -548.3 1. 240 6.544 7.656836 0.854661 
5.905 -551.8 1. 255 6.454 7.64875 0.843798 
6.109 -557.3 1. 275 6.424 7.637996 0.841058 
6.308 -562. 3 1. 300 6.403 7.624596 0.839782 
6.495 -567.4 1.330 6.342 7.608578 0.833533 
6.706 -571. 9 1. 370 6.208 7.587325 0.818207 
6.903 -577.4 1. 410 6.177 7.566191 0.816395 
7.103 -582.7 1. 450 6.127 7.545174 0.812042 
7.328 -588.6 1. 490 6.017 7.524273 0.799679 
7.540 -593.6 1. 520 5.849 7.508673 0.778966 
7.723 -598.3 1. 540 5.625 7.498309 0.750169 
7.968 -605.6 1. 560 5.160 7.487974 0.689105 
8.135 -609.9 1. 570 4.465 7.482817 0.5967 
8.350 -614.0 1. 580 3.660 7.477667 0.489457 
8.609 -620.1 1.590 2.730 7.472524 0.365338 
8.867 -624.2 1.600 1.914 7.467388 0.256315 
9.073 -62 6. 3 1. 610 1. 348 7.46226 0.180642 
9.237 -628.4 1. 620 1. 046 7.457138 0.140268 
9.428 -630.2 1. 635 0.700 7.449469 0.093966 
9.609 -632.6 1. 655 0.460 7.439267 0.061834 
9.802 -635.1 1. 680 0.301 7.426555 0.04053 
10.019 -637.5 1.720 0.195 7.406305 0.026329 
10.204 -638.8 1. 765 0.130 7.383656 0.017606 
10.400 -641. 0 1.825 0.102 7.353672 0.013871 
10.618 -647.0 1.905 0.090 7.314069 0.012305 
11. 04 0 -657.2 2.125 0.090 7.20733 0.012487 
11.510 -671.0 2.675 0.215 6.953632 0.030919 
11. 837 -677.8 3.675 0.613 6.535368 0.093797 
1996-08-27 
Total volume 12.95 ml 
4.42E-03M HEDP + 1.65E-04M Zn (27: 1) 
Page 1 
APPENDIX D2: 
Titration data points of complexation titrations of Zn(II) with 
HEDP 
The titration data is presented as used in Section 4.2.2 
Hedpzn3.pol 
7ml NaCl 0.15M + 40 ul Zn 
pH= 5.042 -0.973V l.09E-06A 
700ul HCl 0.15M 
pH= 1.900 -0.971V l.40E-06A 
pH= 1.900 -0.971V 1.39E-06A 


















































































































































































































5ml 0.01M HEDP + 40ul 0.0209M Zn in 13.440 ml 
3.72E-03M HEDP + 6.22E-05M Zn (60:1) 
Gestoor in hzn-4-st tot hzn-4-35 
Page 1 
APPENDIX D3: 
Titration data points of complexation titrations of Zn(II) with 
MDP 
The titration data is presented as used in Section 4.2.3 
Mdpzn4.pol 
7ml NaCl 0.15M + 40ul Zn 
pH= 4.560 -0.972V 1.55E-06A 
700ul HCl 0.15M 
pH= 1. 911 -0.974V 1.45E-06A 
pH= 1. 911 -0.975Vl.45E-06A 
5ml MDP 0.01M 
pH Ep Ip Vadd Vtot Iexpect 
1. 929 -0.978 8.95 12.74 8.95 
2.018 -0.979 8.67 250 12.99 8.7777521 
2.146 -0.98 8.52 200 13.19 8.644655 
2.311 -0.981 8.07 250 13.44 8.4838542 
2.487 -0.982 7.96 200 13.64 8.3594575 
2.802 -0.984 7.73 250 13.89 8.2089993 
2.909 -0.985 7.55 60 13.95 8.1736918 
3.041 -0.986 7.4 60 14.01 8.1386867 
3.191 -0.987 7.34 60 14.07 8.1039801 
3.37 -0.988 7.28 60 14.13 8.0695683 
3.595 -0.989 7.26 40 14.17 8.046789 
3.709 -0.99 7.24 15 14.185 8.0382799 
3.847 -0.991 7.21 15 14.2 8.0297887 
3.981 -0.992 7.12 10 14.21 8.0241379 
4.151 -0.993 7.06 15 14.225 8.0156766 
4. 292 -0.994 6.9 10 14.235 8.0100457 
4.617 -0.998 6.55 5 14.24 8.0072331 
4.709 -0.999 6.45 6 14.246 8.0038607 
4.806 -1. 001 6.08 6 14.252 8.0004912 
4.902 -1.004 5.96 6 14.258 7.9971244 
4.992 -1. 008 5.6 6 14.264 7.9937605 
5.101 -1. 011 5.14 9 14.273 7.98872 
5.222 -1. 014 4.91 9 14.282 7.9836858 
5.328 -1.018 4.54 9 14.291 7.9786579 
5.631 -1. 028 3.67 10 14.301 7.9730788 
5.711 -1.031 3.45 8 14.309 7.9686211 
5.798 -1. 034 3.19 10 14.319 7.9630561 
5.917 -1. 039 2.79 25 14.344 7.9491774 
6.03 -1.046 2.52 10 14.354 7.9436394 
6.108 -1. 05 2.25 5 14.359 7.9408733 
6.215 -1. 054 2.05 13 14.372 7.9336905 
6.314 -1. 59 1. 72 13 14.385 7.9265207 
6.425 -1.07 1. 45 18 14.403 7.9166146 
6.529 -1. 078 1.1 20 14.423 7.9056368 
6.664 -1. 096 0.924 30 14.453 7.8892272 
1996-03-13 
5 ml MDP+ 40ul Zn in 12.74 ml 
3.925E-03 M MDP + 6.562E-05 M Zn 
Gestoor in mzn-2-st tot mzn-2-35 
Page 1 
APPENDIX D4: 
Titration data points of complexation titrations of Zn(II) with 
APD 
The titration data is presented as used in Section 4.2.4 
Apdzn2.pol 
7ml 0.15M NaCl+ 40ul Zn 
pH= 5.371 -0.998V 6.16E-07A 
700 ul 0.15M HCl 
pH= 1. 928 -0.973V 1. 42E-06A 
pH= 1. 928 -0.974V 1.43E-06A 
5ml 0.01M APD 
pH= 2.051 -0.979V 8.70E-07A 
pH Ep Ip Vadd Vtot I expect 
2.051 -0.979 8.7 12.74 8.7 
2.175 -0.98 8.07 600 13.34 8.3086957 
2.314 -0.981 7.96 200 13.54 8.1859675 
2.444 -0.981 7.85 150 13.69 8.0962747 
2.613 -0.982 7.76 150 13.84 8.008526 
2.776 -0.982 7.65 100 13.94 7.951076 
2.891 -0.983 7.62 50 13.99 7.922659 
3.039 -0.983 7.58 50 14.04 7.8944444 
3.24 -0.984 7.46 50 14.09 7.8664301 
3.398 -0.984 7.37 25 14.115 7.8524973 
3.579 -0.985 7.24 20 14.135 7.8413866 
3.708 -0.986 7.17 10 14.145 7.8358431 
3.81 -0.987 7.08 5 14.15 7.8330742 
3.915 -0.989 6.98 5 14.155 7.8303073 
4.075 -0.992 6.83 7.5 14.1625 7.8261606 
4.223 -0.995 6.63 5 14.1675 7.8233986 
4.365 -1 6.39 15 14.1825 7.8151243 
4.469 -1. 003 6.1 12.5 14.195 7.8082423 
4.586 -1.007 5.46 12.5 14.2075 7.8013725 
4.715 -1. 012 5.19 15 14.2225 7.7931447 
4.824 -1.017 4.51 15 14.2375 7.7849342 
4.977 -1. 021 4.31 10 14.2475 7.7794701 
5.072 -1. 024 4.13 20 14.2675 7.7685649 
5.199 -1. 027 3.62 25 14.2925 7.7549764 
5.301 -1.03 3.26 10 14.3025 7.7495543 
5.42 -1. 034 2.82 15 14.3175 7.7414353 
5.532 -1. 04 2.75 20 14.3375 7.7306364 
5.663 -1. 048 2.33 20 14.3575 7.7198677 
5.781 -1. 054 1. 98 20 14.3775 7.7091288 
5.941 -1. 06 1. 65 30 14.4075 7.6930765 
6.089 -1.064 1. 27 30 14.4375 7.6770909 
6.19 -1. 068 1.12 20 14.4575 7.6664707 
1996-03-15 
5ml APD + 40 ul Zn in 12.740ml 
3. 925E-03M APD + 6.562E-05M Zn (60:1) 
Gestoor in azn-5-st tot azn-5-33 
Page 1 
APPENDIX El-E4: 
A selection of Polarograms recorded for each of the systems; 
Cd(Il)-HEDP, Zn(II)-HEDP, Zn(ll)-MDP and Zn(II)-APD 
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31P and 13C NMR spectra recorded for the system; 
Mg(II)-HEDP 
The spectra are included in the following order 
31P ofHEDP (pH= 2.0) 
31P ofHEDP (pH= 10.5) 
31P ofMg(II)-HEDP (pH= 3.0) 
31P ofMg(II)-HEDP (pH= 5.0) 
·
31p ofMg(II)-HEDP (pH= 7.0) 
31P of Mg(II)-HEDP (pH= 11.0) 
Be of HEDP (pH= 2.0) 
13e of Mg(II)-HEDP (pH= 3.0) 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ECCLES modeling output 
The ECCLES calculation output, with respect to the monitored components, 



































> INCLUDING HO 





)NITORED COMPONENTS: H0+3 APDO 
) SCAN REQUIRED. 
:CLES DATA CHECKING PROCEDURES EMPLOYED. 
IERE ARE 20 SPECIES WITH DEFINED CONCENTRATIONS. 
~TA INPUT SUCCESSFULLY COMPLETED. 
)TAL NUMBER OF COMPONENTS= 54 (LIMIT= 115 ) 
IMBER OF COMPONENTS WITH FIXED FREE CONCENTRATIONS= 13 (LIMIT= 15 ) 
)TAL NUMBER OF SPECIES= 4977 (LIMIT= 5000 ) 
)TAL NUMBER OF COMPONENTS ENTERED IN KEY ARRAY= 17347 (LIMIT= 18000 
CPERIMENTAL PH = 7.398 CALCULATED LOG KW= -13.3116 
MONITOR COMPONENT H0+3 FREE CONC. = 2.5000E-11 
---------------------
SPECIES SPECIES LOG STAB. COMPOSITION. 
NO. CONC. CONST. 
1300 3.1989E-07 57.5% 23.34 APDO(l) H0+3(1) H +1(1) 
1256 1. 6349E-07 29.4% 14.31 CTA3(1) H0+3(1) OH-1(1) 
1257 4.6284E-08 8.3% 19.67 CTA3(1) H0+3(1) OH-1(2) 
1253 9.7623E-09 1. 8% 7.17 CTA3(1) H0+3(1) 
1268 7.6319E-09 1.4% 13.40 SLA2(1) H0+3(1) 
1299 2.3602E-09 .4% 13.81 APDO(l) H0+3(1) 
1274 1. 4 713E-09 .3% 6.26 C032(1) H0+3(1) 
1337 1. 3876E-09 .2% 9.08 CTA3 ( 1) LTAl ( 1) H0+3(1) 
1254 1. 3218E-09 .2% 10.88 CTA3(2) H0+3(1) 
1324 7.6159E-10 .1% 14.10 CYS2(1) CTA3(1) H0+3(1) 
1325 3.2609E-10 .1% 11.19 HISl(l) CTA3(1) H0+3(1) 
1345 2.6193E-10 .0% 10.10 CTA3(1) MLA2(1) H0+3(1) 
1301 2.5530E-10 .0% 27.64 APDO(l) H0+3(1) H +1 ( 2) 
1329 1. 6564E-10 .0% 9.09 S042(1) CTA3(1) H0+3(1) 
1263 1. 2270E-10 .0% 5.70 OXA2(1) H0+3(1) 
1326 9.3871E-11 .0% 13.34 LYSl(l) CTA3(1) H0+3(1) 
1261 8.7412E-ll .0% 5.04 MLA2(1) H0+3(1) 
1331 7.9950E-11 .0% 11.30 CYS2(1) L'rAl(l) H0+3(1) 
1258 5.2559E-11 .0% 3.08 LTAl ( 1) H0+3(1) 
1327 4.6851E-11 .0% 11.49 TRPl ( 1) CTA3(1) H0+3(1) 
1214 4.5931E-11 .0% 5.70 ARGO(l) H0+3(1) 
1332 3.4231E-11 .0% 8.39 HISl(l) LTAl ( 1) H0+3(1) 
1323 3.3396E-11 .0% 11. 89 ASP2(1) CTA3(1) H0+3(1) 
1219 3.2219E-11 .0% 8.14 CYS2(1) H0+3(1) 
1233 3.2142E-11 .0% 5.90 LEUl(l) H0+3(1) 
1346 2.7497E-11 .0% 7.30 LTAl ( 1) MLA2(1) H0+3(1) 
1236 2.2556E-11 .0% 5.90 METl(l) H0+3(1) 
1304 1. 8788E-11 .0% 13.40 CYS2(1) HISl(l) H0+3(1) 
1336 1. 7388E-11 .0% 6.29 S042(1) LTAl ( 1) H0+3(1) 
1225 1. 6735E-11 .0% 11. 21 GLYl(l) H0+3(1) OH-1(1) 
1213 1.5916E-11 .0% 11.16 ALAl(l) H0+3(1) OH-1(1) 
1218 l.5482E-ll .0% 5.69 CITl(l) H0+3(1) 
1339 l.5092E-11 .0% 12.31 CYS2(1) MLA2(1) H0+3(1) 
1223 1.4863E-11 .0% 5.89 GLU2(1) H0+3(1) 
1259 1. 4567E-11 .0% 5.28 LTAl ( 2) H0+3(1) 
1232 1. 3782E-11 .0% 5.90 ILEl ( 1) H0+3(1) 
1228 1. 2785E-11 .0% 5.20 HISl(l) H0+3(1) 
1354 1.0550E-11 .0% 8.23 CTA3(1) PVAl ( 1) H0+3(1) 
1243 9.8573E-12 .0% 4.63 THRl ( 1) H0+3(1) 
1333 9.8543E-12 .0% 10.54 LYSl(l) LTAl ( 1) H0+3(1) 
1318 9.5438E-12 .0% 11. 31 CYS2(1) S042(1) H0+3(1) 
1249 8.0826E-12 .0% 3.20 S042(1) H0+3(1) 
1240 7.3421E-12 .0% 11.90 THRl(l) H0+3(1) H +1(1) 
1224 6.8826E-12 .0% 12.31 GLYl ( 1) H0+3(1) H +1 ( 1) 
1241 6.7552E-12 .0% 16.29 THRl ( 1) H0+3(1) OH-1(2) 
1211 6.7035E-12 .0% 5.90 ABAl ( 1) H0+3(1) 
1340 6.4618E-12 .0% 9.40 HISl(l) MLA2(1) H0+3(1) 
1242 6.3343E-12 .0% 10.35 THRl(l) H0+3(1) OH-1(1) 
1272 6.2500E-12 .0% 5.31 H0+3(1) OH-1(1) 
1239 5.6833E-12 .0% 5.90 PROl(l) H0+3(1) 
1306 5.4086E-12 .0% 15.56 CYS2(1) LYS1(1) H0+3(1) 
1226 5.3898E-12 .0% 16.63 GLYl ( 1) H0+3(1) OH-1(2) 
1334 4.9183E-12 .0% 8.69 TRPl(l) LTAl ( 1) H0+3(1) 
MONITOR COMPONENT APDO FREE CONC. = 1.4622E-12 
SPECIES SPECIES LOG STAB. COMPOSITION. 
NO. CONC. CONST. 
1281 6.8111E-05 80.1% 20.96 APDO(l) CA+2(2) H +1(1) 
1297 5.5343E-06 6.5% 17.26 APDO ( 1) MG+2(1) H +1(1) 
1280 5.3846E-06 6.3% 12.46 APDO(l) CA+2(2) 
1279 2.9521E-06 3.5% 16.65 APDO(l) CA+2(1) H +1(1) 
1276 1. 3156E-06 1.5% 20.75 APDO ( 1) H +1 ( 2) 
1298 1.3035E-06 1.5% 24.03 APDO(l) MG+2(1) H +1(2) 
1300 3.1989E-07 .4% 23.34 APDO(l) H0+3(1) H +1(1) 
1277 5.3849E-08 .1% 26.76 APDO(l) H +1(3) 
1290 8.8524E-09 .0% 20.18 APDO(l) ZN+2(1) H +1 ( 1) 
1296 8.1471E-09 .0% 7.03 APDO(l) MG+2(1) 
1275 5.2127E-09 .0% 10.95 APDO(l) H +1(1) 
1299 2.3602E-09 .0% 13.81 APDO(l) H0+3(1) 
1301 2.5530E-10 .0% 27.64 APDO(l) H0+3(1) H +1(2) 
1291 2.3940E-10 .0% 26.01 APDO(l) ZN+2(1) H +1(2) 
1289 2.2131E-10 .0% 11.18 APDO(l) ZN+2(1) 
1278 7.8206E-13 .0% 29.32 APDO(l) H +1 ( 4) 
1292 9.1821E-14 .0% 13.71 APDO(l) ZN+2(1) OH-1(1) 
1294 1. 4030E-17 .0% 25.38 APDO(l) FE+3(1) H +1 ( 1) 
1293 9.6605E-18 .0% 17.82 APDO(l) FE+3(1) 
1286 6.8716E-19 .0% 21. 07 APDO(l) CU+2(1) H +1(1) 
1285 2.0654E-19 .0% 13.15 APDO(l) CU+2(1) 
1283 1.1670E-19 .0% 18.30 APDO(l) NI+2(1) H +1(1) 
1282 2.7227E-20 .0% 10.27 APDO(l) NI+2(1) 
1284 3.3816E-21 .0% 24.16 APDO(l) NI+2(1) H +1(2) 
1287 1.5457E-21 .0% 25.82 APDO(l) CU+2(1) H +1(2) 
1295 1. 0943E-21 .0% 28.67 APDO(l) FE+3(1) H +1(2) 
1288 3.1838E-23 .0% 15.25 APDO(l) CU+2(1) OH-1(1) 
WELL DONE ECCLES', SAID MORIARTY. 
HEDP AND Sm(III) 
**** **** **** * ***** ***** 
* * * * * 
*** * * * **** ***** 
* * * * * 







> INCLUDING SM 





)NITORED COMPONENTS: SM+3 HED4 
) SCAN REQUIRED. 
:CLES DATA CHECKING PROCEDURES EMPLOYED. 
iERE ARE 20 SPECIES WITH DEFINED CONCENTRATIONS. 
\TA INPUT SUCCESSFULLY COMPLETED. 
)TAL NUMBER OF COMPONENTS= 54 (LIMIT= 115 ) 
JMBER OF COMPONENTS WITH FIXED FREE CONCENTRATIONS= 13 (LIMIT= 15 ) 
)TAL NUMBER OF SPECIES= 4977 (LIMIT= 5000 ) 
)TAL NUMBER OF COMPONENTS ENTERED IN KEY ARRAY= 17352 (LIMIT= 18000 
{PERIMENTAL PH = 7.398 CALCULATED LOG KW= -13.3116 
MONITOR COMPONENT SM+3 FREE CONC. = 2.5000E-ll 
SPECIES SPECIES LOG STAB. COMPOSITION. 
NO. CONC. CONST. 
1291 1. 5807E-07 60.7% 19.20 HED4(1) SM+3(1) H +1(1) 
1256 6.6220E-08 25.4% 13.91 CTA3(1) SM+3(1) OH-1(1) 
1257 2.6057E-08 10.0% 19.42 CTA3(1) SM+3(1) OH-1(2) 
1290 3.1389E-09 1.2% 10.10 HED4(1) SM+3(1) 
1253 3.0203E-09 1.2% 6.66 CTA3(1) SM+3(1) 
1268 l.7504E-09 .7% 12.76 SLA2(1) SM+3(1) 
1274 7.5457E-10 .3% 5.97 C032(1) SM+3(1) 
1327 4.1952E-10 .2% 8.56 CTA3(1) LTAl ( 1) SM+3(1) 
1254 3.5658E-10 .1% 10.31 CTA3(2) SM+3(1) 
1314 l.8502E-10 .1% 13.48 CYS2(1) CTA3(1) SM+3(1) 
1315 9.0955E-ll .0% 10.63 HISl(l) CTA3(1) SM+3(1) 
1335 7.5628E-ll .0% 9.56 CTA3(1) MLA2(1) SM+3(1) 
1319 4.8379E-ll .0% 8.56 S042(1) CTA3(1) SM+3(1) 
1263 3.9705E-ll .0% 5.21 OXA2(1) SM+3(1) 
1261 2.9619E-ll .0% 4.57 MLA2(1) SM+3(1) 
1316 2.4436E-ll .0% 12.76 LYS1(1) CTA3(1) SM+3(1) 
1321 2.1769E-ll .0% 10.73 CYS2(1) LTAl ( 1) SM+3(1) 
1258 l.9528E-ll .0% 2.65 LTAl ( 1) SM+3(1) 
1214 1. 4525E-ll .0% 5.20 ARGO(l) SM+3(1) 
1317 1. 3684E-ll .0% 10.95 TRPl(l) CTA3(1) SM+3(1) 
1322 l.0701E-ll .0% 7.88 HIS1(1) LTAl(l) SM+3(1) 
1233 l.0164E-ll .0% 5.40 LEUl(l) SM+3(1) 
1219 9.6188E-12 .0% 7.62 CYS2(1) SM+3(1) 
1336 8.8978E-12 .0% 6.80 LTAl ( 1) MLA2(1) SM+3(1) 
1313 8.6934E-12 .0% 11. 31 ASP2(1) CTA3(1) SM+3(1) 
1225 7.6495E-12 .0% 10.87 GLYl ( 1) SM+3(1) OH-1(1) 
1213 7.2749E-12 .0% 10.82 ALAl(l) SM+3(1) OH-1(1) 
1236 7.1329E-12 .0% 5.40 METl(l) SM+3(1) 
1326 5.6919E-12 .0% 5.80 S042(1) LTAl ( 1) SM+3(1) 
1218 5.1265E-12 .0% 5.21 CITl(l) SM+3(1) 
1259 4.9358E-12 .0% 4.81 LTAl ( 2) SM+3(1) 
1223 4.8876E-12 .0% 5.41 GLU2(1) SM+3(1) 
1294 4.7196E-12 .0% 12.80 CYS2(1) HISl(l) SM+3(1) 
1241 4.4631E-12 .0% 16.11 THRl ( 1) SM+3(1) OH-1(2) 
1232 4.3583E-12 .0% 5.40 ILEl(l) SM+3(1) 
1228 4.0431E-12 .0% 4.70 HIS1(1) SM+3(1) 
1329 .3. 9243E-12 .0% 11. 73 CYS2(1) MLA2(1) SM+3(1) 
1226 3.4800E-12 .0% 16.44 GLYl(l) SM+3(1) OH-1(2) 
1243 3.4179E-12 .0% 4.17 THRl(l) SM+3(1) 
1344 3.3018E-12 .0% 7.72 CTA3(1) PVAl ( 1) SM+3(1) 
1249 3.2178E-12 .0% 2.80 S042(1) SM+3(1) 
1272 3.1324E-12 .0% 5.01 SM+3(1) OH-1(1) 
1242 3.0318E-12 .0% 10.03 THRl(l) SM+3(1) OH-1(1) 
1221 3.0242E-12 .0% 15.52 GLNl ( 1) SM+3(1) OH-1(2) 
1323 2.8749E-12 .0% 10.01 LYS1(1) LTAl ( 1) SM+3(1) 
1308 2.5104E-12 .0% 10.73 CYS2(1) S042(1) SM+3(1) 
1211 2.1198E-12 .0% 5.40 ABAl(l) SM+3(1) 
1330 1. 929 lE-12 .0% 8.88 HIS1(1) MLA2(1) SM+3(1) 
1240 1. 8443E-12 .0% 11.30 THRl(l) SM+3(1) H +1(1) 
1239 1. 7972E-12 .0% 5.40 PROl(l) SM+3(1) 
1224 1. 7288E-12 .0% 11. 71 GLYl ( 1) SM+3(1) H +1(1) 
1324 1. 6100E-12 .0% 8.20 TRPl(l) LTAl ( 1) SM+3(1) 
1248 1. 4428E-12 .0% 10.19 VALl(l) SM+3(1) OH-1(1) 
MONITOR COMPONENT HED4 FREE CONC. = 9.9732E-09 
SPECIES SPECIES LOG STAB. COMPOSITION. 
NO. CONC. CONST. 
1281 4.3151E-05 50.8% 9.53 HED4(1) CA+2(2) 
1288 l.3516E-05 15.9% 9.70 HED4(1) MG+2(2) 
1287 6.7127E-06 7.9% 13.51 HED4(1) MG+2(1) H +1(1) 
1282 6.6677E-06 7.8% 13.17 HED4(1) CA+2(1) H +1(1) 
1286 5.5570E-06 6.5% 6.03 HED4(1) MG+2(1) 
1275 5.1392E-06 6.0% 10.11 HED4(1) H +1(1) 
1280 2.4656E-06 2.9% 5.34 HED4(1) CA+2(1) 
1276 1.3273E-06 1. 6% 16.92 HED4(1) H +1(2) 
1283 2.8108E-07 .3% 10.45 HED4(1) ZN+2(1) 
1291 l.5807E-07 .2% 19.20 HED4(1) SM+3(1) H +1(1) 
1289 8.9698E-09 .0% 9.15 HED4(1) MG+2(1) OH-1(1) 
1290 3.1389E-09 .0% 10.10 HED4(1) SM+3(1) 
1284 2.1923E-09 .0% 15.74 HED4(1) ZN+2(1) H +1(1) 
1277 4.9547E-11 .0% 19.89 HED4(1) H +1(3) 
1285 2.1036E-12 .0% 20.12 HED4(1) ZN+2(1) H +1(2) 
1278 5.4585E-16 .0% 22.33 HED4(1) H +1(4) 
1279 3.9012E-26 .0% 26.98 HED4(1) H +1(6) 
HEDP, Transferrin and Sm(III) 
**** **** **** * ***** ***** 
* * * * * 
*** * * * **** ***** 
* * * * * 







> INCLUDING SM 





)NITORED COMPONENTS: SM+3 HED4 
) SCAN REQUIRED. 
~CLES DATA CHECKING PROCEDURES EMPLOYED. 
iERE ARE 20 SPECIES WITH DEFINED CONCENTRATIONS. 
~TA INPUT SUCCESSFULLY COMPLETED. 
)TAL NUMBER OF COMPONENTS= 55 (LIMIT= 115 ) 
JMBER OF COMPONENTS WITH FIXED FREE CONCENTRATIONS= 13 (LIMIT= 15 ) 
)TAL NUMBER OF SPECIES= 4977 (LIMIT= 5000 ) 
)TAL NUMBER OF COMPONENTS ENTERED IN KEY ARRAY= 17360 (LIMIT= 18000 
CPERIMENTAL PH = 7.398 CALCULATED LOG KW= -13.3116 
MONITOR COMPONENT SM+3 FREE CONC. = 2.0000E-11 
·---------------------
SPECIES SPECIES LOG STAB. COMPOSITION. 
NO. CONC. CONST. 
1292 1.4547E-06 87.1% 25.49 TFRN(l) C032(1) SM+3(l)OH-1(2 
1291 1.2650E-07 7.6% 19.20 HED4(1) SM+3(1) H +1(1) 
1256 5.2985E-08 3.2% 13.91 CTA3(1) SM+3(1) OH-1(1) 
1257 2.0849E-08 1.2% 19.42 CTA3(1) SM+3(1) OH-1(2) 
1293 3.3838E-09 .4% 49.88 TFRN(l) C032(2) SM+3(2)0H-1(4 
1290 2.5121E-09 .2% 10.10 HED4(1) SM+3(1) 
1253 2.4166E-09 .1% 6.66 CTA3(1) SM+3(1) 
1268 1.4004E-09 .1% 12.76 SLA2(1) SM+3(1) 
1274 6.0362E-10 .0% 5.97 C032(1) SM+3(1) 
1329 3.3568E-10 .0% 8.56 CTA3(1) LTAl ( 1) SM+3(1) 
1254 2.8536E-10 .0% 10.31 CTA3(2) SM+3(1) 
1316 1.4805E-10 .0% 13.48 CYS2(1) CTA3 ( 1) SM+3(1) 
1317 7.2777E-11 .0% 10.63 HIS1(1) CTA3(1) SM+3(1) 
1337 6.0513E-11 .0% 9.56 CTA3(1) MLA2(1) SM+3(1) 
1321 3.8710E-11 .0% 8.56 S042(1) CTA3(1) SM+3(1) 
1263 3.1764E-11 .0% 5.21 OXA2(1) SM+3(1) 
1261 2.3696E-11 .0% 4.57 MLA2(1) SM+3(1) 
1318 1. 9552E-11 .0% 12.76 LYS1(1) CTA3(1) SM+3(1) 
1323 1. 7415E-11 .0% 10.73 CYS2(1) LTAl ( 1) SM+3(1) 
1258 1. 5622E-11 .0% 2.65 LTAl ( 1) SM+3(1) 
1214 1.1620E-11 .0% 5.20 ARGO(l) SM+3(1) 
1319 1. 0949E-11 .0% 10.95 TRPl(l) CTA3(1) SM+3(1) 
1324 8.5609E-12 .0% 7.88 HISl(l) LTAl ( 1) SM+3(1) 
1233 8.1313E-12 .0% 5.40 LEUl(l) SM+3(1) 
1219 7.6951E-12 .0% 7.62 CYS2(1) SM+3(1) 
1338 7.1183E-12 .0% 6.80 LTAl ( 1) MLA2(1) SM+3 ( 1) 
1315 6.9559E-12 .0% 11.31 ASP2(1) CTA3(1) SM+3(1) 
1225 6.1196E-12 .0% 10.87 GLYl(l) SM+3(1) OH-1(1) 
1213 5.8200E-12 .0% 10.82 ALAl(l) SM+3(1) OH-1(1) 
1236 5.7063E-12 .0% 5.40 METl(l) SM+3(1) 
1328 4.5536E-12 .0% 5.80 S042(1) LTAl ( 1) SM+3(1) 
1218 4.1012E-12 .0% 5.21 CITl(l) SM+3(1) 
1259 3.9486E-12 .0% 4.81 LTAl ( 2) SM+3(1) 
1223 3.9101E-12 .0% 5.41 GLU2(1) SM+3(1) 
1296 3.7757E-12 .0% 12.80 CYS2(1) HIS1(1) SM+3(1) 
1241 3.5705E-12 .0% 16.11 THRl ( 1) SM+3(1) OH-1(2) 
1232 .3. 4867E-12 .0% 5.40 ILEl(l) SM+3(1) 
1228 3.2345E-12 .0% 4.70 HISl(l) SM+3(1) 
1331 3.1394E-12 .0% 11. 73 CYS2(1) MLA2(1) SM+3(1) 
1226 2.7840E-12 .0% 16.44 GLYl ( 1) SM+3(1) OH-1(2) 
1243 2.7343E-12 .0% 4.17 THRl(l) SM+3(1) 
1346 2.6419E-12 .0% 7.72 CTA3(1) PVAl ( 1) SM+3(1) 
1249 2.5742E-12 .0% 2.80 S042(1) SM+3(1) 
1272 2.5059E-12 .0% 5.01 SM+3(1) OH-1(1) 
1242 2.4254E-12 .0% 10.03 THRl(l) SM+3(1) OH-1(1) 
1221 2.4194E-12 .0% 15.52 GLNl(l) SM+3(1) OH-1(2) 
1325 2.2999E-12 .0% 10.01 LYSl(l) LTAl ( 1) SM+3(1) 
1310 2.0083E-12 .0% 10.73 CYS2(1) S042(1) SM+3(1) 
1211 1.6959E-12 .0% 5.40 ABAl(l) SM+3(1) 
1332 1. 5433E-12 .0% 8.88 HISl(l) MLA2(1) SM+3(1) 
1240 1.4754E-12 ,0% 11. 30 THRl(l) SM+3(1) H +1(1) 
1239 l.4378E-12 .0% 5.40 PROl(l) SM+3(1) 
1224 1. 3831E-12 .0% 11. 71 GLYl(l) SM+3(1) H +1(1) 
MONITOR COMPONENT HED4 FREE CONC. = 9.9770E-09 
SPECIES SPECIES LOG STAB. COMPOSITION. 
NO. CONC. CONST. 
1281 4.3168E-05 50.8% 9.53 HED4(1) CA+2(2) 
1288 l.3521E-05 15.9% 9.70 HED4(1) MG+2(2) 
1287 6.7153E-06 7.9% 13.51 HED4(1) MG+2(1) H +1(1) 
1282 6.6702E-06 7.8% 13.17 HED4(1) CA+2(1) H +1(1) 
1286 5.5591E-06 6.5% 6.03 HED4(1) MG+2(1) 
1275 5.1412E-06 6.0% 10.11 HED4(1) H +1(1) 
1280 2.4665E-06 2.9% 5.34 HED4(1) CA+2(1) 
1276 1. 3278E-06 1. 6% 16.92 HED4(1) H +1(2) 
1283 2.8119E-07 .3% 10.45 HED4(1) ZN+2(1) 
1291 l.2650E-07 .1% 19.20 HED4(1) SM+3(1) H +1(1) 
1289 8.9732E-09 .0% 9.15 HED4(1) MG+2(1) OH-1(1) 
1290 2.5121E-09 .0% 10.10 HED4(1) SM+3(1) 
1284 2.1931E-09 .0% 15'. 74 HED4(1) ZN+2(1) H +1(1) 
1277 4.9566E-11 .0% 19.89 HED4(1) H +1(3) 
1285 2.1044E-12 .0% 20.12 HED4(1) ZN+2(1) H +1(2) 
1278 5.4606E-16 .0% 22.33 HED4(1) H +1(4) 
1279 3.9027E-26 .0% 26.98 HED4(1) H +1(6) 
'WELL DONE ECCLES', SAID MORIARTY. 
MDP AND Sm(III) 
**** **** **** * ***** ***** 
* * * * * 
*** * * * **** ***** 
* * * * * 







> INCLUDING SM 





8NITORED COMPONENTS: SM+3 MDPO 
:) SCAN REQUIRED. 
~CLES DATA CHECKING PROCEDURES EMPLOYED. 
HERE ARE 20 SPECIES WITH DEFINED CONCENTRATIONS. 
~TA INPUT SUCCESSFULLY COMPLETED. 
JTAL NUMBER OF COMPONENTS= 54 (LIMIT= 115 ) 
UMBER OF COMPONENTS WITH FIXED FREE CONCENTRATIONS= 13 (LIMIT= 15 ) 
JTAL NUMBER OF SPECIES= 4977 (LIMIT= 5000) 
JTAL NUMBER OF COMPONENTS ENTERED IN KEY ARRAY= 17351 (LIMIT= 18000 
l{PERIMENTAL PH = 7.398 CALCULATED LOG KW= -13.3116 
MONITOR COMPONENT SM+3 FREE CONC. = 2.5000E-ll 
·---------------------
SPECIES SPECIES LOG STAB. COMPOSITION. 
NO. CONC. CONST. 
1293 9.2233E-08 47.6% 18.30 MDPO(l) SM+3(1) H +1(1) 
1256 6.6220E-08 34.2% 13.91 CTA3(1) SM+3(1) OH-1(1) 
1257 2.6057E-08 13.4% 19.42 CTA3(1) SM+3(1) OH-1(2) 
1253 3.0203E-09 1.6% 6.66 CTA3(1) SM+3(1) 
1292 2.3058E-09 1.2% 9.30 MDPO(l) SM+3(1) 
1268 1. 7504E-09 .9% 12.76 SLA2(1) SM+3(1) 
1274 7.5457E-10 .4% 5.97 C032(1) SM+3(1) 
1329 4.1952E-10 .2% 8.56 CTA3(1) LTAl ( 1) SM+3(1) 
1254 3.5658E-10 .2% 10.31 CTA3(2) SM+3(1) 
1316 1. 8502E-10 .1% 13.48 CYS2(1) CTA3(1) SM+3(1) 
1317 9.0955E-ll .0% 10.63 HISl(l) CTA3(1) SM+3(1) 
1337 7.5628E-ll .0% 9.56 CTA3(1) MLA2(1) SM+3(1) 
1321 4.8379E-ll .0% 8'.56 S042(1) CTA3(1) SM+3(1) 
1263 3.9705E-ll .0% 5.21 OXA2(1) SM+3(1) 
1261 2.9619E-ll .0% 4.57 MLA2(1) SM+3(1) 
1318 2.4436E-ll .0% 12.76 LYSl(l) CTA3(1) SM+3(1) 
1323 2.1769E-ll .0% 10.73 CYS2(1) LTAl ( 1) SM+3(1) 
1258 l.9528E-ll .0% 2.65 LTAl ( 1) SM+3(1) 
1214 1. 4525E-ll .0% 5.20 ARGO(l) SM+3(1) 
1319 l.3684E-ll .0% 10.95 TRPl(l) CTA3(1) SM+3(1) 
1324 1. 0701E-ll .0% 7.88 HISl(l) LTAl ( 1) SM+3(1) 
1233 l.0164E-ll .0% 5.40 LEUl(l) SM+3(1) 
1219 9.6188E-12 .0% 7.62 CYS2(1) SM+3(1) 
1338 8.8978E-12 .0% 6.80 LTAl ( 1) MLA2(1) SM+3(1) 
1315 8.6934E-12 .0% 11.31 ASP2(1) CTA3(1) SM+3(1) 
1225 7.6495E-12 .0% 10.87 GLYl ( 1) SM+3(1) OH-1(1) 
1213 7.2749E-12 .0% 10.82 ALAl(l) SM+3(1) OH-1 ( 1) 
1236 7.1329E-12 .0% 5.40 METl(l) SM+3(1) 
1328 5.6919E-12 .0% 5.80 S042(1) LTAl ( 1) SM+3(1) 
1218 5.1265E-12 .0% 5.21 CITl(l) SM+3(1) 
1259 4.9358E-12 .0% 4.81 LTAl ( 2) SM+3(1) 
1223 4.8876E-12 .0% 5.41 GLU2(1) SM+3(1) 
1296 4.7196E-12 .0% 12.80 CYS2(1) HIS 1 ( 1) SM+3(1) 
1241 4.4631E-12 .0% 16.11 THRl ( 1) SM+3(1) OH-1(2) 
1232 4.3583E-12 .0% 5.40 ILEl(l) SM+3(1) 
1228 4.0431E-12 .0% 4.70 HISl(l) SM+3(1) 
1331 .3. 9243E-12 .0% 11. 73 CYS2(1) MLA2(1) SM+3(1) 
1226 3.4800E-12 .0% 16.44 GLYl ( 1) SM+3(1) OH-1(2) 
1243 3.4179E-12 .0% 4.17 THRl(l) SM+3(1) 
1346 3.3018E-12 .0% 7.72 CTA3 ( 1) PVAl ( 1) SM+3(1) 
1249 3.2178E-12 .0% 2.80 S042(1) SM+3(1) 
1272 3.1324E-12 .0% 5.01 SM+3(1) OH-1(1) 
1242 3.0318E-12 .0% 10.03 THRl(l) SM+3(1) OH-1(1) 
1221 3.0242E-12 .0% 15.52 GLNl ( 1) SM+3(1) OH-1(2) 
1325 2.8749E-12 .0% 10.01 LYSl(l) LTAl ( 1) SM+3(1) 
1310 2.5104E-12 .0% 10.73 CYS2(1) S042(1) SM+3(1) 
1211 2.1198E-12 .0% 5.40 ABAl ( 1) SM+3(1) 
1332 l.9291E-12 .0% 8.88 HISl(l) MLA2(1) SM+3(1) 
1240 1. 8443E-12 .0% 11. 30 THRl(l) SM+3(1) H +1(1) 
1239 1. 7972E-12 .0% 5.40 PROl(l) SM+3(1) 
1224 1. 7288E-12 .0% 11. 71 GLYl(l) SM+3(1) H +1(1) 
1326 1. 6100E-12 .0% 8.20 TRPl(l) LTAl ( 1) SM+3(1) 
1248 1. 4428E-12 .0% 10.19 VALl ( 1) SM+3(1) OH-1(1) 
MONITOR COMPONENT MDPO FREE CONC. = 4.6226E-08 
SPECIES SPECIES LOG STAB. COMPOSITION. 
NO. CONC. CONST. 
1275 1. 7256E-05 20.3% 9.97 MDPO(l) H +1(1) 
1290 1.6709E-05 19.7% 13.24 MDPO(l) MG+2(1) H +1(1) 
1281 1.4489E-05 17.0% 8.39 MDPO(l) CA+2(2) 
1289 1.1505E-05 13.5% 5.68 MDPO(l) MG+2(1) 
1282 1.0234E-05 12.0% 12.69 MDPO(l) CA+2(1) H +1(1) 
1276 7.0633E-06 8.3% 16.98 MDPO(l) H +1(2) 
1280 3.7841E-06 4.5% 4.86 MDPO(l) CA+2(1) 
1291 2.8635E-06 3.4% 8.36 MDPO(l) MG+2(2) 
1286 9.4382E-07 1.1% 10.31 MDPO(l) ZN+2(1) 
1293 9.2233E-08 .1% 18.30 MDPO(l) SM+3(1) H +1(1) 
1287 1. 0888E-08 .0% 15.77 MDPO(l) ZN+2(1) H +1(1) 
1292 2.3058E-09 .0% 9.30 MDPO(l) SM+3(1) 
1277 5.1412E-10 .0% 20'. 24 MDPO(l) H +1(3) 
1288 1. l 722E-11 .0% 20.20 MDPO(l) ZN+2(1) H +1(2) 
1278 3.1126E-15 .0% 22.42 MDPO(l) H +1(4) 
1283 8.6077E-19 .0% 7.27 MDPO(l) NI+2(1) 
1285 3.2571E-21 .0% 10.76 MDPO(l) NI+2(1) OH-1(1) 
1279 6.7181E-25 .0% 27.55 MDPO(l) H +1(6) 
1284 5.3075E-33 .0% 11. 06 MDPO(l) NI+2(2) 
'WELL DONE ECCLES', SAID MORIARTY. 
MDP, Transferrin and Sm(III) 
***** **** **** * ***** ***** 
* * * * * * 
**** * * * **** ***** 
* * * * * * 







<> INCLUDING SM 
<> 




10NITORED COMPONENTS: SM+3 MDPO 
·m SCAN REQUIRED. 
~CCLES DATA CHECKING PROCEDURES EMPLOYED. 
'~HERE ARE 20 SPECIES WITH DEFINED CONCENTRATIONS. 
')ATA INPUT SUCCESSFULLY COMPLETED. 
~oTAL NUMBER OF COMPONENTS= 55 (LIMIT= 115 ) 
!UMBER OF COMPONENTS WITH FIXED FREE CONCENTRATIONS= 13 (LIMIT= 15 ) 
;_'OTAL NUMBER OF SPECIES = 4977 (LIMIT = 5000 ) 
:~OTAL NUMBER OF COMPONENTS ENTERED IN KEY ARRAY = 17358 (LIMIT = 18000 
~XPERIMENTAL PH= 7.398 CALCULATED LOG KW= -13.3116 
MONITOR COMPONENT SM+3 FREE CONC. = 1. 8000E-ll 
----------------------
SPECIES SPECIES LOG STAB. COMPOSITION. 
NO. CONC. CONST. 
1294 1. 3130E-06 90.0% 25.49 TFRN(l) C032(1) SM+3(l)OH-1(2 
1293 6.6429E-08 4.6% 18.30 MDPO(l) SM+3(1) H +1(1) 
1256 4.7690E-08 3.3% 13.91 CTA3(1) SM+3(1) OH-1(1) 
1257 l.8766E-08 1. 3% 19.42 CTA3(1) SM+3(1) OH-1(2) 
1295 2.7490E-09 .4% 49.88 TFRN(l) C032(2) SM+3(2)0H-1(4 
1253 2.1751E-09 .1% 6.66 CTA3 ( 1) SM+3(1) 
1292 1. 6607E-09 .1% 9.30 MDPO(l) SM+3(1) 
1268 1.2604E-09 .1% 12.76 SLA2(1) SM+3(1) 
1274 5.4326E-10 .0% 5.97 C032(1) SM+3(1) 
1331 3.0213E-10 .0% 8.56 CTA3(1) LTAl ( 1) SM+3(1) 
1254 2.5686E-10 .0% 10.31 CTA3(2) SM+3(1) 
1318 1. 3325E-10 .0% 13.48 CYS2(1) CTA3(1) SM+3(1) 
1319 6.5503E-ll .0% 10'.63 HISl(l) CTA3(1) SM+3(1) 
1339 5.4466E-ll .0% 9.56 CTA3(1) MLA2(1) SM+3(1) 
1323 3.4842E-11 .0% 8.56 S042(1) CTA3(1) SM+3(1) 
1263 2.8587E-ll .0% 5.21 OXA2(1) SM+3(1) 
1261 2.1326E-ll .0% 4.57 MLA2(1) SM+3(1) 
1320 l.7598E-ll .0% 12.76 LYSl(l) CTA3(1) SM+3(1) 
1325 l.5673E-ll .0% 10.73 CYS2(1) LTAl ( 1) SM+3(1) 
1258 1.4060E-11 .0% 2.65 LTAl ( 1) SM+3(1) 
1214 1.0458E-ll .0% 5.20 ARGO(l) SM+3(1) 
1321 9.8549E-12 .0% 10.95 TRPl(l) CTA3(1) SM+3(1) 
1326 7.7048E-12 .0% 7.88 HISl(l) LTAl ( 1) SM+3(1) 
1233 7.3182E-12 .0% 5.40 LEUl(l) SM+3(1) 
1219 6.9256E-12 .0% 7.62 CYS2(1) SM+3(1) 
1340 6.4065E-12 .0% 6.80 LTAl ( 1) MLA2(1) SM+3(1) 
1317 6.2608E-12 .0% 11.31 ASP2(1) CTA3(1) SM+3(1) 
1225 5.5076E-12 .0% 10.87 GLYl(l) SM+3(1) OH-1(1) 
1213 5.2380E-12 .0% 10.82 ALAl(l) SM+3(1) OH-1(1) 
1236 5.1357E-12 .0% 5.40 METl(l) SM+3(1) 
1330 4.0982E-12 .0% 5.80 S042(1) LTAl ( 1) SM+3(1) 
1218 3.6911E-12 .0% 5.21 CITl(l) SM+3(1) 
1259 3.5538E-12 .0% 4.81 LTAl ( 2) SM+3(1) 
1223 3.5191E-12 .0% 5.41 GLU2(1) SM+3(1) 
1298 3.3981E-12 .0% 12.80 CYS2(1) HISl(l) SM+3(1) 
1241 3.2135E-12 .0% 16.11 THRl ( 1) SM+3(1) OH-1(2) 
1232 .3 .1380E-12 .0% 5.40 ILEl(l) SM+3(1) 
1228 2.9111E-12 .0% 4.70 HISl(l) SM+3(1) 
1333 2.8255E-12 .0% 11. 73 CYS2(1) MLA2(1) SM+3(1) 
1226 2.5056E-12 .0% 16.44 GLYl ( 1) SM+3(1) OH-1(2) 
1243 2.4609E-12 .0% 4.17 THRl(l) SM+3(1) 
1348 2.3779E-12 .0% 7.72 CTA3(1) PVAl ( 1) SM+3(1) 
1249 2.3168E-12 .0% 2.80 S042(1) SM+3(1) 
1272 2.2553E-12 .0% 5.01 SM+3(1) OH-1(1) 
1242 2.1829E-12 .0% 10.03 THRl(l) SM+3(1) OH-1(1) 
1221 2.1774E-12 .0% 15.52 GLNl ( 1) SM+3(1) OH-1(2) 
1327 2.0699E-12 .0% 10.01 LYSl(l) LTAl ( 1) SM+3(1) 
1312 l.8075E-12 .0% 10.73 CYS2(1) S042(1) SM+3(1) 
1211 l.5263E-12 .0% 5.40 ABAl(l) SM+3(1) 
1334 1. 3890E-12 .0% 8.88 HISl(l) MLA2(1) SM+3(1) 
1240 l.3279E-12 .0% 11. 30 THRl ( 1) SM+3(1) H +1(1) 
1239 l.2940E-12 .0% 5.40 PROl(l) SM+3(1) 
1224 1. 2448E-12 .0% 11. 71 GLYl(l) SM+3(1) H +1(1) 
MONITOR COMPONENT MDPO FREE CONC. = 4.6241E-08 
SPECIES SPECIES LOG STAB. COMPOSITION. 
NO. CONC. CONST. 
1275 l.7262E-05 20.3% 9.97 MDPO(l) H +1(1) 
1290 1. 6714E-05 19.7% 13.24 MDPO(l) MG+2(1) H +1(1) 
1281 1. 4494E-05 17.1% 8.39 MDPO(l) CA+2(2) 
1289 l.1509E-05 13.5% 5.68 MDPO(l) MG+2(1) 
1282 l.0237E-05 12.0% 12.69 MDPO(l) CA+2(1) H +1(1) 
1276 7.0655E-06 8.3% 16.98 MDPO(l) H +1(2) 
1280 3.7853E-06 4.5% 4.86 MDPO(l) CA+2(1) 
1291 2.8644E-06 3.4% 8.36 MDPO(l) MG+2(2) 
1286 9.4411E-07 1.1% 10.31 MDPO( 1) ZN+2(1) 
1293 6.6429E-08 .1% 18.30 MDPO(l) SM+3(1) H +1(1) 
1287 1. 0891E-08 .0% 15.77 MDPO(l) ZN+2(1) H +1(1) 
1292 1. 6607E-09 .0% 9.30 MDPO(l) SM+3(1) 
1277 5.1428E-10 .0% 20.24 MDPO(l) H +1 ( 3) 
1288 l. l 726E-11 .0% 20.20 MDPO(l) ZN+2(1) H +1(2) 
1278 3.1136E-15 .0% 22.42 MDPO(l) H +1(4) 
1283 8.6104E-19 .0% 7.27 MDPO(l) NI+2(1) 
1285 3.2581E-21 .0% 10.76 MDPO(l) NI+2(1) OH-1(1) 
1279 6.7202E-25 .0% 27.55 MDPO(l) H +1(6) 
1284 5.3091E-33 .0% 11. 06 MDPO(l) NI+2(2) 
'WELL DONE ECCLES', SAID MORIARTY. 
Citrate and Ho(III) 
***** **** **** * ***** ***** 
* * * * * * 
**** * * * **** ***** 
* * * * * * 







<> INCLUDING HO 





~ONITORED COMPONENTS: H0+3 CTA3 
~O SCAN REQUIRED. 
~CCLES DATA CHECKING PROCEDURES EMPLOYED. 
rHERE ARE 20 SPECIES WITH DEFINED CONCENTRATIONS. 
)ATA INPUT SUCCESSFULLY COMPLETED. 
rOTAL NUMBER OF COMPONENTS= 53 (LIMIT= 115 ) 
~UMBER OF COMPONENTS WITH FIXED FREE CONCENTRATIONS= 13 (LIMIT= 15 ) 
rOTAL NUMBER OF SPECIES= 4976 (LIMIT= 5000 ) 
rOTAL NUMBER OF COMPONENTS ENTERED IN KEY ARRAY= 17354 (LIMIT= 18000 
~XPERIMENTAL PH= 7.398 CALCULATED LOG KW= -13.3116 
MONITOR COMPONENT H0+3 FREE CONC. = 2.5000E-11 
----------------------
SPECIES SPECIES LOG STAB. COMPOSITION. 
NO. CONC. CONST. 
1256 1.6349E-07 69.9% 14.31 CTA3(1) H0+3(1) OH-1(1) 
1257 4.6284E-08 19.8% 19.67 CTA3(1) H0+3(1) OH-1(2) 
1253 9.7623E-09 4.2% 7.17 CTA3(1) H0+3(1) 
1268 7.6319E-09 3.3% 13.40 SLA2(1) H0+3(1) 
1274 1.4713E-09 .6% 6.26 C032(1) H0+3(1) 
1310 1. 3876E-09 .6% 9.08 CTA3(1) LTAl ( 1) H0+3(1) 
1254 1.3218E-09 .6% 10.88 CTA3(2) H0+3(1) 
1297 7.6159E-10 .3% 14.10 CYS2(1) CTA3(1) H0+3(1) 
1298 3.2608E-10 .1% 11.19 HISl(l) CTA3(1) H0+3(1) 
1318 2.6193E-10 .1% 10.10 CTA3(1) MLA2(1) H0+3(1) 
1302 1. 6564E-10 .1% 9.09 S042(1) CTA3(1) H0+3(1) 
1263 1.2270E-10 .1% 5.70 OXA2(1) H0+3(1) 
1299 9.3871E-11 .0% 13.34 LYSl(l) CTA3(1) H0+3(1) 
1261 8.7412E-11 .0% 5.04 MLA2(1) H0+3(1) 
1304 7.9950E-ll .0% 11. 30 CYS2(1) LTAl ( 1) H0+3(1) 
1258 5.2559E-ll .0% 3.08 LTAl(l) H0+3(1) 
1300 4.6851E-ll .0% 11.49 TRPl ( 1) CTA3(1) H0+3(1) 
1214 4.5931E-11 .0% 5.70 ARGO(l) H0+3(1) 
1305 3.4231E-ll .0% 8.39 HISl(l) LTAl(l) H0+3(1) 
1296 3.3396E-ll .0% 11. 89 ASP2(1) CTA3(1) H0+3(1) 
1219 3.2219E-11 .0% 8.14 CYS2(1) H0+3(1) 
1233 3.2142E-ll .0% 5.90 LEUl(l) H0+3(1) 
1319 2.7497E-ll .0% 7.30 LTAl ( 1) MLA2(1) H0+3(1) 
1236 2.2556E-ll .0% 5.90 METl(l) H0+3(1) 
1277 1. 8788E-11 .0% 13.40 CYS2(1) HISl(l) H0+3(1) 
1309 1. 7388E-11 .0% 6.29 S042(1) LTAl ( 1) H0+3(1) 
1225 1. 6735E-ll .0% 11. 21 GLYl(l) H0+3(1) OH-1(1) 
1213 1.5916E-ll .0% 11.16 ALAl(l) H0+3(1) OH-1(1) 
1218 1.5482E-11 .0% 5.69 CITl(l) H0+3(1) 
1312 1. 5092E-ll .0% 12.31 CYS2(1) MLA2(1) H0+3(1) 
1223 1.4863E-11 .0% 5.89 GLU2(1) H0+3(1) 
1259 1. 4567E-ll .0% 5.28 LTAl ( 2) H0+3(1) 
1232 1. 3782E-ll .0% 5.90 ILEl(l) H0+3(1) 
1228 1.2785E-11 .0% 5.20 HISl(l) H0+3(1) 
1327 1.0550E-ll .0% 8.23 CTA3(1) PVAl ( 1) H0+3(1) 
1243 9.8573E-12 .0% 4.63 THRl ( 1) H0+3(1) 
1306 9.8543E-12 .0% 10.54 LYSl(l) LTAl ( 1) H0+3(1) 
1291 9.5438E-12 .0% 11.31 CYS2(1) S042(1) H0+3(1) 
1249 8.0826E-12 .0% 3.20 S042(1) H0+3(1) 
1240 7.3420E-12 .0% 11. 90 THRl(l) H0+3(1) H +1(1) 
1224 6.8826E-12 .0% 12.31 GLYl ( 1) H0+3(1) H +1(1) 
1241 6.7552E-12 .0% 16.29 THRl(l) H0+3(1) OH-1(2) 
1211 6.7035E-12 .0% 5.90 ABAl ( 1) H0+3(1) 
1313 6.4617E-12 .0% 9.40 HISl(l) MLA2(1) H0+3(1) 
1242 6.3343E-12 .0% 10.35 THRl(l) H0+3(1) OH-1(1) 
1272 6.2500E-12 .0% 5.31 H0+3(1) OH-1(1) 
1239 5.6833E-12 .0% 5.90 PROl(l) H0+3(1) 
1279 5.4086E-12 .0% 15.56 CYS2(1) LYSl(l) H0+3(1) 
1226 5.3898E-12 .0% 16.63 GLYl ( 1) H0+3(1) OH-1(2) 
1307 4.9183E-12 .0% 8.69 TRPl(l) LTAl ( 1) H0+3(1) 
1221 4.7930E-12 .0% 15.72 GLNl ( 1) H0+3(1) OH-1(2) 
1220 4.3881E-12 .0% 15.31 CYS2(2) H0+3(1) 
1215 4.2549E-12 .0% 4.60 ASNl(l) H0+3(1) 
MONITOR COMPONENT CTA3 FREE CONC. = 2.6401E-05 23.4% 
SPECIES SPECIES LOG STAB. COMPOSITION. 
NO. CONC. CONST. 
1001 5.4287E-05 48.0% 3.26 CTA3(1) CA+2(1) 
1042 3.0034E-05 26.6% 3.34 CTA3 ( 1) MG+2(1) 
4495 5.2168E-07 .5% 4.00 CTA3(1) LTAl ( 1) CA+2(1) 
998 3.3703E-07 .3% 5.50 CTA3(1) H +1(1) 
3993 2.1396E-07 .2% 3.95 CTA3(1) LTAl ( 1) MG+2(1) 
4904 1.7627E-07 .2% 15.65 CTA3 ( 1) P043(1) CA+2(1) H +1(1 
1256 1.6349E-07 .1% 14.31 CTA3(1) H0+3(1) OH-1(1) 
4402 9.1012E-08 .1% 15.70 CTA3 ( 1) P043(1) MG+2(1) H +1(1 
1257 4.6284E-08 .0% 19.67 CTA3(1) H0+3(1) OH-1(2) 
4635 4.6083E-08 .0% 12.20 CTA3(1) GLNl ( 1) CA+2(1) H +1(1 
4125 4.2312E-08 .0% 12.50 CTA3(1) GLNl ( 1) MG+2(1) H +1(1 
1003 4.0434E-08 .0% 7.53 CTA3 ( 1) CA+2(1) H +1(1) 
4537 3.8256E-08 .0% 12·. 95 CTA3(1) ALAl ( 1) CA+2(1) H +1(1 
4650 3.1952E-08 .0% 12.90 CTA3(1) GLYl(l) CA+2(1) H +1(1 
4144 2.9338E-08 .0% 13.20 CTA3 ( 1) GLYl(l) MG+2(1) H +1(1 
4031 2.7901E-08 .0% 13.15 CTA3 ( 1) ALAl(l) MG+2(1) H +1(1 
4769 2.7128E-08 .0% 13.90 CTA3(1) PROl(l) CA+2(1) H +1(1 
4269 2.2199E-08 .0% 14.15 CTA3(1) PROl(l) MG+2(1) H +1(1 
4951 2.0867E-08 .0% 10.00 LTAl ( 1) CTA3(1) CA+2(1) H +1(1 
4814 1. 9614E-08 .0% 12.25 CTA3(1) THRl(l) CA+2 ( l) H +1(1 
4858 l.8200E-08 .0% 12.70 CTA3(1) VALl(l) CA+2(1) H +1(1 
4526 1. 6934E-08 .0% 4.15 CTA3(1) SCA2(1) CA+2(1) 
1002 7.8760E-09 .0% 4.00 CTA3(2) CA+2(1) 
4504 l.5077E-08 .0% 4.20 CTA3(1) MLA2(1) CA+2(1) 
4358 1. 4894E-08 .0% 12.95 CTA3 ( 1) VALl ( 1) MG+2(1) H +1(1 
4791 1. 3260E-08 .0% 12.30 CTA3(1) SERl(l) CA+2(1) H +1(1 
4313 l.2750E-08 .0% 12.40 CTA3(1) THRl(l) MG+2(1) H +1(1 
4710 1. 2187E-08 .0% 12.80 CTA3 ( 1) LEUl(l) CA+2(1) H +1(1 
4012 l.1982E-08 .0% 4.95 CTA3(1) OXA2(1) MG+2(1) 
1044 l.1473E-08 .0% 7.32 CTA3(1) MG+2(1) H +1(1) 
4206 1. 1189E-08 .0% 13.10 CTA3(1) LEUl(l) MG+2(1) H +1(1 
4554 l.0988E-08 .0% 12.40 CTA3(1) ARGO(l) CA+2(1) H +1(1 
4665 l.0852E-08 .0% 12.45 CTA3(1) HISl(l) CA+2(1) H +1(1 
4612 1. 0278E-08 .0% 13.05 CTA3(1) GLU2(1) CA+2(1) H +1(1 
1253 9.7623E-09 .0% 7.17 CTA3(1) H0+3(1) 
4291 9.6712E-09 .0% 12.50 CTA3 ( 1) SERl(l) MG+2(1) H +1(1 
1043 .4. 5628E-09 .0% 4.10 CTA3(2) MG+2(1) 
4161 8.8808E-09 .0% 12.70 CTA3 ( 1) HISl(l) MG+2(1) H +1(1 
4564 8.0854E-09 .0% 12.20 CTA3(1) ASNl(l) CA+2(1) H +1(1 
4045 7.1424E-09 .0% 12.55 CTA3(1) ARGO(l) MG+2(1) H +1(1 
4976 7.0507E-09 .0% 21. 65 P043(1) CTA3(1) CA+2(1) H +1(2 
4020 6.9451E-09 .0% 4.10 CTA3(1) SCA2(1) MG+2(1) 
4101 6.6808E-09 .0% 13.20 CTA3(1) GLU2(1) MG+2(1) H +1(1 
4749 5.9881E-09 .0% 12.30 CTA3(1) PHEl(l) CA+2(1) H +1(1 
4055 5.8970E-09 .0% 12.40 CTA3 ( 1) ASNl(l) MG+2(1) H +1(1 
4693 5.2256E-09 .0% 12.80 CTA3(1) ILEl(l) CA+2(1) H +1(1 
3996 4.9119E-09 .0% 4.05 CTA3 ( 1) MLA2(1) MG+2(1) 
4247 4.9002E-09 .0% 12.55 CTA3 ( 1) PHEl ( 1) MG+2(1) H +1(1 
4189 4.7980E-09 .0% 13.10 CTA3(1) ILEl(l) MG+2(1) H +1(1 
3965 4.7251E-09 .0% 4.15 GLNl ( 1) CTA3(1) MG+2(1) 
4514 4,6301E-09 .0% 4.20 CTA3 ( 1) OXA2(1) CA+2(1) 
4600 4.1472E-09 .0% 12.75 CTA3(1) CIS2(1) CA+2(1) H +1(1 
4090 3.8079E-09 .0% 13.05 CTA3(1) CIS2(1) MG+2(1) H +1(1 
'WELL DONE ECCLES', SAID MORIARTY. 
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:ONITORED COMPONENTS: SR+2 APDO 
0 SCAN REQUIRED. 
CCLES DATA CHECKING PROCEDURES EMPLOYED. 
HERE ARE 18 SPECIES WITH DEFINED CONCENTRATIONS. 
ATA INPUT SUCCESSFULLY COMPLETED. 
OTAL NUMBER OF COMPONENTS= 54 (LIMIT= 115 ) 
UMBER OF COMPONENTS WITH FIXED FREE CONCENTRATIONS= 13 (LIMIT= 15 ) 
OTAL NUMBER OF SPECIES= 4972 (LIMIT= 5000 ) 
OTAL NUMBER OF COMPONENTS ENTERED IN KEY ARRAY= 17364 (LIMIT= 18000 
XPERIMENTAL PH= 7.398 CALCULATED LOG KW= -13.3116 
MONITOR COMPONENT SR+2 FREE CONC. = l.SOOOE-10 
SPECIES SPECIES LOG STAB. COMPOSITION. 
NO. CONC. CONST. 
944 4.8966E-06 98.6% 12.00 P043(1) SR+2(1) 
1020 7.1653E-08 1.4% 10.00 ACA2(1) SR+2(1) 
1078 2.5037E-12 .0% 2.80 CTA3(1) SR+2(1) 
1103 2.0836E-12 .0% .90 LTAl ( 1) SR+2(1) 
969 3.0599E-13 .0% 1. 00 S042(1) SR+2(1) 
1133 1. 9043E-13 .0% 1. 60 MLA2(1) SR+2(1) 
1252 1. 7655E-13 .0% 23.70 APDO(l) SR+2(1) H +1(2) 
1250 l.OlllE-13 .0% 16.06 APDO(l) SR+2(1) H +1(1) 
1238 6.0277E-14 .0% 1. 00 SCA2(1) SR+2(1) 
1167 5.8480E-14 .0% 1.60 OXA2(1) SR+2(1) 
1188 4.4648E-14 .0% .so PVAl ( 1) SR+2(1) 
324 2.3061E-14 .0% .80 GLNl ( 1) SR+2(1) 
756 l.3865E-14 .0% J:. 00 THRl(l) SR+2(1) 
92 1. 3812E-14 .0% 1.40 ARGO(l) SR+2(1) 
724 1. 0517E-14 .0% 1.10 SERl(l) SR+2(1) 
401 7.6713E-15 .0% 1.20 HIS 1 ( 1) SR+2(1) 
258 S.8492E-15 .0% 1. 80 CIS2(1) SR+2(1) 
862 4.5647E-15 .0% 1. 00 VALl(l) SR+2(1) 
659 2.9966E-15 .0% .90 PHEl ( 1) SR+2(1) 
291 2.8923E-15 .0% 1.40 GLU2(1) SR+2(1) 
361 2.8434E-15 .0% .75 GLYl(l) SR+2(1) 
35 2.8317E-15 .0% .72 ALAl(l) SR+2(1) 
516 1. 9285E-15 .0% .90 LEUl(l) SR+2(1) 
185 l.8966E-15 .0% 1. 00 CITl(l) SR+2(1) 
591 1. 2062E-15 .0% .85 METl(l) SR+2(1) 
689 6.8039E-16 .0% 1.20 PROl(l) SR+2(1) 
63 5.0636E-16 .0% 1. 00 ABAl ( 1) SR+2(1) 
158 2.9528E-16 .0% 1.48 ASP2(1) SR+2(1) 
457 3.2317E-17 .0% .40 HYPl(l) SR+2(1) 
959 3.1844E-17 .0% 2.90 SIL2(1) SR+2(1) 
629 8.5269E-18 .0% 1. 00 ORNl(l) SR+2(1) 
562 7.7458E-18 .0% .90 LYSl(l) SR+2(1) 
828 4.1658E-18 .0% .90 TYR2(1) SR+2(1) 
1251 4.4760E-20 .0% 19.53 APDO(l) SR+2(2) H +1(1) 
1213 7.2686E-21 .0% .60 SLA2(1) SR+2(1) 
1249 5.4807E-23 .0% 9.22 APDO(l) SR+2(2) 
MONITOR COMPONENT APDO FREE CONC. = 1.4677E-12 
SPECIES SPECIES LOG STAB. COMPOSITION. 
NO. CONC. CONST. 
1248 6.8370E-05 80.4% 20.96 APDO(l) CA+2(2) H +1(1) 
1268 5.5554E-06 6.5% 17.26 APDO(l) MG+2(1) H +1(1) 
1247 5.4051E-06 6.4% 12.46 APDO(l) CA+2(2) 
1246 2.9634E-06 3.5% 16.65 APDO(l) CA+2(1) H +1(1) 
1243 1. 3206E-06 1. 6% 20.75 APDO ( 1) H +1(2) 
1269 1.3085E-06 1.5% 24.03 APDO(l) MG+2(1) H +1(2) 
1244 5.4054E-08 .1% 26.76 APDO(l) H +1(3) 
1261 8.8861E-09 .0% 20.18 APDO(l) ZN+2(1) H +1(1) 
1267 8.1781E-09 .0% 7.03 APDO(l) MG+2(1) 
1242 5.2325E-09 .0% 10.95 APDO ( 1) H +1(1) 
1262 2.4031E-10 .0% 26.01 APDO(l) ZN+2(1) H +1(2) 
1260 2.2215E-10 .0% 11.18 APDO(l) ZN+2(1) 
1245 7.8504E-13 .0% 29.32 APDO(l) H +1(4) 
1252 1. 7655E-13 .0% 23.70 APDO ( 1) SR+2(1) H +1(2) 
1250 1.0lllE-13 .0% 16.06 APDO(l) SR+2(1) H +1(1) 
1263 9.2170E-14 .0% 13.71 APDO ( 1) ZN+2(1) OH-1(1) 
1265 1. 4083E-l 7 .0% 25.38 APDO(l) FE+3(1) H +1(1) 
1264 9.6973E-18 .0% 17.82 APDO(l) FE+3(1) 
1257 6.8978E-19 .0% 21. 07 APDO(l) CU+2(1) H +1(1) 
1256 2.0732E-19 .0% 13.15 APDO(l) CU+2(1) 
1254 1. l 714E-19 .0% 18.30 APDO ( 1) NI+2(1) H +1(1) 
1251 4.4760E-20 .0% 19.53 APDO(l) SR+2(2) H +1(1) 
1253 2.7331E-20 .0% 10.27 APDO(l) NI+2(1) 
1255 3.3945E-21 .0% 24.16 APDO(l) NI+2(1) H +1(2) 
1258 1. 5516E-21 .0% 25.82 APDO(l) CU+2(1) H +1(2) 
1266 1.0984E-21 .0% 28.67 APDO ( 1) FE+3(1) H +1(2) 
1249 5.4807E-23 .0% 9.22 APDO(l) SR+2(2) 
1259 3.1959E-23 .0% 15.25 APDO ( 1) CU+2(1) OH-1(1) 
APPENDIX Gl: 
ECCLES modeling input files 
See Diskl 
The ECCLES input files contaning the concentrations and complexation 
constants used are presented in the order found in Section 4.4 
NorplHoA.MOD (Ho(III) and APD) 
NorplSmH.MOD (Sm(ill) and HEDP) 
NorplSHT.MOD (Sm(ill), Transferrin and HEDP) 
NorplSmM.MOD (Sm(ill) and MDP) 
_NorplSMT.MOD (Sm(ill), Transferrin and MDP) 
NorplHoC.MOD (Ho(III) and Citrate) 
NorplSrA.MOD (Sr(II) and APD) 
APPENDIXH: 
Blood and Urine clearance values 
The data is included in the following order 
Blood clearance values for 166Ho-APD 
Blood clearance values for 153Sm-EDTMP and 166Ho-EDTMP 
Urine clearance values for 166Ho-APD 
Urine clearance values for 153Sm-EDTMP and 166Ho-EDTMP 




0 113000 1 
3 95200 0.8424779 
6 83640 0.740177 
9 66640 0.5897345 
14 35320 0.3125664 
19 34920 0.3090265 
24 34920 0.3090265 
34 26040 0.2304425 
39 25880 0.2290265 
44 20920 0.1851327 
49 21680 0.1918584 
54 17040 0.1507965 
59 15200 0.1345133 
120 7040 0.0623009 
180 6400 0.0566372 
Blood clearance values for 153Sm-EDTMP and 
166Ho-EDTMP 
0 1 1 
6 0.336 0.621 
12 0.259 0.513 
18 0.223 0.463 
24 0.194 0.428 
30 0.169 0.397 
36 0.147 0.369 
42 0.128 0.343 
48 0.111 0.318 
54 0.097 0.296 
60 0.084 0.275 
90 0.042 0.192 
120 0.021 0.134 
150 0.011 0.095 
180 0.006 0.068 







11r1111111:111:i::1111111 111~111111 111111; 
0 0 
5 5 3.562E-08 
10 15 1.069E-07 
15 30 2 .137E-07 
20 50 3.562E-07 . 
25 75 5.343E-07 
35 110 7.837E-07 
55 165 1.176E-06 
60 225 1.603E-06 
120 345 2.458E-06 
180 525 3.74E-06 
Urine clearance values for 153Sm-EDTMP and 
166Ho-EDTMP 
0 0 0 
6 0.024 0.035 
12 0.0642 0.055 
18 0.105 0.133 
24 0.143 0.175 
30 0.178 0.212 
36 0.211 0.245 
42 0.242 0.273 
48 0.27 0.298 
54 0.297 0.32 
60 0.321 0.338 
90 0.42 0.402 
120 0.489 0.433 
150 0.538 0.449 
180 0.573 0.457 
